EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE

Care of the Patient with Primary Open-Angle Glaucoma

First Edition

AMERICAN OPTOMETRIC ASSOCIATION

About the American Optometric Association

The American Optometric Association (AOA) is the leading authority on and advocate for quality eye health care, representing more than 50,000+ doctors of optometry, optometry students and optometric professionals. As the sole provider in many communities across America, doctors of optometry are often a patient's first entry point into the health care system, and have extensive, ongoing training to examine, diagnose, treat and manage disorders, diseases and injuries that affect the eye and visual system. Through a nationwide public health initiative, AOA's *Eye Deserve More* campaign is fostering awareness of the importance of eye health and vision care and the overall health benefits of in-person, comprehensive eye examinations with AOA doctors of optometry for all Americans.

Disclosure Statement

This evidence-based clinical practice guideline was funded by the AOA without financial support from any commercial sources. The Evidence-based Optometry Guideline Development Group and other guideline participants provided full written disclosure of conflicts of interest prior to each meeting and prior to voting on the quality of evidence or strength of clinical recommendations contained within this guideline.

Disclaimer

Recommendations made in this guideline do not represent a standard of care. Instead, the recommendations are intended to assist the clinician in the decision-making process. Patient care and treatment should always be based on a clinician's independent professional judgment, given the patient's circumstances, and in compliance with state and federal laws and regulations.

The information in this guideline is current to the extent possible at the time of publication.

CARE OF THE PATIENT WITH PRIMARY OPEN-ANGLE GLAUCOMA

Developed by the AOA Evidence-based Optometry Guideline Development Group

Approved by the AOA Board of Trustees October 5, 2024

243 N. Lindbergh Blvd., St. Louis, MO 63141-7881

aoa.org • 800.365.2219

TABLE OF CONTENTS

EVIDENCE-BASED CLINICAL GUIDELINES

A. WHAT IS THE EVIDENCE-BASED PROCESS?

Evidence-based clinical practice guidelines provide for the use of current best evidence in conjunction with clinical expertise and patient values to guide health care decisions. Scientific support for diagnosis and treatment strategies is essential to ensuring that services are safe and effective. The clinical recommendations in this guideline are evidence-based statements regarding patient care that are supported by the scientific literature or consensus of professional opinion when no quality evidence was discovered.

As a result of the Medicare Improvements for Patients and Providers Act of 2008, Congress commissioned the Secretary of Health and Human Services to create a public-private program to develop and promote a common set of standards for the development of clinical practice guidelines (CPGs). These standards address the structure, process, reporting and final products of systematic reviews of comparative effectiveness research and evidence-based CPGs.

The Institute of Medicine (IOM), now the Health and Medicine Division of the National Academies of Sciences, Engineering and Medicine (NASEM), in response to a request from the Agency for Healthcare Research and Quality (AHRQ), issued two reports in March 2011: *Clinical Practice Guidelines We Can Trust*[1] *and Finding What Works in Health Care: Standards for Systematic Reviews.*[2]

In *Clinical Practice Guidelines* We Can Trust, the IOM redefined CPGs as follows:

> *"Clinical practice guidelines are statements that include recommendations intended to optimize patient care that are informed by a systematic review of the evidence and an assessment of the benefits and harms of alternative care options."*

The report states that to be trustworthy, guidelines should:

- Be based on a systematic review of existing evidence
- Be developed by a knowledgeable, multidisciplinary panel of experts and key stakeholders
- Consider important patient subgroups and preferences, as appropriate
- Be based on a transparent process that minimizes conflicts of interest and biases
- Provide a clear explanation of the logical relationships between alternative care options and health outcomes
- Provide a grading of both the quality of evidence and the strength of the clinical recommendation
- Be revised as appropriate when new evidence warrants modifications of recommendations.

Based on the IOM/NASEM reports, the AOA Evidence-based Optometry (EBO) Committee developed a 14-step process to meet the new evidence-based recommendations for trustworthy guidelines.

AOA's 14 Steps to Evidence-based Clinical Practice Guideline Development	
1.	**Guideline Development Group (GDG):** The Evidence-based Optometry (EBO) Committee selects a multidisciplinary panel of experts, including patient and public representatives, to act as the Guideline Development Group (GDG).
2.	**Transparency and COI:** The GDG manages all conflict of interest (COI), which is documented by AOA staff and reviewed during face-to-face meetings.
3.	**Clinical Questions:** The GDG defines the literature search criteria and identifies all clinical questions through a question formulation meeting.
4.	**Search for Evidence:** *The AOA staff sends the search criteria and clinical questions for a systematic review of the literature (outside researchers) and provides all obtained papers to the Guideline Development Reading Group (GDRG). Systematic reviews, when available, are included in the guideline. No systematic review authors are participants in the GDG or GDRG.* **Inclusion Criteria (must meet all):** *Scientific studies written in English that address the clinical question and that meet the patient population or age range being addressed.* **Exclusion Criteria (meets any of the following):** *Scientific studies that are not in English, animal studies, studies outside the patient population or age range (if relevant), studies not addressing any topic of the clinical questions searched.*
5.	**Grade Evidence/Quality:** One scientific reader and one member from the GDRG are randomly selected to read and grade each paper. They separately grade the paper for quality of evidence based on predetermined grading criteria and state the clinical recommendation(s). In the case of a disagreement, a third reader is assigned.
6.	**Articulate Clinical Recommendations/Strength*:** The GDRG and GDG clinical experts review all clinical recommendations and articulate each for inclusion in the guideline during an "articulation of recommendations" meeting(s). There are single and/or aggregate recommendations made and a strength level is assigned. Potential benefits and harms, costs, and patient preferences are identified, as well as any gaps in research, and each is documented.
7.	**Write the Draft:** The AOA staff sends the articulation results to the writer to develop draft 1.
8.	**Draft Review and Edits*:** The GDG reads draft 1, discusses and edits.
9.	**Rewrite/Final Drafts:** The AOA staff sends the draft results to the writer for writing/revisions for draft 2 (peer review draft) and sends to medical editor for copy editing. Additional reviews are completed as necessary.
10.	**Approval and Posting for Peer Review:** The AOA staff and/or EBO Committee chair sends the peer review draft to the AOA Board of Trustees for approval to post for peer and public review. The draft is posted on the AOA website, along with a comment form, and the review period is announced. Comments are solicited/collected electronically and comment authors are not made public.
11.	**Final Document Produced*:** The GDRG and GDG clinical experts review all peer comments and revise the final document. They may choose to include the peer review comment, not include the comment, and/or identify further gaps to review when preparing the next edition. All comments are documented regarding actions taken/not taken and the final draft is produced.
12.	**Final Draft Approval and Legal Review:** The final draft is reviewed by the AOA Board of Trustees and AOA Legal Counsel for approval and verification that the GDG followed the evidence-based process as outlined by the National Academies of Sciences, Engineering, and Medicine (NASEM) – Health and Medicine Division, previously the Institute of Medicine.
13.	**Post Guidelines:** The AOA staff posts the evidence-based guideline to the AOA website for public use.
14.	**Schedule Reviews:** The GDG schedules a review to meet the NASEM guideline development standards and reviews all previously identified gaps in medical research and any new evidence and revises the evidence-based guideline every 2 to 5 years.

**Denotes virtual meetings in 2020/2021/2022 due to the COVID-19 pandemic*

B. HOW TO USE THIS GUIDELINE

The following table provides the grading system used in this guideline for rating evidence-based clinical statements. Grades are provided for both quality of the evidence and strength of clinical recommendations.

Key to Evidence Quality and Strength of Clinical Recommendation Levels	
	Study Type
Grade	

A	• **Meta-Analysis**
	• **Systematic Review**
	• **Randomized Clinical Trial**
	• **Diagnostic Studies** (Grade A)
	  ○ Do not have a narrow population
	  ○ Do not use a poor reference standard
	  ○ No case control studies of diseases or conditions

B	• **Randomized Clinical Trial** (weaker design)
	• **Cohort Studies**
	  ○ Retrospective
	  ○ Prospective
	• **Diagnostic Studies** (Grade B - only *one* of the following)
	  ○ Narrow population
	  ○ Sample used does not reflect the population to whom the test would apply
	  ○ Uses a poor reference standard
	  ○ Comparison between the test and reference standard is not blinded
	  ○ Case control studies of diseases or conditions

C	• **Case Control Studies**
	  ○ Study of sensitivity and specificity of a diagnostic test, population-based descriptive study of diseases or conditions
	  ○ Retrospective
	  ○ Prospective
	• **Diagnostic Studies** (Grade C - at least *two or more* of the following)
	  ○ Narrow population
	  ○ Sample used does not reflect the population to whom the test would apply
	  ○ Uses a poor reference standard
	  ○ Comparison between the test and reference standard is not blinded
	• **Studies of Strong Design**
	  ○ With substantial uncertainty about conclusions or serious doubts about generalizations, bias, research design, or sample size
	• **Nonrandomized Trials**

D	• **Cross-sectional Studies** • **Case Reports/Series** • **Reviews** • **Position Papers** • **Expert Opinion** • **Reasoning from Principle**

Strength of Clinical Recommendation Levels
Strong Recommendation: The benefits of the recommendation clearly exceed the harms (or the harms clearly exceed the benefits in the case of a negative recommendation) and the quality of evidence is excellent (Grade A or B). In some clearly identified circumstances, a strong recommendation may be made on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms. *This recommendation should be followed unless a clear and compelling rationale for an alternative approach is present.*
Recommendation: The benefits of the recommendation exceed the harms (or the harms exceed the benefits in the case of a negative recommendation), but the quality of evidence is not as strong (Grade B or C). In some clearly identified circumstances, a recommendation may be made on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms. *This recommendation should generally be followed but remain alert for new information.*
Discretional: The current evidence is insufficient to assess the balance of benefits and harms of the recommendation. Evidence may be lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined. *There should be an awareness of this recommendation but a flexibility in clinical decision-making, as well as remaining alert for new information.*

Clinical Notes and Statements shown throughout the guideline may have quality of evidence grades (A, B, C, or D). For example, a clinical note or statement with a quality of evidence grade of "B" is shown as "(Evidence Grade: B)."

Evidence-based Action Statements will be highlighted in an "Action" box, with the quality of evidence, level of confidence and clinical recommendation grading information listed. For example:

EVIDENCE-BASED ACTION STATEMENT: Early medical treatment should be considered for individuals with ocular hypertension (OH) who are at moderate or high risk of developing primary open-angle glaucoma (POAG).[10,11,73]
Evidence Quality: Grade A. Study type(s): Randomized Clinical Trials, Case Control **Level of Confidence:** High **Clinical Recommendation Level:** Strong Recommendation. This recommendation should be followed unless clear and compelling rationale for an alternative approach is present.
Evidence Statements: Clinicians should consider initiating treatment for individuals with ocular hypertension who are at moderate or high risk for developing POAG.[73] (Evidence Grade: A) There is little absolute benefit of early treatment in low-risk OH patients.[11] (Evidence Grade: A) Patients with OH at low risk of conversion to POAG can generally be followed without treatment, as long as they are monitored regularly for signs of early disease. The use of a five-factor baseline risk model (age, IOP, CCT, larger C/D ratio and higher VF PSD) has reasonable accuracy in distinguishing high from low-risk OH patients. The benefit of early treatment is greatest in high-risk OH patients.[10] (Evidence Grade: B)

Potential Benefits: Early treatment may reduce or delay onset of POAG.	**Potential Risks/Harms:** Side effects of medication.

Benefits and Harms Assessment: Benefits significantly outweigh harms.
Potential Costs: Cost of medication.
Value Judgments: None.
Role of Patient Preferences: Moderate.
Intentional Vagueness: None.
Gaps in Evidence: None identified.

The Action Statement profile provides additional information related to the development and implementation of the clinical recommendation. The following is an explanation of the categories listed in the profile:

Evidence Quality – The quality of evidence grade (A, B, C, or D) or the aggregate quality of evidence grade (if multiple studies were available for review) and the type of research study or studies reviewed.

Level of Confidence – The consistency of the evidence and the extent to which it can be trusted specified as high, medium, or low.

Clinical Recommendation Level – The level (Strong Recommendation, Recommendation, or Discretional) assigned to the implementation of the clinical recommendation made in the Action Statement.

Evidence Statements – The clinical statements derived from research studies reviewed that support the Action Statement.

Potential Benefits – Favorable changes which would likely occur if the Action Statement was followed.

Potential Risks/Harms – Adverse effects or unfavorable outcomes that may occur if the Action Statement was followed.

Benefits and Harms Assessment – A comparison of the relationship of benefits to harms specified as "benefits significantly outweigh harms" (or vice versa) or a "balance of benefits and harms."

Potential Costs – Direct and indirect costs may include the costs of the procedure, test or medication; time spent by the eye doctor counseling the patient; administrative time; patient/parent/caregiver time off from work, etc.

Value Judgments – Determinations made by the Guideline Development Group (GDG) in the development of the Action Statement relating to guiding principles, ethical considerations or other priorities.

Role of Patient Preference – The role the patient has in shared decision-making regarding implementation of the Action Statement specified as large, moderate, small or none.

Intentional Vagueness – Specific aspects of the Action Statement that are left vague due to factors such as the role of clinical judgment, patient variability, concerns over setting legal precedent, etc.

Gaps in Evidence – Areas identified during searches and evaluations of the research that show gaps in available evidence.

Consensus-based Action Statements, based on consensus by the Guideline Development Reading Group (GDRG), will be highlighted in an "Action" box, without any quality of evidence or strength of clinical recommendation grading information listed. For example:

CONSENSUS-BASED ACTION STATEMENT: The frequency and scope of follow-up examinations of persons diagnosed with primary open-angle glaucoma (POAG) should be individualized based on the severity and stability of their disease and should occur at regular intervals to monitor progression and treatment efficacy.
Evidence Quality: There is a lack of published research to support or refute the use of this recommendation.
Benefits and Harms Assessment: Implementation of this recommendation is likely to result in the earlier diagnosis and treatment of any disease progression. The benefits of this recommendation were established by expert consensus opinion.

C. SUMMARY LISTING OF ACTION STATEMENTS

The following is a listing of the evidence-based and consensus-based recommendations for care contained in this guideline:

- The examination of a person suspected of having primary open-angle glaucoma (POAG) should include all aspects of a comprehensive eye and vision examination, with emphasis on the evaluation of the anterior chamber angle, optic nerve head (ONH), peripapillary retinal nerve fiber layer (RNFL), macula and visual fields (VF), and measurement of intraocular pressure (IOP) and central corneal thickness (CCT).[71,77,179,185,188,227] *(Evidence Grade: B, Recommendation)*
- The use of prostaglandin analogs (PGAs) should be considered as an initial therapy in patients with ocular hypertension (OH) or primary open-angle glaucoma (POAG), unless contraindicated.[275,283] *(Evidence Grade: A, Strong Recommendation)*
- Patients prescribed topical intraocular pressure (IOP) lowering therapy may experience decreased tear film stability and elevated tear osmolarity and should be evaluated for ocular surface disease (OSD).[311,312,314,315,317-319,323,325] *(Evidence Grade: C, Recommendation)*
- Pharmacological treatment of primary open-angle glaucoma (POAG) should be used with caution during pregnancy and lactation. *(Consensus Statement)*
- Selective laser trabeculoplasty (SLT) should be considered as an initial/alternative or additive therapy to medication for achieving intraocular pressure (IOP) control in patients with ocular hypertension (OH) or primary open-angle glaucoma (POAG).[160,333,343-347] *(Evidence Grade: A, Strong Recommendation)*
- The frequency and scope of follow-up examinations of persons diagnosed with primary open-angle glaucoma (POAG) should be individualized based on the severity and stability of their disease and should occur at regular intervals to monitor progression and treatment efficacy. *(Consensus Statement)*
- Progress examinations of patients with primary open-angle glaucoma (POAG) should include, but are not limited to, an interval history, measurement of visual acuity and intraocular pressure (IOP), and evaluation of the optic nerve head (ONH), with periodic gonioscopy, retinal nerve fiber layer (RNFL) evaluation and visual field (VF) testing. *(Consensus Statement)*
- Patient self-monitoring of intraocular pressures (IOP) should be considered to help support the diagnosis and/or management of patients at risk for or diagnosed with primary open-angle glaucoma (POAG).[372,380,381] *(Evidence Grade: C, Recommendation)*
- Early medical treatment should be considered for individuals with ocular hypertension (OH) who are at moderate or high risk of developing primary open-angle glaucoma (POAG).[10,11,73] *(Evidence Grade: A, Strong Recommendation)*
- Eye doctors should be persistent in providing education and training to patients with primary open-angle glaucoma (POAG) to improve adherence/compliance with recommended therapy.[416-418,424,425,431,432,451-453] *(Evidence Grade: B, Recommendation)*
- Patients with primary open-angle glaucoma (POAG) who are prescribed pharmacological treatment should receive instructions on eyedrop instillation.[431,455,460,461] *(Evidence Grade: B, Recommendation)*
- Ocular telehealth programs can provide increased access to care but should not be used alone or for the assessment or management of moderate or advanced disease in patients with primary open-angle glaucoma (POAG).[501-503] *(Evidence Grade: B, Strong Recommendation)*

I. INTRODUCTION AND GUIDELINE OBJECTIVES

Glaucoma is a chronic, generally bilateral but often asymmetric optic neuropathy characterized by progressive damage to the optic nerve and retinal nerve fiber layer (RNFL) that can lead to permanent loss of vision. It is a worldwide leading cause of visual dysfunction and irreversible blindness. Primary open-angle glaucoma (POAG) is the most common form of the disease.[3]

Although generally asymptomatic in early stages, if untreated or inadequately treated, patients who have POAG can suffer vision loss.[4] Although the 20-year probability of blindness due to POAG in at least one eye decreased over a 45-year period from 1965 to 2009, a significant proportion of patients still progress to blindness despite diagnostic and therapeutic advancements.[5] Therefore, it is important to address modifiable risk factors for vision loss such as advanced disease at diagnosis, high intraocular pressure (IOP), fluctuating IOP during treatment and poor patient compliance with treatment in order to decrease risk of vision loss in glaucoma patients.[6] (Evidence Grade: A)

This Evidence-based Clinical Practice Guideline on Care of the Patient with Primary Open-Angle Glaucoma provides examination, treatment and management recommendations designed to help preserve vision and maintain vision-related quality of life in persons with POAG. The objectives of this guideline are to assist doctors of optometry in achieving the following:

- Identification of individuals who are undiagnosed or at risk for POAG.
- Preservation of vision by reducing the risk of vision loss in persons with POAG through timely diagnosis, treatment, determination of need for additional or ongoing evaluations, and appropriate management/co-management and/or referral.
- Education of individuals and health care practitioners regarding the risks and complications of POAG.
- Education and counseling of individuals with POAG on the importance of compliance/adherence to prescribed treatment, as well as potential ocular and systemic side effects.
- Provision of, or referral for, vision rehabilitation services for persons with vision loss from POAG.
- Improvement in the quality of care rendered to people with POAG.

II. BACKGROUND

A. DISEASE DESCRIPTION

Glaucoma is a group of ocular disorders characterized by progressive optic neuropathy involving multiple risk factors and featuring recognizable patterns of structural change (e.g., neuroretinal rim of the optic disc, retinal nerve fiber layer) and functional (visual field) loss. IOP and age have been identified as important risk factors in all clinical forms of open-angle glaucoma.[7-9]

The main classifications of open-angle glaucoma (OAG) discussed in this guideline are:

- Ocular hypertension
- Primary open-angle glaucoma
- Normal tension glaucoma.

Ocular hypertension (OH) is a condition where IOP is elevated, but glaucomatous optic neuropathy is not detectable. Persons with untreated OH have an estimated 10% risk of developing glaucoma over five years.[10] (Evidence Grade:

B) Those at low risk of conversion to POAG can generally be followed without treatment, as long as they are monitored regularly for signs of early disease.[11]

Primary open-angle glaucoma (POAG) is a subtype of glaucoma where the angle formed at the junction of the iris and cornea is open and there is no other overt disease. It is a chronic, progressive optic neuropathy in which there is a characteristic acquired atrophy of the optic nerve head (ONH) and loss of retinal ganglion cells (RGCs) and their axons, without other causes.

The susceptibility of the ONH and surrounding tissues to IOP is multifactorial. It varies with age, region of the ONH and from person to person.[7,12-14] Large-scale population studies have established that mean human IOP is about 16 mmHg. POAG risk increases in the presence of IOP in excess of two standard deviations above this mean or 21 mmHg.[15] Although elevated IOP is often associated with POAG and risk increases with increasing IOP, elevated IOP by itself is not necessary and sufficient to make the diagnosis.[15-17]

Normal tension glaucoma (NTG) is a subtype of POAG in which elevated IOPs outside of the "normal range" are never clinically observed.[15,18] Although certain distinguishing phenotypic features of NTG have been noted, such as increased disc hemorrhage (DH) frequency, acquired ONH pits, and both characteristic ONH cupping patterns and visual field (VF) loss, there is considerable overlap of the clinical findings of NTG and POAG suggesting that NTG is likely part of the POAG continuum.[19] They differ primarily in that the level of IOP is the predominant risk factor in POAG while additional IOP-independent factors take increasing importance in NTG.

B. SCOPE OF THE PROBLEM

Early in the course of the disease, most persons with POAG rarely present with visual symptoms.[20] Therefore, there may be delays in detection, diagnosis and treatment. Untreated POAG usually progresses slowly. The rate of untreated POAG progression is quite variable, however, and treatment may not completely halt vision loss. POAG also progresses in some eyes despite aggressive treatment.[21]

Persons with POAG may face challenges including compromise to peripheral and central vision and decreased contrast sensitivity.[22-24] These can lead to difficulties in walking,[25,26] issues with falling,[27-29] reading[30-33] and driving,[34] and subsequent poor quality of life.[4,20,35]

- Quality of life

Once diagnosed, even if good subjective vision is maintained by treatment, the use of medications and/or surgery often leads to dry eye symptoms,[36,37] increased cost burden[38-41] and subsequent decrease in quality of life.[36,42] A high proportion of patients with glaucoma report either visual complaints or ocular surface disease symptoms.[43]

Glaucoma treatment creates an additional burden for patients that is distinct from the disease burden itself. It negatively affects quality of life and can potentially cause vision-threatening issues with both medication and appointment adherence.[44] Knowledge of the presence of the disease, even in the absence of symptoms, can lead to anxiety, depression, and fears of loss of independence, the ability to work and blindness.[45-48] In addition, losses in psychosocial function (e.g., self-image, psychological well-being, reduced confidence in health care) may occur.[49]

- Risk of falling

Decreased vision is a significant contributor to falls in adults 65 years and over.[50] Persons with mild glaucoma have a higher risk of falls than individuals without glaucoma and those with moderate to advanced glaucoma may have a higher fear of falling and avoid at-risk activities.[51] Interventions to decrease falls and improve emotional and social well-being should be considered in patients with glaucoma starting early in the disease course.[52] (Evidence Grade: D) Visual acuity in the worse eye, history of previous falls, hypertension and diabetes mellitus (DM),[53] as well as rate of VF loss,[54] appear to be particular risk factors for falls in POAG patients.

- Visual impairment and blindness

A study of treated patients with POAG in the United States found a 9% probability of bilateral blindness and 26% probability of blindness in at least one eye at 20 years after diagnosis of glaucoma.[55] In another study, 15% of patients were found to be blind from glaucoma over a 14-year period. Higher IOP, a worse VF status at time of diagnosis and older age at death are important risk factors for blindness associated with glaucoma.[56]

C. EPIDEMIOLOGY OF PRIMARY OPEN-ANGLE GLAUCOMA

1. Prevalence of Primary Open-Angle Glaucoma

Glaucoma is a leading cause of irreversible blindness around the world.[57] It is estimated that over 64 million people world-wide had glaucoma in 2013 and this number is projected to increase to almost 112 million by 2040, disproportionally affecting people residing in both Asia and Africa.[58] In 2021, the worldwide prevalence of POAG in persons 40 years of age or older was estimated to be 2.4% with the highest prevalence in Africa (4.0%).[59] A systematic review of population surveys estimated POAG prevalence in African ancestry populations of 5.2% at 60 years of age, increasing to 12.2% at 80 years of age.[60] Both Whites and Hispanics have shown high increases in prevalence per decade of life, and men were more likely to have POAG than women.[60]

A meta-analysis[61] estimated 2.71 million POAG cases in the United States in 2011, with the highest prevalence among populations 70-79 years of age (31%), women (53%), and non-Hispanic Whites (44%). More recently, overall prevalence of glaucoma in the United States was estimated by ONH photography at slightly more than 2%, or 2.9 million individuals. This study found the prevalence was greatest among non-Hispanic African Americans, and included 1.4 million women, 1.5 million men, and 2.3 million people more than 60 years old.[62]

The prevalence of POAG increases with higher IOP, family history, some racial groups, myopia and systemic diseases (e.g., DM, hypothyroidism) and is directly related to age.[16,63,64] In the Baltimore Eye Survey, POAG age-adjusted associations with a family history of the same disease were 3.7 times higher in siblings and 2.2 times higher in parents relative to individuals with no family history.[65] Persons of African heritage are at greater risk for developing POAG.[66] The Baltimore Eye Survey also found that the overall prevalence of POAG among African Americans was 4.3 times that found in Whites.[67]

2. Vision Loss in Primary Open-Angle Glaucoma

The majority of treated POAG patients retain useful vision for life, but a significant proportion will become visually impaired or blind.[4] One large worldwide meta-analysis calculated that 2.1 million people were blind and 4.2 million people visually impaired due to glaucoma in 2010. Glaucoma caused 6.6% of all blindness and 2.2% of all moderate and severe vision impairment.[68]

D. RISK FACTORS FOR PRIMARY OPEN-ANGLE GLAUCOMA

1. Ocular and Systemic Risk Factors for Primary Open-Angle Glaucoma

Several ocular and systemic conditions (See Table 1) have been found to be risk factors for POAG.

Table 1
Modifiable and Non-modifiable Risk Factors for Primary Open-Angle Glaucoma

Modifiable Risk Factors	
Elevated IOP	Several studies have confirmed that IOP is a significant risk factor for the development of POAG.[7,69,70] The Early Manifest Glaucoma Trial (EMGT) suggested that any elevated IOP is a strong factor for glaucoma progression.[71] (Evidence Grade: B)
Non-modifiable Risk Factors	
Increasing age	The Rotterdam Study[76] (Evidence Grade: B), Ocular Hypertension Treatment Study (OHTS)[7] (Evidence Grade: B) and the Barbados Eye Study[69] confirm that baseline age is a predictive risk factor for POAG, with the incidence of POAG increasing significantly with age.
Genetics and positive family history	There is a high genetic disposition in all types of glaucoma,[77] especially in mothers and siblings of individuals with glaucoma.[78] (Evidence Grade: C)
Race/ethnicity	The Baltimore Eye Survey reported African-Americans are at higher risk of POAG than Whites.[79] The Los Angeles Latino Eye Study (LALES) found prevalence of open-angle glaucoma is high among Latinos of Mexican ancestry.[80]
Myopia	Individuals with myopia have an increased risk of developing POAG.[81,82,83] (Evidence Grade: A) The prevalence of glaucoma-like optic neuropathy (GON) increases with longer axial lengths in highly myopic eyes.[84] (Evidence Grade: D) POAG patients with myopia >6 diopters (D) had a greater progression of VF loss.[85,86] (Evidence Grade: C)[87] Myopia <1D, however, may be a risk factor for increased VF loss in NTG.[88]
Corneal thickness	Central corneal thickness (CCT) is an important independent risk factor for OAG.[7,89,90] Persons with thin CCTs (≤555um) have a significantly higher prevalence of OAG than those with normal or thick CCTs at all levels of IOP.
Type 2 diabetes mellitus (DM)	Individuals with type 2 DM have an increased risk of developing POAG.[91]
Hypertension/hypotension	Systemic hypertension increases the risk for developing POAG.[92] Low nocturnal blood pressure (BP), especially more than 10 mmHg below daytime mean arterial pressure, is predictive of progression of VF defects in NTG.[93] (Evidence Grade: B)
Corneal hysteresis	Corneal hysteresis (an assessment of the cornea's ability to absorb and dissipate energy) was significantly associated with the rate of VF loss in a cohort of glaucoma patients over time. Eyes with lower baseline hysteresis tended to progress significantly faster than those with higher hysteresis values.[94] (Evidence Grade: B) Assessment of corneal biomechanical properties supports corneal hysteresis as a glaucoma progression risk factor.[95] (Evidence Grade: B)[96] (Evidence Grade: B)

2. Drugs That Influence Primary Open-Angle Glaucoma Risk

Various systemic medications can affect optic nerve perfusion, RGC survival and aqueous humor outflow facility suggesting these medications modulate both POAG risk and disease progression.[97] Corticosteroids are known to elevate IOP leading to POAG like disease.[98,99] Risk increases with frequency, duration and relative drug potency. All modes of corticosteroid administration have the potential to elevate IOP,[100] but risk is somewhat lower with systemic use than when locally applied.[99,101]

Additional drugs that can elevate IOP include, but are not limited to:

- Anti-neoplastic agents (docetaxel and paclitaxel)[99]
- Selective serotonin reuptake inhibitor antidepressants[102]
- Anticholinergics[103]
- Systemic calcium channel antagonists[104]
- Intravitreal anti-vascular endothelial growth factor (anti-VEGF)[105]

Other drugs may increase IOP through pupillary dilation, swelling of the crystalline lens or forward movement of the lens-iris diaphragm (e.g., topiramate). Mechanical mechanisms (e.g., acute increased ocular volume and/or clogging of the trabecular meshwork), and other agents and procedures (e.g., visco-elastic agents, silicone oil, anti-VEGF agents surgically injected into the globe seven or more times annually and scleral buckle surgery) can also elevate IOPs.[106-109]

E. CO-MORBIDITIES ASSOCIATED WITH PRIMARY OPEN-ANGLE GLAUCOMA

Patients with POAG are believed to be at increased risk for several chronic conditions and comorbidities (See Table 2). These conditions negatively affect POAG patients' health and quality of life.

Table 2
Comorbidities Associated with Primary Open-Angle Glaucoma

Dementia/cognitive decline	Both research and clinical findings point to a possible common causal relationship between Alzheimer's disease and POAG.[110] Both diseases share a strong age-related incidence, RGC degeneration and extracellular fibular deposition.[111] Although one study showed a strong association between POAG and subsequent Alzheimer's dementia,[112] the relationship between POAG and Alzheimer's disease (and other dementia) remains controversial.[113]
High/low blood pressure	The relationship between BP and POAG is both controversial and complex.[114] Both high and low BP (and especially low nighttime diastolic pressure) have been associated with glaucoma. Low BP is particularly associated with progression in NTG.[93] Ocular perfusion pressure (OPP) reflects the vascular status of the ONH and is a biologically plausible etiology of RGC damage at the ONH. It may be more relevant in POAG than BP alone.[115] Low OPP, high systolic and low diastolic BPs, and high mean BP were all associated with POAG in LALES.[116] South Korean patients diagnosed with high BP (both high systolic and diastolic BP) were also more likely (1.16 times) to develop POAG.[117]

Type 2 DM	The relationship between type 2 DM and POAG is unclear, however, both the presence and duration of type 2 DM were associated with POAG in LALES.[118] Of the metabolic syndrome components, both hypertension and impaired glucose tolerance contributed to an increased risk of NTG in other research.[119]
Cardiovascular disorders	Both migraine and vasospasm (e.g., Raynaud's phenomenon) have been associated with risk of ONH damage and glaucoma progression. Also, atrial fibrillation, independent of other known cardiovascular risk factors, increases the risk of NTG.[120]
Sleep disorders	Sleep disorders are more prevalent in patients with glaucoma, especially NTG.121 Obstructive sleep apnea (OSA) has been reported to be a potential risk factor in the development of glaucoma,[122,123] though there is evidence to the contrary, especially if patients are matched for known OSA risk factors.[124-126]
Depression/anxiety	POAG has been associated with both depression and anxiety.[127-129] Reduced health-related quality of life (HRQOL) scores are common in both surgically and medically treated glaucoma patients.[130]

F. NATURAL HISTORY OF PRIMARY OPEN-ANGLE GLAUCOMA

Although there is a clear, direct and dose-dependent relationship between IOP elevation and POAG in many patients, it is also clear that many POAG patients continue to lose VF sensitivity with IOPs never elevated above or consistently maintained at "normal" levels. Many patients with elevated IOPs also never develop glaucomatous ocular damage. This pair of observations have led to the exploration of other pathogenic mechanisms.

The identification of IOP and age as important and independent factors in all clinical forms of OAG has prompted ongoing research on how the optic disc and surrounding tissues respond to IOP and aging to better understand the pathophysiology of glaucoma. Early experiments involving both acute and sustained elevation of IOP in a primate model identified the ONH as the primary site for disturbances in ganglion cell axonal transport[131-133] and that displacement of the lamina cribrosa was related to increases in IOP.[134,135]

With the availability of more advanced imaging technologies, these findings have been further quantified and the effects of acute changes in IOP on load-bearing structures of the posterior segment have been studied in healthy and diseased eyes.[136-144] These studies, along with histological evidence, have identified the peripapillary connective tissue, lamina cribrosa, neural tissue and optic nerve vasculature as structures susceptible to IOP- related stress.[145-147]

Over a lifetime, the ONH connective tissues are exposed to substantial levels of IOP-related stress and strain at normal levels of IOP, which increases further when IOP is elevated. These biomechanical forces at a given level of IOP are physiologic or pathophysiologic depending on the response of the tissues.[148] IOP therefore is not so much "normal" as "physiologic" or "pathophysiologic" and what distinguishes these will vary depending upon the susceptibility of the tissue. Therefore, in the setting of more susceptible tissue, even a "normal" range of IOP could produce a pathologic response (e.g., NTG) while less susceptible tissues may withstand higher levels of IOP (e.g., OH).

Principal causes of ONH susceptibility likely include the level of IOP, the geometry and material properties of the ONH and surrounding tissues, age-related alterations in the ONH biomechanics, the volume flow and perfusion pressure of blood within the capillaries of the lamina cribrosa, nutrient diffusion to the astrocyte, the molecular response of astrocytes and glia to physical strain and the presence of physiologic stress within their microenvironment. Additionally, RGC factors that make axons more susceptible to damage within the ONH, or its stroma more susceptible to apoptosis in response to axonal distress, may also play a role.[148]

Increased susceptibility of the ONH to the effects of IOP may reflect a structural predisposition for pathophysiologic change, the consequence of the tissue response to increased IOP or some combination of variables.[149] Given the multifactorial nature of glaucoma, the clinical management of the condition should be individualized based on the susceptibility of the optic nerve and surrounding tissues, and variables associated with the delivery of care.

The well-established roles of family history,[150] ocular anatomy and race (or ethic group) also suggest genetic influence if not etiology for many, if not all, types of glaucoma. While the functions of genes and genomic loci remain incompletely understood, about 20 genetic loci (perhaps up to 100) on many chromosomes have been associated with glaucoma, and >15 loci in particular have been suggested to play a role in POAG.[151-153] It is most likely that multiple genes and/or environmental factors contribute to the complex inheritance of POAG.[154]

G. LANDMARK GLAUCOMA STUDIES

Evidence-based clinical trials such as the Ocular Hypertension Treatment Study (OHTS), the Collaborative Normal Tension Glaucoma Study (CNTGS) and the Laser in Glaucoma and Ocular Hypertension Study (LiGHT) provide important data on POAG disease progression and treatment. Table 3 provides summaries of the results of landmark glaucoma clinical trials of current clinical relevance.

Table 3
Major Glaucoma Clinical Trials

Clinical Trial	Study Results
Early Manifest Glaucoma Trial (EMGT) (Study began in 1992)	The EMGT evaluated the effect of immediate treatment to reduce IOP in early, previously untreated open-angle glaucoma patients as compared with no initial treatment or later treatment. Treated patients had argon laser trabeculoplasty and received topical betaxolol hydrochloride twice daily.[155] Analysis showed considerable beneficial effects of treatment that significantly delayed progression. Patients treated had half of the progression risk of those not receiving treatment. Although progression varied across patient categories, treatment effects were present in both older and younger patients, high- and normal-tension glaucoma, and eyes with less and greater visual field loss.[74] (Evidence Grade: A) After a median of eight years of treatment and follow-up, IOP continued to have a marked influence on progression, regardless of baseline IOP. Other significant factors were age, bilaterality, exfoliation and DH. Lower systolic perfusion pressure, lower systolic BP and cardiovascular disease history emerged as predictors, suggesting a vascular role in glaucoma progression.[21] (Evidence Grade: B)
Collaborative Normal-Tension Glaucoma Study (CNTGS) (Study began in 1998)	The CNTGS analyzed the effect of a 30% IOP reduction on the subsequent course of glaucoma. In the study, one eligible eye of 145 individuals with NTG was randomized either to no treatment (control) or to a 30% IOP reduction from baseline.[156] Progression of VF defects (5-7 years follow-up) was noted in 60% of untreated NTG individuals, while treatment targeting IOP-lowering of >30% decreased progression to 20%.[156] After more than eight years, 20% of the patients progressed despite treatment, 30% had a slowed loss of VF in response to reduction of IOP of at least 30% and 65% remained stable in the absence of treatment. High peak IOP was a significant factor for progression.[157] (Evidence Grade: B) The CNTGS concluded that patients with NTG benefit from lowering of IOP. Treatment should be individualized according to the stage of disease and rate of progression.

Ocular Hypertension Treatment Study (OHTS) (Study began in 1994)	The goals of the OHTS were to determine the safety and efficacy of topical ocular hypotensive medication in delaying or preventing the onset of POAG in patients with OH and to identify baseline clinical and demographic factors that predict which patients would or would not develop POAG. Participants with no evidence of glaucomatous damage and with an IOP between 24 mmHg and 32 mmHg were randomized to either observation or treatment with commercially available topical ocular hypotensive medication. The goal in the medication group was to reduce the IOP by 20% or more and to reach an IOP of 24 mmHg or less.[73] (Evidence Grade: A) The OHTS[7] (Evidence Grade: B) found that the conversion rate from OH to POAG over five years was 4.4% in treated patients (IOP decreased 20%) compared with 9.5% in untreated patients. Of OHTS participants evaluated in a 20-year follow-up cohort, about 45% converted to POAG (49% in the observation and 42% in the treatment groups) and 25% developed VF loss in one or both eyes.[158] (Evidence Grade: B) The study found that topical ocular hypotensive medication was effective in delaying or preventing the onset of POAG in individuals with elevated IOP,[73] (Evidence Grade: A) and the greatest benefit was seen in high-risk individuals.[11] (Evidence Grade: A) OHTS findings suggest that 19 people would need to be treated unnecessarily to prevent one person with OH converting to POAG, not considering other risk factors. Baseline risk factors associated with the conversion to POAG included advanced age, CCT lower than the study mean, increased ONH cup-to-disc ratio and increased VF pattern standard deviation.
Laser in Glaucoma and Ocular Hypertension Trial (LiGHT) (Study began in 2012)	The LiGHT Trial evaluated whether initial treatment with selective laser trabeculoplasty (SLT) is superior to initial treatment with topical medication for POAG or OH. Patients in the study were randomized to initial SLT followed by medical therapy or medical therapy without laser treatment. Primary SLT achieved comparable early absolute IOP lowering in OH versus OAG eyes. Drop-free disease control was achieved at 36 months after one or two SLTs, with 58.2% of these after a single SLT and 74.6% after two SLTs.[159] (Evidence Grade: A) This clinical trial showed that SLT is safe and effective as a first-line treatment for POAG and OH. SLT provided superior IOP stability to drops, at a lower cost and it allowed almost three quarters of patients to be successfully controlled without drops for at least three years after starting treatment.[160] (Evidence Grade: A) After six years of treatment and monitoring, SLT safely provided IOP control without the need for medical or surgical treatment in approximately 70% of eyes with OH or POAG, while demonstrating a reduction in progression rates and the need for glaucoma surgery.[161] (Evidence Grade: A)
Advanced Glaucoma Intervention Study (AGIS) (Study began in 1988)	AGIS was designed to study the long-term clinical course and comparative outcomes of two sequences of surgical treatments in patients with medically uncontrolled glaucoma. One sequence began with argon laser trabeculoplasty (ALT), followed by trabeculectomy, should ALT fail to control the disease, and by a second trabeculectomy should the first trabeculectomy fail (ATT). The other sequence began with trabeculectomy, followed by ALT should the trabeculectomy fail, and by a second trabeculectomy should ALT fail (TAT).[162] Although IOP was lowered in both sequences in African American and White patients, long-term visual function outcomes were better for the ATT sequence in African American patients and better for the TAT sequence in White patients.[163,164] Both intervention sequences were shown to be effective in slowing the progression of VF deterioration in POAG patients who were uncontrolled medically. Specifically, maintaining IOP below 12 mmHg was shown to be effective in reducing VF deterioration.[9] (Evidence Grade: A)

Collaborative Initial Glaucoma Treatment Study (CIGTS) (Study began in 1993)	CIGTS evaluated whether medical therapy or trabeculectomy is the better initial treatment for patients with OAG. While both surgical and medication treatments were effective at lowering IOP during initial POAG treatment, surgery reduced IOP more than topical medications (2.2 mmHg). Age, gender and race were not predictive factors over time in treatment outcomes; however, smoking negatively impacted IOP reduction in surgically treated patients.[165] (Evidence Grade: B) The CIGTS intervention protocol led to a lowering of IOP that persisted over time in both treatment groups. The study concluded that initial surgery may be beneficial for subjects who present with more advanced VF loss, but detrimental for patients with diabetes.[166] The results also support considering more aggressive treatment when undue elevation or variation in IOP is observed.[167] (Evidence Grade: A)
Tube vs Trabeculectomy (TVT) Study (Study began in 2010)	The Tube Versus Trabeculectomy (TVT) Study was a multicenter randomized clinical trial comparing the safety and efficacy of Baerveldt tube shunt surgery to trabeculectomy with mitomycin-C (MMC) in eyes with previous cataract and/or unsuccessful glaucoma surgery.[168] The incidence of postoperative complications was higher after trabeculectomy with MMC than tube shunt surgery. Serious complications resulting in reoperation and/or vision loss occurred with similar frequency with both surgical procedures.[169] (Evidence Grade: A) No statistical difference in Vision Specific Quality of Life (QoL), nor QoL changes over five years of follow-up were found with either surgical intervention.[170] (Evidence Grade: A) Tube shunt surgery had a higher success rate compared to trabeculectomy with MMC during five years of follow-up. Both procedures were associated with similar IOP reduction and use of supplemental medical therapy. Additional glaucoma surgery was needed more frequently after trabeculectomy with MMC than tube shunt placement. Study results show that both are surgical options for treating medically uncontrolled glaucoma in patients with previous cataract extraction or failed filtering surgery.[171] (Evidence Grade: A)
United Kingdom Glaucoma Treatment Study (UKGTS) (Study began in 2007)	The UKGTS tested the hypothesis that treatment with a topical prostaglandin analog (latanoprost 0.005%), compared with a placebo, reduces the frequency of VF deterioration events in patients with open-angle glaucoma by 50% over a two-year period.[172] At 24 months, mean reduction in IOP was 3.8 mmHg in 231 patients in the latanoprost group and 0.9 mmHg in 230 patients in the placebo group. The study demonstrated preservation of visual function, notably VF, in patients treated with latanoprost.[75] (Evidence Grade: A) In addition, bilateral disease, higher IOP and DH were confirmed as risk factors for VF deterioration.[173] (Evidence Grade: A)

III. CARE PROCESS

A. SCREENING FOR PRIMARY OPEN-ANGLE GLAUCOMA

The role of community screening for glaucoma is controversial. The United States Preventive Services Task Force (USPSTF) reviewed published literature to evaluate benefits and harms of glaucoma screening. It found that the evidence was insufficient to assess the benefits and harms of glaucoma screening in asymptomatic adults. Screening tests can identify persons with glaucoma and treatment was associated with a lower risk of glaucoma progression, but evidence of improvement in visual outcomes, quality of life and function remains lacking.[174] (Evidence Grade: A)

In addition, screening for glaucoma in the general population has not been found to be cost-effective.[175] Many individuals who are identified as possibly having POAG at a screening fail to attend a subsequent professional examination. Even providing counseling and prescheduled appointments are only modestly successful when other social barriers exist (e.g., poor access to transportation, low income).[176] A lack of adequate knowledge about glaucoma may be more significantly associated with poor follow-up rates than true lack of access to care (e.g., medical insurance, availability of local eye doctors).[177]

B. PRIMARY OPEN-ANGLE GLAUCOMA EXAMINATION

The goals of a POAG examination should be to:

- Make a differential diagnosis
- Establish a disease baseline
- Estimate the risk of future glaucomatous damage
- Decide whether, by what method, and/or how aggressively to initially treat
- Determine the timing of future monitoring examinations.

In addition to the testing included in a comprehensive eye and vision examination [*Comprehensive Adult Eye and Vision Exam.pdf* (aoa.org)], a POAG confirmatory examination should include expanded investigations in the following areas:

1. Patient History

Clinicians should obtain an in-depth family history, which should be continually updated during follow-up visits based on the importance of genetics in glaucoma.[77] (Evidence Grade: D) The patient's personal and family history should include questioning about:

- Systemic or ophthalmic surgeries (including refractive surgeries which can affect refractive error, central corneal thickness and IOP readings) and traumas.
- Personal and/or familial history of glaucoma and eye drop use, including which relatives, (especially mothers and siblings)[78] and level of severity.
- Systemic history of hypertension, cardiovascular disease, asthma, migraine, vasospasm and DM.
- All medications both prescribed and over the counter.
- Allergies and previous reactions to medication.

2. Tonometry

Tonometry, by itself, is not a valid nor effective screening or diagnostic tool to identify glaucoma. However, any elevated IOP is a risk factor for glaucoma development or progression.[71] (Evidence Grade: B) Therefore, it is an important test for use in diagnosis and monitoring of OH or POAG.

The current standard for tonometry is the Goldmann applanation tonometer, which is available in several forms, but there are also alternative methods, including both contact and non-contact devices. One newer technology, rebound tonometry, correlates well with Goldmann results and is similarly affected by central corneal thickness.[178] (Evidence Grade: C) IOP measurement with either rebound tonometry or Tonopen are comparable to Goldmann applanation tonometry but are not interchangeable.[179] (Evidence Grade: C) The device used, as well as time of day of the measurement, should be noted.

> ***Clinical note:*** *High baseline IOP is a significant risk factor for glaucoma progression.[180] (Evidence Grade: B)*

IOP is not a constant. It is known to peak in early morning, decline progressively throughout the day, and then peak again during nocturnal periods. POAG patients are known to have greater IOP fluctuations throughout the 24-hr cycle than do non-glaucomatous patients,[181] (Evidence Grade: D) and long-term IOP variation is a significant factor in NTG progression.[182] (Evidence Grade: B)

Monitoring the circadian IOP pattern may help the clinician to better manage glaucoma, mainly when progression occurs despite apparently adequate IOP control.[183] (Evidence Grade: D) Clinicians should also consider the significantly higher supine IOP typically peaking in early morning, which may be missed with normal in-office IOP measurements. This may be useful in unexplained progressive glaucoma.[184] (Evidence Grade: D)

> ***Clinical note:*** *It may be helpful to obtain several IOP measurements at different times of day prior to initiating treatment to help establish a baseline IOP from which to judge treatment effectiveness. Tonometry should be performed before gonioscopy and pupil dilation.*

3. Gonioscopy

The diagnosis of POAG requires the ruling out of angle closure glaucoma (ACG) and other forms of secondary glaucoma. Careful gonioscopic evaluation of each anterior chamber angle will help determine the presence of ACG, pigment dispersion, peripheral anterior synechiae, angle recession or neovascularization.

> ***Clinical note:*** *Gonioscopy is superior to the Van Herick technique to evaluate the anterior chamber angle in both differentiation of POAG from ACG, as well as determining whether it is safe to pharmacologically dilate the pupil.[185] (Evidence Grade: B)*

Anterior segment-optical coherence tomography (AS-OCT) demonstrates good sensitivity for differentiating between an open angle and a closed angle. However, it should not serve as a replacement for gonioscopy.[186] (Evidence Grade: A) Clinicians should consider whether the diagnostic accuracy of AS-OCT is acceptable for their specific clinical use before adopting it.

4. Pachymetry

Measurement of central corneal thickness (CCT) is indicated as part of the evaluation of the patient with suspected glaucoma or OH.[187] CCT is not only a critical measure at initial presentation to help the clinician evaluate POAG risk, but also the risk of both progression and severity.[188] (Evidence Grade: C) This procedure is generally performed once for purposes of assessing POAG risk but may be repeated as medically necessary.

Reduced CCT of 555um or less was found to be a powerful predictive factor for conversion from OH to POAG in the OHTS.[7] (Evidence Grade: B) POAG predictive models, however, do not improve by adjusting IOP for CCT even while IOP and CCT remain individually significant.[189] (Evidence Grade: B)

> ***Clinical note:*** *Thin corneas (e.g., from keratorefractive surgery or corneal ectatic diseases) can give misleadingly low IOP readings, which may be mistaken for "normal range" IOP readings.[190,191]*

5. Structural Assessment

The following tests can provide evidence of structural changes:

a. Ophthalmoscopy

Careful binocular ophthalmoscopy of the ONH through a dilated pupil with sufficient magnification to evaluate glaucomatous damage is essential. The optic nerve size, both horizontal and vertical meridians, and cup-to-disc (C/D) ratio should be evaluated and recorded.

> ***Clinical note:*** *If the vertical or horizontal C/D ratio is not the largest, the clinician should note the meridian with the largest C/D ratio.*

This assessment may be documented with (stereo) photography or a detailed drawing. Clinical biomicroscopic examination of the optic nerve and nerve fiber layer yields a true stereoscopic view of the structures that may reveal glaucomatous features that are not visible from imaging technology (e.g., optical coherence tomography), such as optic DH and cases of severe glaucoma.[192] Direct monocular ophthalmoscopy views of the ONH may be of additional value in some instances where greater magnification is more helpful than stereoscopic impressions.

Unfortunately, there are no pathognomonic glaucoma-specific ONH characteristics. But the following are all suggestive of possible glaucomatous ONH damage:

- Vertical elongation of the cup - Especially cupping 0.7-disc diameters or greater.
- Asymmetry between the two cups - A 0.2-disc diameters or greater difference in either axis in the absence of other known etiologies (e.g., anisometropia, asymmetric disc size). While observation of vertical C/D ratio asymmetry should initiate a more comprehensive glaucoma workup, it is not an appropriate standalone screening tool for glaucoma.[193] (Evidence Grade: D)
- Optic disc size - Accurate identification of glaucomatous optic neuropathy is significantly influenced by optic disc size. Optic discs meeting structural criteria for glaucoma are larger than normal nerves.[194] Typically, large diameter ONHs have corresponding larger cups, which can be clinically deceiving. Misdiagnosis is more likely when observing glaucomatous smaller ONHs and normal larger ONHs.[195] (Evidence Grade: B)
- RNFL dropout - The loss of retinal ganglion cell axons leads to characteristic changes in the optic nerve appearance such as an inferior temporal and/or superior temporal wedge-shaped RNFL defect. These defects are usually seen in association with notching of the neuro-retinal rim, vertical elongation of the cup or following disc hemorrhages (DH).[196,197]
- Narrowing or notching of the optic disc rim - The normal ONH neuro-retinal rim is widest inferiorly, followed in width by the superior rim, then the nasal rim, and least at the temporal rim. The mnemonic for this clinical observation has been termed the "ISNT rule,"[198] violations of which should lead the clinician to consider glaucoma as a diagnosis. Myopic tilted discs are particularly challenging, however, so the clinician may have to consider other signs for diagnosis and monitoring.[199,200]
- Acquired pits of the optic nerve (APON) - Patients with APON show a significantly faster rate of VF deterioration, specifically faster decay rate in mean deviation (MD), Visual Field Index (VFI) and Glaucoma Rate Index (GRI), than do non-APON POAG patients.[201] (Evidence Grade: B)
- Retinal arteriolar narrowing - Early vascular changes involved in the pathogenesis of glaucoma suggest that quantitative measurements of retinal vessel caliber from retinal photographs may be useful to identify people with an increased risk of developing POAG.[202]
- Vascular signs - ONH signs of blood vessel baring, bayoneting or nasalization may be noted clinically.[203,204]

- Optic DH - Patients with DH have a greater risk of developing POAG across many populations.[205,206] DH has a 20% positive predictive value of glaucomatous optic nerve damage and there is a higher frequency of DH in NTG than in POAG.[207] (Evidence Grade: D) Predictive factors for DH in POAG are a smaller neuro-retinal rim and perhaps larger β-zone parapapillary atrophy.[208] (Evidence Grade: B) DH in NTG was associated with migraine, baseline narrower neuro-retinal rim width, low systolic BP, mean arterial ocular perfusion pressure and use of systemic beta-blockers.[209] (Evidence Grade: A)
- β-zone parapapillary atrophy - Glaucomatous eyes, with β-zone parapapillary atrophy, are at increased risk for progressive RNFL thinning.[210] The volume of choroid adjacent to the ON was significantly reduced in POAG eyes when β-zone parapapillary atrophy was present. This suggests that β-zone parapapillary atrophy may be a measurable factor for juxtapapillary choroidal atrophy and associated POAG vascular compromise.[211] (Evidence Grade: B)

  Clinical note: *Clinicians should consider any loss of RNFL in the parapapillary β-zone, any thinning of the RNFL and/or any defects or arcuate gaps suggestive of RGC damage.*

b. Fundus Photography

Results from the OHTS revealed that stereophotographic assessment is more sensitive at detecting optic DH than clinical examination.[212] Serial color ONH stereophotography has been considered a complementary method for documenting qualitative ONH appearance and for following any changes to assist in monitoring various types of glaucoma.[213] Although stereoscopic slide film has traditionally been the gold standard technology, film has now been displaced by digital imaging in photography. Compressed two and three-dimensional digital imaging is comparable to previous film for this application.[214] (Evidence Grade: C)

The classification of glaucomatous ONH features on stereophotographs such as vertical C/D ratio and neural retinal rim width (especially the inferior-temporal rim) can differentiate healthy eyes from those with or suspected of glaucoma by standard automated perimetry (SAP) and spectral domain-optical coherence tomography (SD-OCT).[215] (Evidence Grade: D) However, stereophotographic signs of focal damage (e.g., neuro-retinal rim thinning, RNFL loss) could also be due to intrasubject variability and limitations in stereophotography to define the optic disc margin.[216] (Evidence Grade: C)

Although a useful source of cross-sectional data, clinical and photographic review of glaucoma progression is less sensitive to changes over time. In fact, when using stereophotographs to detect progression, it is difficult to achieve consensus, even among glaucoma experts.[217,218] OCT overcomes some of the limitations of the clinical evaluation and can be used to provide objective and quantifiable measurements of the RNFL, ONH and macula, which are useful for glaucoma diagnosis and progression analysis.[219]

c. Optical Coherence Tomography

Computer-based digital imaging provides quantitative information to supplement the clinical examination. OCT is useful for documenting the status and progression of the ONH, RNFL and other aspects of the posterior segment. Objective structural analysis with OCT is complementary to subjective functional analysis such as VF testing for monitoring glaucoma progression. Generally, structural glaucomatous characteristics can be observed clinically before functional loss is evident.

Because no clinical test can be expected to demonstrate 100% sensitivity and specificity, relying solely on automated imaging classification to diagnose glaucoma or using this as a replacement for VF testing is not recommended.[192] Clinicians should incorporate OCT results into the broader clinical assessment of their patients, including other related factors (e.g., age, IOP, clinical ONH/RNFL examination, CCT, family history and VF status).

Use of OCT enables objective quantitative assessment of glaucomatous structural loss. SD-OCT provides objective and reliable data on peripapillary nerve fiber layer, macular ganglion cell (MGC) thicknesses and ONH parameters.

OCT Assessment of the ONH

OCT can image and measure clinically/photographically invisible extensions of Bruch's membrane (BM) inside the disc margin and accounts for the rim tissue orientation.[220] The two-dimensional parameter Bruch's Membrane Opening-Minimum Rim Area (BMO-MRA) shows comparable levels of diagnostic power to detect glaucoma compared to established parameters such as RNFL thickness.[221] In the setting of tilted discs, OCT-derived Bruch's Membrane Opening-Minimum Rim Width (BMO-MRW) analysis provides significantly greater specificity than RNFL irrespective of the refractive error, and it is more specific than Ganglion Cell Analysis (GCA) in tilted discs with moderate myopia.[222] In addition, rim area measurement accuracy was not affected by disc size in one study using a high-definition OCT.[223] (Evidence Grade: B)

OCT Assessment of the Retinal Nerve Fiber Layer

SD-OCT measured RNFL thickness parameters (global, inferior and superior) performed well in detecting (but not necessarily following progression in) glaucoma across the disease spectrum, but both increased myopia and age might be challenging confounding factors.[224] (Evidence Grade: D) Asymmetry of OCT derived RNFL thickness profiles between an individual's two eyes may be as helpful in diagnosing glaucoma as comparisons with normative data.[225] (Evidence Grade: B) SD-OCT demonstrates RNFL loss in the contralateral eyes of patients with previously diagnosed unilateral glaucoma progression (by VF and stereophotographic changes).[226] (Evidence Grade: C) OCT also provides quantitative information about the ONH, RNFL and ganglion cell layers (peripapillary and macular) with high reproducibility and is useful in detecting onset of glaucoma stages.[227] (Evidence Grade: B)

> ***Clinical note:*** *OCT RNFL thickness measurement may be more effective at detecting glaucoma progression than VF evaluation in patients with mild VF defects.[228] (Evidence Grade: C)*

Characteristic patterns of the OCT deviation map can provide useful clues to distinguish glaucomatous changes from false-positive findings.[229] (Evidence Grade: D) Research has demonstrated the overall rate of false-positive diagnostic classification of SD-OCT GCA and RNFL maps as 40.4% and 30.8%, respectively. Abnormal GCA diagnostic classification was associated with longer axial length and larger fovea-disc angle, whereas longer axial length and smaller disc area were associated with abnormal RNFL diagnostic classification.

Within RNFL scans, the nasal and temporal parameters are more poorly diagnostic than the average superior and inferior parameters. The diagnostic capacity of OCT measured RNFL is similar to segmented macular regions and better than total macular thickness.[230] (Evidence Grade: A)

SD-OCT localized RNFL thinning and rates of change are modestly statistically associated with pointwise 24-2 VF sensitivity loss at all locations.[231] (Evidence Grade: B) OCT RNFL thickness assessment was able to detect glaucomatous change before the appearance of Humphrey visual field (HVF) 24-2 [Swedish Interactive Threshold Algorithm (SITA)] changes,[232] (Evidence Grade: C) especially during early stages of disease. Some patients, however, have a glaucomatous VF without detectable structural abnormalities.[233] Additionally, an increase in disease severity at baseline increased the chance that the eye would be detected as progressing by SAP but not SD-OCT.[234] The extent to which structural and functional glaucomatous damage agree likely depends upon various factors, such as the particular test and test measures used, and the baseline conditions for a particular patient.[235,236]

OCT Assessment of Macular Ganglion Cells

Decreases in macular thickness that are believed to be due to loss of RGCs and that correlate significantly with glaucoma status of both RNFL thickness and VF defects have been reported in glaucomatous eyes. Macular thickness changes are well correlated with changes in visual function and RNFL structure in glaucoma[237] and may be a surrogate indicator of RGC loss.[238]

Macular measurements are particularly helpful in glaucoma progression analysis by SD-OCT due to the high density of ganglion cells in this area and the frequent early involvement of the macula in the glaucomatous process.[239] (Evidence Grade: D) SD-OCT data also suggests that segmented inner plexiform layer (IPL) thicknesses [RNFL, ganglion cell layer, ganglion cell-inner plexiform layer (GCIPL), macular GCC] are all reduced in association with POAG degree.[240] However, measuring the whole macular thickness as a surrogate for glaucoma has the disadvantage of taking into account cell layers (e.g., outer retinal layers) that are not affected in glaucoma, thus obscuring the actual contribution of the RGC layer to the process.[241]

Focusing macular scans on the retinal nerve fiber and ganglion cell layers may increase the predictive value of these scans. Whether or not to combine or separately analyze the IPL in macular OCT scans is unclear. Preliminary work isolating the IPL has suggested a glaucoma-related increase in IPL density, along with the altered reflectance pattern. This may be a consequence of dendritic remodeling (and accompanying mitochondrial redistribution for synapse maintenance and/or glial response for tissue cleaning), rather than dendrite atrophy, even in the absence of detectable alterations in the RGC layer and RNFL.[242] Combined or not, the influence of glaucoma on macular layers may be particularly useful in assessment of glaucomatous eyes with tilted discs or significant peripapillary atrophy.[243] (Evidence Grade: C)

Combining RNFL and Macular Ganglion Cell Assessments

Combining optic nerve parameters, RNFL and macular ganglion cell SD-OCT structural measurements improves the diagnostic sensitivity for glaucoma compared with any one of these variables while maintaining high specificity.[244] (Evidence Grade: D) Careful observation of both the average 6 and 11 o'clock RNFL sectors and inferotemporal and minimum GCIPL thicknesses can be particularly helpful for evaluating glaucoma progression by SD-OCT.[245]

- OCT-Angiography

Because there is evidence of vascular dysfunction in glaucoma pathogenesis, highly repeatable and reproduceable OCT-A measurement of both peripapillary retina and macula vascular density may be useful.[246-248] OCT-A can image glaucomatous peripapillary capillary density changes[249] (Evidence Grade: B), which significantly corelates with VF damage severity independent of structural loss.[250] (Evidence Grade: D) Although OCT-A has shown promise in monitoring glaucoma, evidence to date of reliability has been conflicting.

6. Functional Assessment

a. Visual Fields

Evaluating visual function with standard automated perimetry (SAP) is a fundamental test for detecting VF loss and for monitoring the rate of VF change over time. SAP is used to evaluate the threshold sensitivity within the central 10 degrees, 24 degrees and 30 degrees from fixation using varying stimulus size to detect a VF defect. If SAP cannot be performed, then an alternative form of testing for diagnosing and monitoring glaucoma, such as threshold frequency doubling technology (FDT), can be considered.[251] (Evidence Grade: B)

Although classically POAG damages the peripheral VF (in patterns such as arcuate scotomata, nasal steps, generalized depression and temporal wedge defects), glaucomatous patients also suffer paracentral vision loss.[7,252,253] Macular damage (within 8 degrees of the central field) to retinal ganglion cells and associated central VF defects may occur in glaucoma, even in early stages. A 10-2 VF testing model showed a stronger association with the National Eye Institute Visual Function Questionnaire (NEI-VFQ)-25 score than did a 24-2 VF model. Patients with disproportionately low quality of vision relative to patients with 24-2 VF damage may have damage on the central field missed by the 24-2 grid.[254] (Evidence Grade: C)

Perimetry is subjective and highly variable. Therefore, it is important to confirm VF defects in patients who have glaucoma and who are glaucoma suspects.[7,255] When a VF defect is detected by SAP, it is preferable to confirm the

defect with the same VF testing modality. Confirming VF abnormalities increases confidence in the functional status of patients.[256] (Evidence Grade: D)

SAP VFs also have special value in helping clinicians distinguish between rapid and slow POAG progressors, which assists in determining the aggressiveness of therapeutic intervention. Three examinations per year are required to identify an overall change in MD of 4 dB over two years in a patient with average visual field variability.[257]

EVIDENCE-BASED ACTION STATEMENT: The examination of a person suspected of having primary open-angle glaucoma (POAG) should include all aspects of a comprehensive eye and vision examination, with emphasis on the evaluation of the anterior chamber angle, optic nerve head (ONH), peripapillary retinal nerve fiber layer (RNFL), macula and visual fields (VF), and measurement of intraocular pressure (IOP) and central corneal thickness (CCT).[71,77,179,185,188,227]
Evidence Quality: Grade B, Study type(s): Diagnostic, Case Control, Cohort-prospective, Cohort-retrospective, Cross-sectional **Level of Confidence:** Medium. **Clinical Recommendation Level:** Recommendation. This recommendation should generally be followed but remain alert for new information.
Evidence Statements: Any elevated IOP is a strong factor for glaucoma development or progression.[71] (Evidence Grade: B) Therefore, it is an important test for use in the diagnosis and monitoring of OH or POAG. Gonioscopy is superior to the Van Herick technique to evaluate the anterior chamber angle in differentiation of POAG from ACG.[185] (Evidence Grade: B) OCT provides quantitative information about the ONH, RNFL and ganglion cell layers (peripapillary and macular) with high reproducibility and is useful in detecting onset of glaucoma stages.[227] (Evidence Grade: B) Central corneal thickness (CCT) is not only a critical measure at initial presentation to help the clinician evaluate POAG risk, but also the risk of both progression and severity.[188] (Evidence Grade: C) IOP measurement with either rebound tonometry or Tonopen are comparable to Goldmann applanation tonometry but are not interchangeable.[179] (Evidence Grade: C) Clinicians should obtain an in-depth family history of glaucoma, which should be continually updated during follow-up visits based on the importance of genetics in glaucoma.[77] (Evidence Grade: D)
Potential Benefits: Enhanced ability to effectively diagnose and manage patients with POAG and OH. / **Potential Risks/Harms:** None.
Benefits and Harms Assessment: Benefits significantly outweigh harms.
Potential Costs: Direct and indirect cost of testing.
Value Judgments: None.

Role of Patient Preferences: Moderate.
Intentional Vagueness: None.
Gaps in Evidence: Research is needed to further evaluate the utility of anterior segment-optical coherence tomography (AS-OCT), including longitudinal studies to determine the significance of eyes classified to have closed angles by AS-OCT but open by gonioscopy.

7. Primary Open-Angle Glaucoma Staging Systems

Staging systems allow classifying patients according to the severity of their disease. Staging also gives clinicians an opportunity to explain to their patients the relative severity of their condition and to monitor the course of patients' disease, whether stable, worsening or improving.[258]

Several POAG and VF staging systems (e.g., Hodapp-Parish-Anderson, Bascom Palmer Glaucoma Staging System, Enhanced Glaucoma Staging System, Visual Field Index) have been proposed to facilitate both proper diagnosis, care, and medical coding.[259,260] Some use criteria from the AGIS or the CIGTS.[233,261,262] Glaucoma staging systems (GSSs)[263] typically score VF defects and no other clinical factors such as ONH and nerve fiber layer evaluations. Each GSS has its own distinct advantages and disadvantages and stage severity differently.[264] Also, as these staging paradigms do not utilize macular measures, disease severity could be underestimated in at least some patients.265

The Mean Deviation (MD) Index can also be used to clinically stage the severity of glaucoma. It measures the average difference between a patient's overall visual field sensitivity compared to an age-matched reference database. AGIS and CIGTS scores and MD VF indices are more or less equivalent and relate to structural measurements equally.[266] (Evidence Grade: D)

The International Classification of Diseases -10th revision (ICD-10)[267] has staged glaucoma into mild, moderate or advanced disease. The following staging applies to all forms of glaucoma, including POAG:

- Mild or Early: Definite optic disc, RNFL or macular imaging abnormalities consistent with glaucoma and no visual field abnormalities.
- Moderate: Definite optic disc, RNFL or macular imaging abnormalities consistent with glaucoma and visual field abnormalities in one hemifield that are not within five degrees of fixation.
- Advanced, Late, Severe: Definite optic disc, RNFL, or macular imaging abnormalities consistent with glaucoma and visual field abnormalities in both hemifields and/or loss within five degrees of fixation in at least one hemifield.
- Indeterminate: Inability of patient to perform visual field testing, unreliable/uninterpretable visual field test results or visual fields not yet performed.

IV. TREATMENT AND MANAGEMENT OF PRIMARY OPEN-ANGLE GLAUCOMA

Medical, laser and surgical treatments for open-angle glaucoma lower intraocular pressure and reduce the risk for optic nerve damage over the short- to medium-term. However, the direct effect of treatments on visual impairment and the comparative efficacy of different treatments are not clear.[268] (Evidence Grade: A)

The goal of treatment is to minimize the risk of visual impairment over the lifetime of the patient while also minimizing the expense and side effects of treatments. An individualized treatment plan should be developed and modified based on the aggressiveness of the disease and may utilize medical, laser and/or surgical interventions alone or in combination. *(See Appendix 1: Optometric Management of the Patient with Open-Angle Glaucoma: A Flowchart)*

A. DETERMINING A TARGET PRESSURE

As reducing IOP continues to be the primary treatment of all types of OAG, often a "target IOP" or "target range of IOP," specific or approximate, is determined as well as the time course of additional monitoring examinations. The goal of establishing a "target pressure" for treating patients with POAG is to maintain their IOP within a range at which visually significant VF loss is unlikely to occur. The specific target pressure is initially an estimate and may be determined as a percentage reduction from the patient's baseline IOP or as an absolute IOP level.[269]

Factors clinicians should consider when choosing a target pressure range include baseline IOP, the degree of optic nerve damage and/or VF loss, age of patient and prior rate of progression.[8] In mild glaucoma, the initial target IOP range could be set at 15-17 mmHg, for moderate glaucoma 12-15 mmHg, and in the severe stage of glaucomatous damage 10-12 mmHg.[270] The IOP target range may also be based on a percentage reduction from baseline. (See Table 4)

The effectiveness of the target pressure chosen should be periodically reevaluated by comparing optic nerve status and VF testing with results from previous examinations. The target IOP may change depending on the results of long-term monitoring.

Table 4:
Baseline IOP, IOP Reduction Goal, Progression and Clinical Endpoint in Studies of Open-Angle Glaucoma

Study	Baseline IOP	IOP Reduction	Progression	Clinical Endpoint
Ocular Hypertension Treatment Study[271]	24.9 mmHg	20%	4.4% in treated patients/9.5% in untreated	19.3 mmHg
Early Manifest Glaucoma Trial[272]	20.6 mmHg	25%	45% in treated patients/62% in untreated	Mean reduction 5.2 mmHg
Collaborative Normal Tension Glaucoma Study[12]		30%	12% in treated patients/35% in untreated	
Collaborative Initial Glaucoma Treatment Study[167]				
(Medical treatment)	27 mmHg	38%	15% progressed and 15% improved	17-18 mmHg
(Surgical treatment)	27 mmHg	46%		14-15 mmHg
Advanced Glaucoma Intervention Study[9]	23.7 -24.8 mmHg	IOP mean 12.3 mmHg	Did not progress	
Stewart, et al. Factors associated with long-term progression or stability in POAG.[273]	19.5 ± 3.8 mmHg		0% 6% 26%	<12 mmHg <17 mmHg ≥18 mmHg

Adapted from reference #270: Sihota R, Angmo D, Ramaswamy D, Dada T. Simplifying "target" intraocular pressure for different stages of primary open-angle glaucoma and primary angle closure glaucoma. Indian J Ophthalmol 2018:495-505.

B. MEDICAL TREATMENT

Medical treatment is generally used initially for most forms of POAG. Topical treatment is minimally invasive and avoids first pass metabolism of drugs in the liver, as well as permitting selective targeting of the ocular anterior chamber. However, only 1-7% of the instilled drug reaches the ocular anterior chamber due to the combined effects of pre-corneal tear drainage, the corneal epithelial layer barrier and patient compliance.[274]

There are several principles of topical treatment:

- Start with the medication that provides the least patient risk and most efficacious treatment, considering ocular and systemic side effects, costs, patient preferences and dosage inconvenience.
- Prostaglandin analogs (PGAs) have been found to provide the best IOP-lowering among all the monotherapy topical drugs. Combining a PGA and another category of topical drug further enhances IOP decrease. Incidents of adverse effects of medication should be considered, not just its IOP-lowering efficacy.[275] (Evidence Grade: A)
- Drugs within a glaucoma medication class share similar mechanisms of action and efficacy, and therefore generally can be expected to result in similar IOP reduction. It is usually best to change class or add a medication of a different class to improve therapy. Switching within a class, however, may minimize systemic or local adverse reactions.[276] (Evidence Grade: D)
- Combining glaucoma medications (e.g., adding a second and perhaps third drop) to the treatment regimen, usually from different classes, may be beneficial to patients who require a lower IOP,[277] (Evidence Grade: A) but use as few medications as reasonable to decrease toxicity and compliance complexity.
- If more than one drug is to be topically applied, educate patients to allow time in between drops of at least three to five minutes to allow for proper absorption.
- Proper eye drop technique helps in achieving good IOP control, decreasing risk of contamination and reducing systemic absorption. Educate patients to avoid touching the bottle tip to the eyes or face, to place just one drop into the inferior cul de sac, and to employ lid and/or nasolacrimal duct closure to enhance drug effectivity while minimizing systemic absorption.[189,278,279]

Multiple pharmaceutical agents are currently available for the treatment of POAG. To access to the most current information on specific medications to treat glaucoma, see the following Glaucoma Research Foundation's online Medication Guide:

Medication Guide | glaucoma.org

1. Prostaglandin Analogs

Prostaglandin analogs (PGAs) increase uveo-scleral outflow and decrease IOP about 25% to 30%. Because of generally good IOP-lowering effectivity,[280] limited systemic and ocular side effects, and once-daily dosing at bedtime (HS), PGAs have become "first-line" treatment for many of the glaucomas.[281] (Evidence Grade: D) Currently available PGAs include bimatoprost, latanoprost, travoprost and tafluprost.

Monotherapy with topical travoprost, for example, was shown to consistently control IOP over 24 hours in a significant proportion of POAG patients.[282] (Evidence Grade: B) Side effects of PGAs can include, but are not limited to, eye color change, darkening of eyelid skin, eyelash growth, ptosis, orbital soft tissue changes, anterior uveitis, cystoid macular edema, stinging, eye redness and itching.

> ***Clinical note:*** *A large meta-analysis concluded that overall, PGAs are more efficacious in lowering IOP at three months than beta-blockers, alpha-agonists or carbonic anhydrase inhibitors. Bimatoprost, latanoprost and travoprost are among the most efficacious drugs at lowering IOP, and the within class differences are small and may not be clinically meaningful.[283] (Evidence Grade: A)*

EVIDENCE-BASED ACTION STATEMENT: The use of prostaglandin analogs (PGAs) should be considered as an initial therapy in patients with ocular hypertension (OH) or primary open-angle glaucoma (POAG), unless contraindicated.[275,283]
Evidence Quality: Grade A. Study type(s): Systematic Reviews **Level of Confidence:** High **Clinical Recommendation Level:** Strong Recommendation. This recommendation should be followed unless clear and compelling rationale for an alternative approach is present.
Evidence Statements: PGAs have been found to provide the best IOP-lowering among all the monotherapy topical drugs. Combining a PGA and another category of topical drug further enhances IOP decrease. Incidents of adverse effects of medication should be considered, not just its IOP-lowering efficacy.[275] (Evidence Grade: A) Overall, PGAs are more efficacious in lowering IOP at three months than beta-blockers, alpha-agonists, or carbonic anhydrase inhibitors. Bimatoprost, latanoprost and travoprost are among the most efficacious drugs at lowering IOP, and the within-class differences are small and may not be clinically meaningful.[283] (Evidence Grade: A)

Potential Benefits: Preventing and/or minimizing vision loss.	**Potential Risks/Harms:** Side effects of medication.

Benefits and Harms Assessment: Benefits significantly outweigh harms.
Potential Costs: Cost of medication.
Value Judgments: None.
Role of Patient Preferences: Moderate.
Intentional Vagueness: None.
Gaps in Evidence: Research on current medical treatments compared with surgery is needed, particularly for people with severe glaucoma and in ethnic groups.

2. Adrenergic Antagonists (Beta Blockers)

Betaβblockers (β-blockers) act by inhibiting ultrafiltration in the ciliary body, thereby limiting aqueous humor secretion. Ophthalmic β-blockers can be either non-selective (inhibiting both β1 and β2 receptors) or cardio-selective (inhibiting β1>β2). Non-selective β-blockers have greater IOP-lowering effects but also more systemic side effects. β-blockers include timolol maleate, levobunolol, metipranolol and betaxolol HCL.

Ocular side effects are usually mild but include dry eye, lid ptosis, conjunctival hyperemia, corneal anesthesia and blurred vision. Non-selective β-blockers should be avoided in patients with asthma, chronic obstructive pulmonary disease, atrioventricular block, bradyarrhythmia, unstable congestive heart failure, depression, myasthenia gravis and persons with DM who are prone to hypoglycemic events or patients using calcium channel blockers. β-blockers also reduce the effectiveness of epinephrine used in anaphylactic crisis and should be avoided in patients who might experience such events.

Clinical note: *Non-selective β-blockers significantly affect lung function and increase asthma morbidity and should be avoided if better, safer agents are available for these patients.[284] (Evidence Grade: A)*

The safety of ophthalmic β-blockers can be increased by minimizing systemic absorption (such as by having the patient practice self-punctal occlusion during drop application).[285] (Evidence Grade: D)

3. Adrenergic Agonists

Adrenergic agonists affect both alpha- and beta-adrenergic receptors, if non-selective, and reduce IOP by both decreasing aqueous formation and resistance at the trabecular meshwork (TM). Brimonidine tartrate and apraclonidine HCL are currently available alpha-adrenergic agonists.

- Non-selective -The side effects of rare cardiac arrhythmias, conjunctival injection and cystoid macular edema, as well as the development of pigment spots on the tarsal conjunctiva, limit current usage.
- Selective alpha-2 receptor agonists - These drugs are contraindicated in patients taking monoamine oxidase (MAO) inhibitors (risk of hypertensive crisis) and in children (risk of cardiorespiratory and central nervous system depression). They may potentiate syndromes associated with vascular insufficiency and may cause, but are not limited to, lid retraction, anterior uveitis, fatigue/drowsiness, dizziness and dry nose/mouth. There are also concerns for the development of both allergic (especially follicular) conjunctivitis, dermatitis and tachyphylaxis, especially with use of apraclonidine.[286,287] (Evidence Grade: D)

4. Carbonic Anhydrase Inhibitors

Carbonic anhydrase inhibitors (CAIs) are known to lower IOP by suppressing aqueous production through blockade of carbonic anhydrase in local tissues, increasing CO2 and/or lowering pH to result in vascular dilation and increased blood flow. CAIs include acetazolamide, brinzolamide, dorzolamide HCL and methazolamide.

Allergies and previous reactions to sulfa drugs may limit the use of CAIs. Topical CAIs (e.g., dorzolamide, brinzolamide) have fewer systemic concerns and may be used as monotherapy, though they are most often used in combination with other glaucoma medications.

5. Rho-kinase Inhibitors

Rho-kinase inhibitors (e.g., netarsudil) decrease IOP 25% to 30% by decreasing TM resistance.[288,289] (Evidence Grade: D) These medications may serve well as adjuncts to established glaucoma medications.

Local side effects include blurred vision, tearing, conjunctival hyperemia and hemorrhage, cornea haze and verticillate. Despite more patients using netarsudil choosing to discontinue treatment due to adverse effects than those using timolol or latanoprost, netarsudil works well with lower IOPs and may have a role in treating NTG.[290] (Evidence Grade: D)

6. Cholinergic Agents

Cholinergic agents act by stretching the TM, which decreases IOP by increasing trabecular aqueous outflow.[291,292] Available medications include pilocarpine HCL and carbachol. Cholinergics can be used alone or combined with other glaucoma medications.

Ocular and systemic side effects include miosis, ciliary muscle spasm (leading to increased myopia and brow-headaches in patients capable of accommodation), stinging and burning, posterior synechiae, narrowed anterior chamber angle, cataract, retinal detachment, brachycardia, bronchospasm, central nervous system depression and gastrointestinal distress. These side effects and the need for frequent dosing limit current use.[291,292]

7. Combination Products

POAG patients commonly benefit from the synergy of the concomitant use of several classes of IOP-lowering topical agents. When dual therapy is indicated, offering a single bottle with multiple active drugs may enhance patient adherence and compliance, while decreasing complexity, inconvenience, (preservative) toxicity and perhaps cost.[281] (Evidence Grade: D)

Many such combinations are available in both commercial and compounded preparations including:

- A brinzolamide 1%/brimonidine 0.2% combination showed good 24hr IOP-lowering efficacy[293] while reducing the treatment burden in patients who require multiple IOP-lowering medications.[294] (Evidence Grade: A)
- A fixed combination of dorzolamide/timolol was found to be both safe and effective in treating NTG.[295] (Evidence Grade: B)
- A fixed combination of latanoprost and netarsudil lowered IOP more than either drug alone.[296] (Evidence Grade: D)
- Non-preserved fixed combination timolol/dorzolamide drops were effective at reducing IOP and better tolerated in benzalkonium chloride (BAK)-sensitive patients than preserved drops.[297] (Evidence Grade: B)
- Both brimonidine/timolol and dorzolamide/timolol therapies tended to increase OPP and retrobulbar blood flow, with no statistically significant differences between treatments after one month in patients with POAG and well-controlled IOP.[298] (Evidence Grade: B)

8. Generic Formulations

Ophthalmic generic drugs must have therapeutic equivalence and be identical in strength, dosage form, route of administration, have the same indications/contraindications and abide by the same Good Manufacturing Practices as the innovator agent. A meta-analysis noted no evidence of difference between generic and original formulations of ophthalmic PGAs regarding efficacy or tolerability.[299] (Evidence Grade: A) For example, both generic latanoprost and Xalatan (brand name of latanoprost) were effective in reducing IOP about 28% in one study.[300] (Evidence Grade: A)

Generic compounds may differ from innovator agents with regards to performance under environmental stress, relative acidity, and bottle size/rigidity. Matching ingredient profiles may therefore not result in consistently comparable drug compositions and clinical effects.[301] (Evidence Grade: D)

9. Relative Effectivity Trials

Several studies have shown the effectiveness of different topical medications in lowering IOP:

- In both POAG and OH patients, latanoprost, brimatoprost and travoprost are equally effective at lowering IOP, equally well tolerated systemically, but significantly fewer patients reported ocular hyperemia with latanoprost.[302] (Evidence Grade: A)
- Topical latanoprost and bimatroprost produce a statistically significant IOP reduction compared to timolol but are associated with a higher risk of conjunctival hyperemia.[303] (Evidence Grade: A)
- Both bimatoprost .001% and timolol 0.5% lower mean 24hr IOP effectively, but timolol is not as effective in nocturnal IOP control.[304] (Evidence Grade: B)
- Tafluprost had better overall IOP-lowering effect when compared to timolol 0.5% with decreased diurnal IOP and fewer overall adverse events.[305] (Evidence Grade: B)
- Brimonidine provides greater IOP-lowering efficacy than topical CAIs as adjunctive therapy to β-blockers or PGAs. Alpha adrenergics, as adjunctive therapy, seem to be better tolerated than CAI adjunctive therapy.[306] (Evidence Grade: B)

- Unpreserved timolol gel 0.1% maintained the efficacy of preserved latanoprost drops and reduced intolerance signs and symptoms in almost all OAG or OH patients using preserved latanoprost.[307] (Evidence Grade: B)
- Latanoprostene bunod 0.024% dosed once in the evening is well tolerated and is non-inferior to timolol 0.5% used twice a day. It results in significantly reduced mean diurnal IOP over three months of treatment in both OAG and OH patients.[308] (Evidence Grade: A) Latanoprostene bunod used every evening demonstrated greater IOP-lowering effect throughout the day than timolol used twice a day over three months of treatment. The drug was found to be safe in adults with POAG and OH.[309] (Evidence Grade: A)

10. Sustained Drug Delivery

The glaucoma treatment paradigm may soon undergo changes as novel sustained drug delivery systems become available to individuals with OH or POAG. Several options (e.g., ocular inserts, medication-eluting contact lenses, intraocular implants) will likely become available soon to ease the burden of daily topical administration of chronic therapy with IOP-lowering drugs.[310] (Evidence Grade: D)

11. Ocular Surface Disease in Glaucoma Therapy

Glaucoma patients using topical IOP-lowering therapy have a significantly higher prevalence of ocular surface disease (OSD) symptoms than is found in the general population.[311] (Evidence Grade: B)[312] (Evidence Grade: C) This is probably related to the drop preservatives, long treatment durations and patient's age.[313] (Evidence Grade: D) More attention should, therefore, be given to the ocular surface status of patients on long-term anti-glaucoma medications with consideration for alternatives that have a less toxic effect on the ocular surface.[314] (Evidence Grade: C)

Active ingredients, preservatives, the number of concomitant drugs, and the number of eye drops instilled per day are felt to all be elements able to induce different ocular surface changes, potentially with synergistic effects.[315] (Evidence Grade: B) There is insufficient evidence, however, to suggest that patients without OSD need to use preservative-free glaucoma medications, especially if they require few medications (defined as 1-2 drops/day).[316] (Evidence Grade: B)

Anti-glaucoma medications have shown toxic effects on conjunctival epithelium,[317] (Evidence Grade: B) meibomian glands,[318] (Evidence Grade: D) and the development of dry eye symptoms.[319] (Evidence Grade: C) Use of combinations of anti-glaucoma topical medications were also found to be a contributing factor for the development of lacrimal duct obstruction.[320] (Evidence Grade: D) Chronic use of preserved topical drops may affect the ocular surface indigenous bacterial flora. The long-term use of preserved PGA drops has been found to affect bacterial resistance to antibiotics.[321] (Evidence Grade: C)

Preservative free eye drops are associated with less ocular irritation symptoms than preserved eye drops.[322] (Evidence Grade: D) The use of less toxic ophthalmic preservatives or the reduction of the number of preserved eye drops used per day can significantly reduce some clinical OSD signs.[323] (Evidence Grade: D) Reducing exposure to preservatives may lessen adverse events, which may lead to better tolerability, higher adherence and lower treatment discontinuation in patients treated with glaucoma medications. Preservative-free formulations may provide clinically relevant benefits for patients who are highly sensitive to preservatives because of preexisting or concomitant ocular surface disease, who receive a combination of two or more drugs, who are at risk for undergoing surgery, or who will need treatment for several decades.[324] (Evidence Grade: D)

> ***Clinical note:*** *Recognition and treatment of OSD in glaucoma patients may improve patient quality of life, medication adherence, and both patient and physician satisfaction.[325] (Evidence Grade: D)*

Controlling OSD may lead to improved management of glaucoma.[326] Co-treatment for osmo-protection with an artificial tear solute of 0.5% carboxymethylcellulose and 0.9% glycerin significantly improved the ocular surface of patients taking topical β-blockers or PGAs[327] (Evidence Grade: B) and improved IOP control.[328] (Evidence Grade: D)

Even though many POAG patients using preserved topical medications present with OSD signs and symptoms, many remain highly satisfied with their treatments. Treatment change should be considered, however, with either clinical signs or patient reported symptoms.[329] (Evidence Grade: D)

EVIDENCE-BASED ACTION STATEMENT: Patients prescribed topical intraocular pressure (IOP) lowering therapy may experience decreased tear film stability and elevated tear osmolarity and should be evaluated for ocular surface disease (OSD).[311,312,314,315,317-319,323,325]
Evidence Quality: Grade C. Study type(s): Cohort-prospective, Cohort-retrospective, Case Control, Cross-sectional, Review/Position paper, Case Series **Level of Confidence:** Medium **Clinical Recommendation Level:** Recommendation. This recommendation should generally be followed but remain alert for new information.
Evidence Statements: Glaucoma patients using topical IOP-lowering therapy have a significantly higher prevalence of ocular surface disease (OSD) symptoms than is found in the general population.[311] (Evidence Grade: B) [312] (Evidence Grade: C) Active ingredients, preservatives, the number of concomitant drugs, and the number of eye drops instilled per day are felt to all be elements able to induce different ocular surface changes, potentially with synergistic effects.[315] (Evidence Grade: B) Anti-glaucoma medications have shown toxic effects on conjunctival epithelium,[317] (Evidence Grade: B) meibomian glands,[318] (Evidence Grade: D) and the development of dry eye symptoms.[319] (Evidence Grade: C) More attention should be given to the ocular surface status of patients on long-term anti-glaucoma medications with consideration for alternatives that have a less toxic effect on the ocular surface.[314] (Evidence Grade: C) The use of less toxic ophthalmic preservatives or the reduction of the number of preserved eye drops used per day, can significantly reduce some clinical OSD signs.[323] (Evidence Grade: D) Recognition and treatment of OSD in glaucoma patients may improve patient quality of life, medication adherence, and both patient and physician satisfaction.[325] (Evidence Grade: D)
Potential Benefits: Improved ocular surface health and patient adherence to medication use. | **Potential Risks/Harms:** None.
Benefits and Harms Assessment: Benefits significantly outweigh harms.
Potential Costs: Direct and indirect costs of testing.
Value Judgments: None.
Role of Patient Preferences: Moderate.
Intentional Vagueness: None.
Gaps in Evidence: Research to evaluate the complex relationship between glaucoma medication and ocular surface disease.

12. Pharmacological Treatment in Pregnancy

Medical management of the pregnant patient with POAG presents a need to balance the risk of glaucoma progression against concerns for the safety of the fetus. It is important to coordinate ophthalmic care with the patient's obstetrician and neonatologist. Pharmacological treatment of glaucoma during pregnancy and lactation should follow United States Food and Drug Administration (FDA) safety profiles and consider glaucoma severity and pregnancy stage.

Sympathomimetics (e.g., brimonidine) are a Category B IOP-lowering drug with presumed safety in pregnancy based on animal studies, but brimonidine is believed to be secreted in breast milk and should be discontinued late in the third trimester out of concern for central nervous system depression, hypotension and apnea in infants.[330] (Evidence Grade: D) Other IOP-lowering medications (β-blockers, CAIs, PGAs and parasympathomimetics) are all Category C with known side effects in animal studies but no human data.

To minimize exposure to potentially harmful medical therapy, consider early surgical management, especially laser procedures[330] (Evidence Grade: D) in advanced or high-risk patients, and recommend punctal occlusion to minimize systemic absorption in pregnant patients utilizing medical therapies.[331] (Evidence Grade: D) Laser and other surgical glaucoma treatment options are all alternatives to medication except in the first trimester.[332] (Evidence Grade: D)

CONSENSUS-BASED ACTION STATEMENT: Pharmacological treatment of primary open-angle glaucoma (POAG) should be used with caution during pregnancy and lactation.
Evidence Quality: A systematic evaluation of research to support or refute the use of this recommendation was not conducted for this guideline
Benefits and Harms Assessment: Implementation of this recommendation is likely to enhance safety when treating patients with OH or POAG who are also pregnant (prenatal, perinatal, postnatal). The benefits of this recommendation were established by expert consensus opinion.

C. LASER THERAPY

Initially considered as adjunctive treatment for eyes not achieving IOP control with topical medications, selective laser trabeculoplasty (SLT) has become increasingly used for the initial treatment of OH and POAG. This is especially the case for patients at risk due to poor medication adherence and/or professional follow-up compliance.

SLT treatments consist of an application of a series of laser burns to the TM leading to increased outflow facility. Both 180 and 360 degree treatments have been well studied in SLT and are reasonable as initial therapy for POAG and OH.[333] (Evidence Grade: A) The application of 360 degree SLT appears to be an effective treatment with approximately 60% of eyes achieving an IOP reduction of 30% or more.[334] (Evidence Grade: B) Laser trabeculoplasties appear successful in lowering intraocular pressure for patients with OAG.[335]

> ***Clinical note:*** *Laser treatments commonly lose efficacy over time. Therefore, it is important to continue regular monitoring of treated patients.[336] (Evidence Grade: D)*

Acute IOP elevation after laser therapy is a common adverse effect. Most of these IOP elevations are transient, but even temporarily elevated IOP may cause further optic nerve damage, worsening of glaucoma or loss of vision. IOP increase ("spikes") is a concern with heavily pigmented TMs, as is corneal endothelial cell loss. Perioperative medications (apraclonidine or brimonidine) are superior to no medication or placebo to suppress IOP spikes and enhance IOP reduction during the first two hours and up to 24 hours following laser trabeculoplasty.[337] (Evidence Grade: A)

1. Argon Laser Trabeculoplasty

Argon laser trabeculoplasty (ALT) has been shown to be a relatively safe and effective procedure.[338] However, clinically, it has been replaced by SLT in the treatment of POAG.

2. Selective Laser Trabeculoplasty

A systematic review of published studies found that SLT therapy was not inferior to medication-only treatment in IOP reduction and success rate of IOP control. It significantly decreased the mean number of medications needed. SLT was found to be a safe procedure during long-term follow-up and may be a choice of first-line therapy in OAG.[333] (Evidence Grade: A)

SLT uses lower energy than ALT, so it causes less tissue damage and therefore is repeatable. Patients who demonstrate an initial IOP decrease from SLT with subsequent loss of effect over time should expect a similar result from a repeat SLT.[339] (Evidence Grade: C) In those glaucoma patients who may benefit from repeat SLT, either SLT or ALT were found to be about equal in IOP-lowering effect one year post operative (about 3 mm Hg).[340] (Evidence Grade: A)

Repeat SLT is effective at achieving IOP control in OAG and OH eyes requiring retreatment within 18 months of initial SLT. It may provide an equivalent and possibly longer duration of clinical benefit than after initial SLT alone. Repeat SLT is reported to be safe, with minimal laser-related side effects.[341] (Evidence Grade: B) SLT induces little and only short-lived anterior segment inflammation and the IOP-lowering effect of the SLT is not influenced by the use of anti-inflammatory medication after laser treatment.[342] (Evidence Grade: A)

SLT is considered an established and effective glaucoma treatment in early to moderate stages of OAG. It may also be effective in patients with advanced glaucoma, those with moderate IOP elevation on maximum topical medications and those with co-existing systemic diseases or medication (e.g., warfarin, phenprocoumon), which makes filtering surgery difficult or potentially dangerous.[343] (Evidence Grade: B)

In the LiGHT Study, SLT was shown to be a safe and effective drop-free alternative to achieve good IOP control in glaucoma patients for a period of at least three years; 58% of patients were successfully controlled with one treatment while an additional 17% were successful after two treatments. At six-year follow-up, no significant differences were found. SLT is a safe treatment for OAG and OH, providing better long-term disease control than initial drop therapy, with reduced need for incisional glaucoma and cataract surgery.[161] (Evidence Grade: A)

SLT offers a promising primary treatment strategy for POAG patients in lieu of topical drop glaucoma regimen, with notable improved quality of life.[160] (Evidence Grade: A) A slightly greater proportion of OH and OAG patients initially treated with topical medical therapy underwent rapid VF progression compared to those treated initially with SLT. Treating patients first with SLT may delay VF progression in comparison with initial medical therapy.[344] (Evidence Grade: A)

In a randomized clinical trial of POAG and OH patients who were well-controlled with medical therapy, SLT maintained good IOP control with reduction in number of medications. SLT as replacement therapy may reduce problems of non-compliance and medication side-effects.[345] (Evidence Grade: A)

Two other clinical trials found that SLT seems to have equivalent efficacy to topical latanoprost monotherapy over 12 months independent of angle pigmentation[346] (Evidence Grade: B) and IOP reduction was similar for SLT and PGA medication upon initial therapy for POAG.[347] (Evidence Grade: B) One study, however, found SLT was not superior to medication as a first line therapy in improving glaucoma-specific quality of life scores. IOP reduction was superior in the medication arm of the study.[348] (Evidence Grade: A)

EVIDENCE-BASED ACTION STATEMENT: Selective laser trabeculoplasty (SLT) should be considered as an initial/alternative or additive therapy to medication for achieving intraocular pressure (IOP) control in patients with ocular hypertension (OH) or primary open-angle glaucoma (POAG).[160,333,343-347]

Evidence Quality: Grade A. Study type(s): Randomized Clinical Trials, Systematic Review, Cohort-prospective, Cohort-retrospective, Case Series

Level of Confidence: High

Clinical Recommendation Level: Strong Recommendation. This recommendation should be followed unless clear and compelling rationale for an alternative approach is present.

Evidence Statements: SLT offers a promising primary treatment strategy for POAG patients in lieu of topical drop glaucoma regimen, with notable improved quality of life.[160] (Evidence Grade: A)

SLT therapy was not inferior to medication-only treatment in IOP reduction and success rate of IOP control. SLT significantly decreased the mean number of medications needed and was observed to be a safe procedure during the long-term follow-up.[333] (Evidence Grade: A)

Treating patients first with SLT may delay visual field progression in comparison with initial medical therapy.[344] (Evidence Grade: A)

In POAG or OH patients who were well-controlled with medical therapy, SLT maintained good IOP control with reduction in number of medications. SLT as replacement therapy may reduce problems of non-compliance and medication side-effects.[345] (Evidence Grade: A)

SLT seems to have equivalent efficacy to topical latanoprost monotherapy over 12 months independent of angle pigmentation.[346] (Evidence Grade: B)

IOP reduction was similar for SLT and PGA medication upon initial therapy for POAG.[347] (Evidence Grade: B)

SLT is considered an established and effective glaucoma treatment in early to moderate stages of open angle glaucoma. SLT may also be effective in patients with advanced glaucoma and moderate IOP elevation, on maximum topical medications, and with co-existing systemic diseases or medication.[343] (Evidence Grade: B)

Potential Benefits: Preservation of vision through effective lowering of IOP, increased adherence and decreased need for medications.	**Potential Risks/Harms:** Complications from laser treatment.

Benefits and Harms Assessment: Benefits significantly outweigh harms.

Potential Costs: Direct and indirect costs of laser treatment.

Value Judgments: None.

Role of Patient Preferences: High.

Intentional Vagueness: None.

Gaps in Evidence: None identified.

D. SURGICAL TREATMENT

Surgical treatment becomes an option when IOP cannot be sufficiently reduced with medical or laser therapy. Surgery may also be an appropriate initial treatment for eyes with very advanced damage, uncontrolled IOP or known rapid POAG progression. Surgical IOP treatment can significantly reduce the incidence and rate of VF progression in patients with glaucoma who demonstrate preoperative progression and it may prevent subsequent VF progression in eyes with unsatisfactory IOP control prior to surgery.[349]

1. Cataract Surgery

Cataract surgery can decrease IOP, at least initially, by up to a few mmHg.[350] A more anteriorly positioned crystalline lens prior to phacoemulsification was significantly predictive for a greater post-operative IOP reduction in non-glaucomatous eyes. Such a relationship also existed for glaucomatous eyes but with less significance.[351] (Evidence Grade: C)

For patients with POAG (including NTG) that is controlled with one or two topical medications, phacoemulsification results in a modest IOP decrease, (13%) reduced medication requirement (12%) and seems to be relatively safe. Some patients (up to 26%), however, experience worse IOP control and may require additional medications, laser surgery or both.[352] (Evidence Grade: B) Combined cataract extraction and endoscopic cyclophotocoagulation (CPC) resulted in a greater postoperative IOP reduction and number of medications than phacoemulsification alone in POAG.[353] (Evidence Grade: C)

2. Minimally Invasive Glaucoma Surgery

Several “minimally invasive” glaucoma surgery (MIGS) devices are available as alternatives to more invasive surgical approaches. MIGS produce direct channels from the anterior chamber to Schlemm’s canal, the subconjunctival space or the suprachoroidal space, thus bypassing the juxtacanicular TM and inner wall of Schlemm’s canal (believed to be the site of greatest aqueous flow resistance in POAG). MIGS are characterized by minimal external dissection, short operating times, relatively good safety profiles and rapid recoveries.[354] MIGS devices have been shown to provide a safe surgical approach and may provide good long-lasting intraocular pressure–lowering effectiveness and the opportunity to reduce or eliminate ocular hypotensive medications.[355] (Evidence Grade: D)

To minimize the risk of additional surgeries, many MIGS are utilized at the time of cataract surgery, where both the removal of the crystalline lens and implantation of one or more MIGS devices have shown a good combined effect.[356] (Evidence Grade: B) Trabectome surgery may be used in combination with cataract surgery to ablate and remove a portion of the TM and inner layer of Schlemm’s canal. It may also be considered a viable procedure for patients with failed filtering blebs and uncontrolled IOP.[357] (Evidence Grade: D)

MIGS may also be a stand-alone procedure for the right patient with certain types and severity of glaucoma. Overall, while MIGS as a class have some advantages, there are also some individual device and class disadvantages such as insufficient IOP reduction and complications (e.g., device failure, adverse events). Larger randomized trials and real-world observational studies are needed for MIGS devices to better assess clinical and economic effectiveness.[358] (Evidence Grade: A)

3. Canaloplasty

Canaloplasty is a non-penetrating surgery for the reduction of IOP. It is a non-filtering, bleb-free, visco-canalostomy using a 360-degree tension suture within Schlemm’s canal to restore the physiological outflow pathways of the aqueous humor. Canaloplasty is indicated in patients with mild to moderate POAG, and the combination with cataract phacoemulsification may provide further intraocular pressure reduction. Compared to trabeculectomy, however, canaloplasty is not as effective in lowering IOP but has less risk of complications.[359,360]

4. Trabeculectomy

Trabeculectomy is commonly used to treat medically uncontrolled POAG. An alternative aqueous humor outflow path is surgically created from the anterior chamber through the sclera (guarded sclerectomy) to the sub-conjunctival space to create a filtering bleb from which fluid passes through the conjunctiva to the tear layer.

Long-term (up to seven years) complications of patients randomized to trabeculectomy in the CIGTS were mainly cataract. Extraction was noted to occur earlier and more frequently than for patients initially treated with medications. Rates of endophthalmitis and bleb-related complications such as bleb leak, hypotony and blebitis were all low.[361] (Evidence Grade: B) However, the potential efficacy of trabeculectomy must be weighed against the long-term risk of complications, especially endophthalmitis, when selecting treatments for patients. Although risks are low, they can lead to significant loss of vision if they occur. These are lifelong risks not just in the postoperative period.

A study in the United Kingdom found that after 20 years, 57% of patients who had trabeculectomy were classified as a complete success, 88% were classified as qualified success, and 15% had become blind. Patient age, preoperative topical medication use, glaucoma type and glaucoma severity independently influenced this outcome. Trabeculectomy surgery is therefore a long-term management option for IOP control.[362] (Evidence Grade: B)

5. Glaucoma Drainage Devices

Glaucoma Drainage Devices (GDD) compete with trabeculectomy in the treatment of advanced glaucoma or glaucoma resistant to medical and laser management. Also called "tube shunts," with many different names (e.g., Moltino, Krupin, Optimed, Baerveldt, Ahmed), these devices directly connect an eye's anterior chamber with the conjunctiva to bypass the TM and reduce IOP.

Both Ahmed and Baerveldt GDDs had similar surgical success measured at five years post-operative. Baerveldt GDDs resulted in greater IOP reduction but more early and serious complications than was encountered with patients receiving Ahmed valves.[363] (Evidence Grade: A) Known complications of GDDs include diplopia, endophthalmitis, superchoroidal hemorrhage, retinal detachment, hypotony, cataract, corneal edema, tube or plate erosion, hyphema, choroidal effusion and superior orbital vein occlusion.

6. Ciliary Body Ablation

Ciliary body ablation or destructive procedures use diathermy, cryotherapy or ultrasound to directly damage the ciliary body of eyes with refractory severe glaucoma, impairing the ability to produce aqueous humor. Laser cyclophotocoagulation (CPC) has become the common method. However, such procedures are often a last resort after all other treatments have failed.

CPC procedures include transpupillary, transvitreal, endoscopic (performed from inside the eye and thus having less collateral ocular damage but more attendant risk from surgery) and transscleral, based on the different paths used to approach the ciliary body. Common complications include hypotony, intraocular inflammation, hemorrhage and pain.

Patients treated with endocyclophotocoagulation (ECP) via the pars plana had lower IOPs, needed fewer glaucoma medications, and had a higher success (with up to two years of follow-up) than patients similarly treated via the limbus (anterior ECP), even after adjusting for other confounding factors such as degree of treatment, preoperative metrics, and whether or not the surgery was combined with phacoemusification.[364] (Evidence Grade: B)

E. PRIMARY OPEN-ANGLE GLAUCOMA PROGRESS EXAMINATION

Progress evaluations for POAG should be specific to each patient. Use of dynamic and personalized testing schedules can enhance the efficiency of POAG progression detection and reduce diagnostic delay, compared to fixed yearly monitoring intervals.[365] Patients who are early in their care process or who appear less stable might be followed

every few weeks or months, while those who have "well-controlled" IOPs and seemingly stable ONHs and VFs should require less frequent visits. Treatment should be adjusted at each visit as needed. Delays in appropriate care for any reason can result in deterioration of vision.[366]

> ***Clinical note:*** *Patients with advanced glaucoma should be seen more often and treated more aggressively than patients with OH, or early to moderate glaucoma.[367] (Evidence Grade: B)*

Because glaucomatous progression is so highly variable, identifying factors that predict progression should guide clinical practice, and patient treatment and monitoring. Bilateral disease, higher baseline IOP and DH at baseline were risk factors for VF deterioration while older age, systolic OPP and CCT were not confirmed as progression risk factors in the UKGTS.[173] (Evidence Grade: A) Macular GCC focal loss as determined by SD-OCT and VF studies, along with thinner CCT values, are strong baseline predictors for determining rate of glaucoma progression.[368] (Evidence Grade: C)

CONSENSUS-BASED ACTION STATEMENT: The frequency and scope of follow-up examinations of persons diagnosed with primary open-angle glaucoma (POAG) should be individualized based on the severity and stability of their disease and should occur at regular intervals to monitor progression and treatment efficacy.
Evidence Quality: There is a lack of published research to support or refute the use of this recommendation.
Benefits and Harms Assessment: Implementation of this recommendation is likely to result in the earlier diagnosis and treatment of any disease progression. The benefits of this recommendation were established by expert consensus opinion.

A progress evaluation (not a comprehensive eye and vision examination) should include, but is not limited to:

- Interval history noting any changes in vision or general health, evaluation of medication utilization to assess patient adherence and consideration of any symptoms or side effects.
- Measurement of best corrected visual acuities
- Tonometry
- ONH evaluation looking for changes in the neuro-rim, disc vessels and/or DH as signs of POAG progression.

With periodic retesting based on disease severity:

- RNFL and ONH imaging should be repeated at least yearly for the first several years of follow-up.
- Gonioscopy should be assessed periodically and when there is a suspicion of anterior chamber angle abnormalities or if there is an unexplained change in IOP.
- VF testing should be conducted as needed to obtain sufficient information to identify patients who are rapidly progressing, gain a sense of each patient's variability and establish a baseline. Semi-annual testing in the initial years following diagnosis may be a reasonable compromise for obtaining sufficient statistical power to rule out rapid VF progression while minimizing the testing burden.[369]

  > ***Clinical note:*** *Patients with more advanced VF loss or presenting with mild damage at a younger age may require more frequent VF testing when considering risk factors for progression and factors such as age and life expectancy.[370] (Evidence Grade: C)*

CONSENSUS-BASED ACTION STATEMENT: Progress examinations of patients with primary open-angle glaucoma (POAG) should include, but are not limited to, an interval history, measurement of visual acuity and intraocular pressure (IOP), and evaluation of the optic nerve head (ONH), with periodic gonioscopy, retinal nerve fiber layer (RNFL) evaluation and visual field (VF) testing.

Evidence Quality: There is a lack of published research to support or refute the use of this recommendation.

Benefits and Harms Assessment: Implementation of this recommendation is likely to result in the earlier diagnosis and treatment of any disease progression. The benefits of this recommendation were established by expert consensus opinion.

F. PATIENT SELF- OR HOME-BASED MONITORING

To assist in care, several devices are being developed for home use by patients with glaucoma. Both IOP and VF monitoring devices are being considered and may eventually prove useful in the care process.[371-374] Several studies suggest the use of tablet computers, smart phones and head-mounted functional testing devices as alternative, inexpensive, highly portable and compact platforms for VF testing.[375-378]

IOP home monitoring may be feasible for some patients. Self-tonometry (e.g., rebound) has the potential to address an unmet need by more effectively engaging patients in their own care,[379] as well as providing IOP measurements over the entire diurnal cycle.[380] (Evidence Grade: C) Self-tonometry also has the potential to assist clinicians in both supporting the diagnosis and assessing the effectiveness of treatment earlier than the standard clinical review period of two-to-four weeks, hence reducing delays to effective reduction of IOP for patients initiating treatment.[372] (Evidence Grade: C)

Patient-measured rebound tonometry demonstrates good agreement with Goldmann applanation tonometry performed by clinicians and may be suitable for measurement of IOP outside of the clinical setting.[381] (Evidence Grade: C) However, one study suggests that it over-estimates IOP relative to Goldmann applanation tonometry measurments.[382] (Evidence Grade: C)

EVIDENCE-BASED ACTION STATEMENT: Patient self-monitoring of intraocular pressures (IOP) should be considered to help support the diagnosis and/or management of patients at risk for or diagnosed with primary open-angle glaucoma (POAG).[372,380,381]

Evidence Quality: Grade C. Study type(s): Case Control, Cohort-prospective, Diagnostic

Level of Confidence: Medium.

Clinical Recommendation Level: Recommendation. This recommendation should generally be followed but remain alert for new information.

Evidence Statements: Self-tonometry has the potential to assist clinicians in both supporting the diagnosis and assessing effectiveness of treatment earlier than the standard clinical review period of two to four weeks, hence reducing delays to effective reduction of intraocular pressure for patients initiating treatment.[372] (Evidence Grade: C) IOP home monitoring may be feasible for some patients. The use of a rebound tonometry self-monitoring device has the potential to address an unmet need by providing more frequent IOP measurements over the entire diurnal cycle.[380] (Evidence Grade: C) Patient-measured rebound tonometry demonstrates good agreement with Goldmann applanation tonometry performed by clinicians and may be suitable for measurement of IOP outside of the clinical setting.[381] (Evidence Grade: C)	
Potential Benefits: Provides more frequent monitoring of IOP and may reduce delays in initiating treatment.	**Potential Risks/Harms:** None.
Benefits and Harms Assessment: Benefits significantly outweigh harms.	
Potential Costs: Cost of IOP monitoring device.	
Value Judgments: None.	
Role of Patient Preferences: Large.	
Intentional Vagueness: None.	
Gaps in Evidence: Research to investigate the use of self-tonometry for the measurement of diurnal intraocular pressure fluctuation.	

G. INITIATION OF TREATMENT AND PATIENT MONITORING

1. Ocular Hypertension

The OHTS established that medically treating OH is efficacious in delaying or preventing the onset of glaucoma. However, not all patients with borderline or elevated IOP should receive medication.[73] (Evidence Grade: A) There is little absolute benefit of early treatment in low-risk OH patients.[11] (Evidence Grade: A) In addition, clear evidence does not exist that "intensive monitoring" is of benefit in persons with OH from a scientific or financial standpoint.[383] (Evidence Grade: A)

While early medical treatment of OH patients reduced the five-year incidence of POAG by 60% in the OHTS, the benefit of early treatment is greatest in high-risk OH patients. Clinicians should consider initiating treatment for individuals with OH who are at moderate or high risk for developing POAG.[73] (Evidence Grade: A) The use of a five-factor baseline risk model (age, IOP, CCT, larger C/D ratio and higher VF pattern standard deviation [PSD]) has reasonable accuracy in distinguishing high from low-risk OH patients. Clinicians and patients can decide on the potential benefit of early treatment based on risk level, patient age, health status, life expectancy and personal preference.[10] (Evidence Grade: B)

A risk calculator can assist in making treatment recommendations and thereby improve the consistency and confidence of clinician decision-making.[384] (Evidence Grade: C) The following link provides two methods that can be

used to estimate the five-year risk of developing POAG. The predictions derived using these methods are designed to aid but not to replace clinical judgment.

Risk Calculators for Primary Open-Angle Glaucoma - American Academy of Ophthalmology (aao.org)

Patients with OH at low risk of conversion to POAG can generally be followed without treatment, as long as they are monitored regularly for signs of early disease.[10] (Evidence Grade: B) It is necessary to continually assess structural and functional parameters in OH patients to determine if POAG has developed and/or is progressing. Measuring the rate of structural change (e.g., rim area loss is faster in eyes that develop POAG) can provide important information for the clinical management of OH patients.[385] (Evidence Grade: A)

> ***Clinical note:*** *Observation of DH is a strong predictor of the subsequent conversion to POAG.[205] (Evidence Grade: B)*

In addition, OH eyes that develop POAG and display both optic disc and VF change, not necessarily concurrently, had significantly more rapid VF deterioration than eyes developing POAG but only displaying change in their VF or in their optic disc. In persons with OH, VF changes occur at only a small number of locations. Local change is more likely to cause Corrected Pattern Standard Deviation (CPSD) or Glaucoma Hemifield Test (GHT) change.[386] (Evidence Grade: B)

EVIDENCE-BASED ACTION STATEMENT: Early medical treatment should be considered for individuals with ocular hypertension (OH) who are at moderate or high risk of developing primary open-angle glaucoma (POAG).[10,11,73]	
Evidence Quality: Grade A. Study type(s): Randomized Clinical Trials, Case Control **Level of Confidence:** High **Clinical Recommendation Level:** Strong Recommendation. This recommendation should be followed unless clear and compelling rationale for an alternative approach is present.	
Evidence Statements: Clinicians should consider initiating treatment for individuals with OH who are at moderate or high risk for developing POAG.[73] (Evidence Grade: A) There is little absolute benefit of early treatment in low-risk OH patients.[11] (Evidence Grade: A) Patients with OH at low risk of conversion to POAG can generally be followed without treatment, as long as they are monitored regularly for signs of early disease. The use of a five-factor baseline risk model (age, IOP, CCT, larger C/D ratio and higher VF PSD) has reasonable accuracy in distinguishing high from low-risk OH patients. The benefit of early treatment is greatest in high-risk OH patients.[10] (Evidence Grade: B)	
Potential Benefits: Early treatment may reduce or delay onset of POAG.	**Potential Risks/Harms:** Side effects of medication.
Benefits and Harms Assessment: Benefits significantly outweigh harms.	
Potential Costs: Cost of medication.	
Value Judgments: None.	
Role of Patient Preferences: Moderate.	

Intentional Vagueness: None.
Gaps in Evidence: None identified.

2. Primary Open-Angle Glaucoma

Monitoring POAG progression involves evaluation of both structural and functional changes. Differentiating clinically relevant disease progression from inherent variability and fluctuation is a major challenge in managing POAG. Worsening optic disc excavation, RNFL atrophy and deterioration in visual function are all evidence of the progression of glaucoma. If progression is confirmed, management needs to be modified or enhanced to prevent further irreversible loss of the patient's visual function.

a. Monitoring Structural Changes

There may be good agreement between structural (OCT) and functional (VF) tests used to evaluate glaucoma progression in early disease.[387] (Evidence Grade: C) Decreases in the RNFL may be helpful in monitoring early and moderate POAG, but OCT may not be as useful as SAP in advanced glaucoma.

Progressive structural OCT changes often precede functional VF loss, and patients who show faster changes in OCT are at increased risk of worsening VF loss.[388] Characteristic patterns of the OCT deviation map can provide useful clues to distinguish glaucomatous changes from false-positive findings.

> ***Clinical note:*** *OCT is more likely to detect progression in early glaucoma; VF and stereo-disc photos may be better at detecting progression in advanced glaucoma.[389] (Evidence Grade: C)*

Progressive RNFL thinning is predictive of detectable functional VF decline in glaucoma,[390] (Evidence Grade: B) which suggests that RNFL thinning may indicate the need for more aggressive IOP lowering. For detecting glaucomatous local RNFL progression, the OCT "region of interest" (a specific region around the ONH that was abnormal at an earlier visit) approach appears superior to global[391] (Evidence Grade: C) or circumpapillary[392] (Evidence Grade: C) RNFL thickness change.

> ***Clinical note:*** *OCT measured rate of structural ONH rim loss is five times faster in eyes that convert to POAG than in those that remain OH.[385] (Evidence Grade: A)*

OCT allows detection of localized and diffuse RNFL loss and measurement of RNFL thickness rate of change, which is beneficial in discerning glaucoma progression course, disease progression prediction and evaluation of treatment response. The inferior temporal sector was the most frequent location showing progression.[393] (Evidence Grade: C) VF progression was related to OCT GPA RNFL topographic progression characteristics (widening or deepening pattern). Other topographic characteristics (e.g., location, size and shape) may also have utility in determining the risk of VF progression.[394] (Evidence Grade: B)

b. Monitoring Functional Changes

Numerous factors impact VF progression interpretation, such as reliability indices, fixation tracking and cognitive decline.[369] Cognitive decline was associated with increased VF variability in fixation losses, false positive and negative errors. Screening and monitoring cognitive dysfunction may be important in the assessment of glaucomatous VF progression as patient concentration and cooperation is increasingly affected. Clinicians may need to become more reliant on structural alterations to monitor for progression.[395] (Evidence Grade: B)

SAP remains the reference standard to detect glaucomatous VF progression. There is no evidence that short wavelength automated perimetry (SWAP) and frequency-doubling perimetry have any significant benefits over SAP in monitoring glaucoma progression.[396] (Evidence Grade: B)

It is important to retest unreliable or suspected progression of VFs to ensure repeatability. Interpretation of test results can be improved using statistical packages that analyze the data relative to age-matched norms (total deviation) or scan for focal defects by eliminating the influence of diffuse loss (pattern deviation). Due to the diffuse nature of early functional damage in glaucoma, relying on pattern deviation may underestimate the degree of damage which has occurred.[271] (Evidence Grade: B)

> ***Clinical note:*** *In eyes with manifest glaucoma, progression in the VF was detected first more than four times as often as progression in the optic disc in the EMGT. Among fellow eyes without VF loss at baseline, progression was detected first as frequently in the optic disc as in the VF.[272] (Evidence Grade: A)*

In a study of patients with treated POAG, DH was the single most significant predictor for VF deterioration.[397] (Evidence Grade: B) Rates of progressive VF loss in eyes with DH were significantly faster that in eyes without hemorrhages, confirming the role of DH as an important risk factor for glaucoma progression. Rates of functional loss after an episode of DH were significantly related to IOP reduction, suggesting a treatment benefit in decreasing progression rates in these eyes.[398] (Evidence Grade: B)

Both trend and event analyses can be used for establishing change within a series of VF evaluations. Event-based analyses take into account expected localized test-retest variabilities in sensitivity, and trend-based analyses are helpful for determining and predicting overall visual function.[399] Clinicians may benefit from reviewing the results of cluster trend analysis in addition to whole VF trend analyses and pointwise VF sensitivity for determining the rate of VF progression.[400] (Evidence Grade: C)

> ***Clinical note:*** *VF threshold values below 15-19 dB should be interpreted with caution as they may not be reliable for assessing the true level of damage or of glaucomatous progression.[401] (Evidence Grade: C)*

Both IOP-dependent and -independent factors affect POAG VF progression in treated glaucoma. Peak IOP may be a better predictor of progression than is mean IOP or fluctuation, but other clinical information (e.g., ophthalmoscopy observed peripapillary atrophy) influences risk assessment for future progression.[402] (Evidence Grade: B) Treated glaucomatous eyes with documented optic nerve progression are at increased risk of visual field loss over time, with moderate agreement between the location of optic nerve change and the hemifield with the most rapid sensitivity decline. For a given similar rate of MD progression (conventionally measured in dB/year), eyes with different levels of baseline damage can have very different progression rates. This reflects the rate of RGC and RNFL thickness loss leading to the need for customized individual progression concepts.[403] (Evidence Grade: B)

3. Normal Tension Glaucoma

The general principles of treatment for NTG patients do not differ from that of managing chronic POAG. Treatment should be directed at lowering the IOP substantially from what is thought to be a damaging level in that individual. NTG patients tend to progress more slowly and have a lower risk of rapid evolution to blindness than patients with POAG. High intragroup variability exists, however, and specific treatment for all NTG patients should be guided by individual presentation and course.

Clinicians may initiate treatment of patients with mild to moderate NTG with PGAs without waiting for further progression.[404] (Evidence Grade: D) However, an initially non-glaucomatous fellow eye of a unilaterally NTG patient may be observed without treatment until or unless glaucoma can be diagnosed.[405] (Evidence Grade: B)

Distinguishing NTG from non-glaucomatous optic neuropathies is often challenging. Assessment of ONH cupping by OCT evaluation of the minimum rim width at Bruch's membrane opening suggests a way to discriminate between

NTG and other ONH disease.[406] (Evidence Grade: C) The key to the assessment remains identifying the presence of ONH cupping.

In one study of patients with NTG followed for an average of twelve years, the amount of IOP reduction using topical medications was related to NTG progression and lower percentage reduction in IOP was a consistent risk factor for progression. DH was another important risk factor for NTG progression, implying the presence of a non-IOP-dependent mechanism.[407]

Some cases of NTG progress more rapidly than others. Although approximately half of cases in one study showed a confirmed localized VF deterioration by seven years, the change was typically small and slow, often insufficient to measurably affect the MD index.[408] In another study, over half of the patients with NTG showed glaucoma progression despite treatment after more than eight years. High peak IOP was a significant risk factor for progression. Identifying patients at risk may warrant closer follow up and more aggressive treatment in order to preserve visual function in patients with NTG.[157] (Evidence Grade: B)

H. PATIENT EDUCATION AND COUNSELING

Educating patients about glaucoma and the use of medical, laser and/or surgical treatment in preventing blindness is vitally important.[409] Although there is a need for improved glaucoma education across all patients, those of a lower socioeconomic status may have a greater need for information about the disease.[410,411]

Patients with decreased health literacy skills also may benefit from educational efforts tailored to address their health literacy level and learning style.[412] (Evidence Grade: A) They may have poorer compliance, worse disease understanding and greater disease progression compared to individuals with adequate health literacy.[413] (Evidence Grade: D) One study, however, found that individuals with lower health literacy did not appear to have worse overall vision-related quality of life compared to those with higher literacy.[414] (Evidence Grade: D)

> ***Clinical note:*** *Education programs for increasing glaucoma awareness and knowledge may be a key to improving quality of life in patients with glaucoma.[415] (Evidence Grade: D)*

Targeted educational interventions and counseling should focus on the patient's understanding of the risk of irreversible blindness from glaucoma, the long-term nature of treatment and the importance of attending follow-up visits despite the lack of visual symptoms.[416] (Evidence Grade: C) Brief instructional sessions offered to newly diagnosed glaucoma patients can result in better one-year persistence.[417] (Evidence Grade: B)

Providing educational materials at a readable level (6-8th grade) may enhance patient understanding of treatment and management strategies and aid in self-care and adherence in POAG.[418] (Evidence Grade: A) In a study in both academic and community practice settings, about 30% of glaucoma patients had marginal or inadequate literacy skills. It found that patients better comprehend and were more receptive to educational materials written at 5th grade reading level with illustrations, regardless of initial literacy level.[419] (Evidence Grade: A)

Current doctor-patient communication is often physician-centered rather than patient-centered.[420] (Evidence Grade: B) Patient-centered physician-provided education and communication improves medical glaucoma therapy outcomes[421] (Evidence Grade: D) [422] (Evidence Grade: D) and patient satisfaction.[423] (Evidence Grade: D) Patient discussions should include open-ended questioning regarding medication use and recommendations for how to best fit the medication into the patient's life and address any identified barriers.[424] (Evidence Grade: D)

Patient communication, including question/answer discussions, are important with patients who have POAG to remove any barriers regarding medication use, improve their understanding of treatment strategies and create an open, approachable relationship with their eye care provider.[425] (Evidence Grade: D) A simple validated questionnaire administered on arrival of a patient at glaucoma follow-up visits could allow issues impacting adherence to be immediately addressed.[426] (Evidence Grade: D)

Telephone-based counseling about glaucoma followed by mailed information, in addition to the usual physician delivered care and information, improved knowledge and reduced anxiety in newly diagnosed glaucoma patients.[427] (Evidence Grade: A) Intensive educational mailings to patients and their physicians alone, however, did not improve medication adherence in a large cohort of elderly glaucoma patients.[428] (Evidence Grade: A)

Patients' desires for personalized one-on-one discussions with clinicians, as well as printed and online materials, create an opportunity for doctors to provide and/or direct patients to high quality educational resources and thereby enhance patient self-management.[429] While it is important to discuss visual quality of life with all glaucoma patients, African American and younger patients were less likely to discuss this with their doctors.[430] (Evidence Grade: C)

> ***Clinical note:*** *Clinicians should always educate, simplify medication regimens and personally provide positive verbal reinforcement regarding medication use.[431] (Evidence Grade: B) [432] (Evidence Grade: A)*

1. Patient Adherence/Compliance

Poor adherence to prescribed glaucoma treatment protocols is quite common.[433] (Evidence Grade: B) It poses an ongoing[434] (Evidence Grade: A) and refractory challenge to treating clinicians,[435] especially when motivation is weak (e.g., when disease is mostly asymptomatic). Patients diagnosed with POAG are reported to be more compliant with pharmacotherapy than those diagnosed with OH.[436] (Evidence Grade: B) Although doctors recognize that nonadherence with glaucoma medication is a problem, most lack the skill set to identify non-adherent patients and the causes of nonadherence.

Poor adherence in POAG treatment often results in both VF and sensitivity loss as well as unnecessary additional medications and surgeries.[437] In the CIGTS, an increase in the number of visits at which a patient reported a missed medication dose was significantly associated with a decrease (worsening) in MD (estimated at 0.14 dB per missed dose visit).[438] (Evidence Grade: B)

> ***Clinical note:*** *Patient adherence to glaucoma medications over the first year of treatment tends to be indicative and reflective of adherence over subsequent years. Therefore, effective means of maximizing adherence during the first year of treatment will likely lead to better adherence thereafter.[439] (Evidence Grade: B)*

Multiple barriers to medication adherence exist, with low self-efficacy (lack of confidence) and forgetfulness being commonly reported factors.[440] (Evidence Grade: D) Additional factors that have been shown to contribute to medication nonadherence are listed in Table 5.

Table 5:
Factors That Affect Medication Nonadherence

Cost of medication[441] (Evidence Grade: B)	Inability to correctly instill drops[442] (Evidence Grade: C)
Patient's age, sex and baseline IOP[443] (Evidence Grade: B)	Choice of therapy[444] (Evidence Grade: B)
Regimen complexity[445] (Evidence Grade: C)	Race/ethnicity[416] (Evidence Grade: C)
Socioeconomic status[446] (Evidence Grade: C)[410] (Evidence Grade: C)	Lack of social support, educational level[447] (Evidence Grade: C)
Higher level of glaucoma-related distress[447] (Evidence Grade: C) and psychosocial issues (e.g., depression, hypochondriasis)[448] (Evidence Grade: B)	Poor physician-patient communication[449]

Clinical note: *The bureaucratic and administrative hurdles insurers and pharmacy benefit managers use to motivate patients to switch from brand-name products to generics are often effective at persuading many patients to switch to the cheaper generic products; however, there is a subset of patients who are unable to effectively make the switch to the generic product. These patients, who end up going untreated, are at increased risk for worsening of their OAG and later ultimately may require costly surgical interventions.[433] (Evidence Grade: B)*

Patients with lower health literacy are less likely to express medication related problems, side effects or poor adherence.[450] (Evidence Grade: D) Medication adherence likely improves with a comprehensive strategy consisting of both education and reminder systems.[451] (Evidence Grade: A) A multipronged approach using audio-visual aids to improve physician-patient communication along with an automated reminder system helps to improve glaucoma medication administration adherence.[452] (Evidence Grade: A)

When clinicians educate patients and assess their views about glaucoma and its treatment, patients report higher medication self-efficacy. Patients who ask more medication questions may have less confidence in their ability to overcome adherence barriers.[453] (Evidence Grade: B)

Clinical note: *Numerous potential barriers can affect a patient's proper adherence to glaucoma medication. It is incumbent on the clinician to promote proper adherence, as well as utilize the patients' primary care physician in the promotion of adherence.[454] (Evidence Grade: B)*

EVIDENCE-BASED ACTION STATEMENT: Eye doctors should be persistent in providing education and training to patients with primary open-angle glaucoma (POAG) to improve adherence/compliance with recommended therapy.[416-418,424,425,431,432,451-453]

Evidence Quality: Grade B. Study type(s): Randomized Clinical Trials, Systematic Reviews, Cohort-prospective, Case Series, Cross-sectional

Level of Confidence: Medium

Clinical Recommendation Level: Strong Recommendation. This recommendation should be followed unless clear and compelling rationale for an alternative approach is present.

Evidence Statements: Medication adherence likely improves with a comprehensive strategy consisting of both education and reminder systems.[451] (Evidence Grade: A)

Providing education materials at a readable level (6-8th grade) may enhance patient understanding of treatment and management strategies and aid in self-care and adherence in POAG.[418] (Evidence Grade: A)

A multipronged approach using an audiovisual aid to improve physician-patient communication along with an automated reminder system helped to improve glaucoma medication administration adherence.[452] (Evidence Grade: A)

Clinicians should always educate, simplify medication regimens, and personally provide positive verbal reinforcement regarding medication use.[431] (Evidence Grade: B)[432] (Evidence Grade: A)

Brief instructional sessions offered to newly diagnosed glaucoma patients can result in better persistence rates over one year follow-up.[417] (Evidence Grade: B)

When clinicians educate patients and assess their views about glaucoma and its treatment, patients report higher medication self-efficacy. Patients who ask more medication questions may have less confidence in their ability to overcome barriers to adherence.[453] (Evidence Grade: B) Targeted educational interventions and counseling should focus on the patient's understanding of the risk of irreversible blindness from glaucoma, the long-term nature of treatment, and the importance of attending follow-up visits despite the lack of visual symptoms.[416] (Evidence Grade: C) Patient discussions should include open-ended questioning regarding medication use and recommendations by the physician for how to best fit the medication into the patient's life and address any identified barriers.[424] (Evidence Grade: D) Patient communication, including question/answer discussions, are important with patients who have POAG to remove any barriers regarding medication use, improve their understanding of treatment strategies, and foster an open, approachable relationship with their eye care provider.[425] (Evidence Grade: D)	
Potential Benefits: Counseling and educating patients may improve adherence to help maintain ocular health and visual function.	**Potential Risks/Harms:** None.
Benefits and Harms Assessment: Benefits significantly outweigh harms.	
Potential Costs: Direct and indirect costs of counseling and educational services.	
Value Judgments: None.	
Role of Patient Preferences: Moderate.	
Intentional Vagueness: None.	
Gaps in Evidence: Research to identify medication persistence rates in patients with glaucoma at different stages of disease progression.	

2. Medication Instillation Training

Education about how to administer glaucoma drops is positively associated with adherence.[431] (Evidence Grade: B) Most glaucoma patients may not be correctly instilling eye drops. This can lead to serious consequences resulting in reduced quality of life. It also highlights the importance of patient education with regard to eye drop instillation whenever glaucoma topical medications are prescribed.[455] (Evidence Grade: D)

Variability in the force required to apply drops from different bottle design,[456,457] as well as older age and worse visual acuities,[458] can lead to patients who are challenged to properly apply medications.[459] (Evidence Grade: B) In one study, increasing age was found to be an independent risk factor for the inability to correctly instill drops resulting in considerable wasting of doses.[442] (Evidence Grade: C)

Poor eye drop technique is a significant impediment to achieving good control of intraocular pressure in glaucoma. Showing a short clinical education video when patients are prescribed eye drops is likely to improve their drops installation techniques significantly.[460] (Evidence Grade: A) Positive value was found in eye drop technique videos, especially those about performing punctal occlusion, closing the eye after instillation, correctly mixing medication, cap hygiene, not touching the eye and installing the drop accurately.[461] (Evidence Grade: B) There is often sufficient wait

time during both new and return evaluations which could be utilized for key portions of glaucoma education such as eye drop instillation technique(s).[462] (Evidence Grade: B)

Additional approaches to enhancing medication compliance may include:

- Educational workshops[463] (Evidence Grade: D) and organized patient support groups which enhance all aspects of compliance/adherence (e.g., drug utilization, appointment keeping, prescription refills[464] and health literacy.[465,466])
- Use of automated, interactive, telephone-based reminder protocols.[467,468] (Evidence Grade: A)
- A glaucoma logbook may influence glaucoma knowledge, possibly due to enhanced engagement.[469] (Evidence Grade: D)
- An eye drop satisfaction questionnaire used as a tool to evaluate adherence problems that need to be addressed.[470] (Evidence Grade: D)
- A modest adherence-contingent rebate can provide a financial incentive to significantly improve medication adherence rates.[471] (Evidence Grade: A)

EVIDENCE-BASED ACTION STATEMENT: Patients with primary open-angle glaucoma (POAG) who are prescribed pharmacologic treatment should receive instructions on eye drop instillation.[431,455,460,461]
Evidence Quality: Grade B. Study type(s): Randomized Clinical Trial, Cohort-prospective, Cross-sectional **Level of Confidence:** Medium **Clinical Recommendation Level:** Recommendation. This recommendation should generally be followed but remain alert for new information.
Evidence Statements: Showing a short clinical education video when patients are prescribed eye drops is likely to improve their drop instillation technique significantly.[460] (Evidence Grade: A) Positive value was found in eye drop technique videos, especially those about performing punctal occlusion, closing the eye after instillation, correctly mixing medication, cap hygiene, not touching the eye and instilling the drop accurately.[461] (Evidence Grade: B) Education about how to administer glaucoma drops and patient glaucoma medication adherence self-efficacy are both positively associated with adherence.[431] (Evidence Grade: B) Most glaucoma patients may not be correctly instilling eye drops. This can lead to serious consequences resulting in reduced quality of life of patients. It also highlights the importance of patient education with regard to eye drop instillation whenever glaucoma topical medications are prescribed.[455] (Evidence Grade: D)
Potential Benefits: Better adherence to and efficacy of treatment. / **Potential Risks/Harms:** None.
Benefits and Harms Assessment: Benefits significantly outweigh harms.
Potential Costs: Direct and indirect costs of counseling and educational services.
Value Judgments: None.

Role of Patient Preferences: Moderate.
Intentional Vagueness: None.
Gaps in Evidence: None identified.

3. Low Vision Rehabilitation and Counseling

Low vision rehabilitation emphasizes care for people who have degraded visual function such as reduced visual acuity, VFs or contrast sensitivity to the point that restoration of previous visual skills with standard optical corrective techniques like glasses and contact lenses or surgical procedures is no longer possible. Low vision is a deficit in one or more of the three primary visual functions leading to less-than-optimal quality of life:

- Visual acuity generally in the range of 20/60 to 20/400
- VF deficit to 20 degrees diameter or impacting potential to use VF for planning and/or execution of a task for which VF is essential
- Contrast sensitivity deficit resulting in unsatisfactory functional ability to perform daily tasks.

Individuals with glaucoma are at increased risk of chronic vision loss, subsequent functional impairment and resultant disability. Visual impairment has physical, psychological, behavioral and social consequences that affect patients, their family, friends and caregivers. Health care providers and stakeholders may be unaware of the overall impact of vision loss on the health and well-being of the patient.

Providing counseling to maximize patients' independence at work, home and in the community should be considered. Concurrent with medical interventions, vision rehabilitation services, including disease education, are of great value and can be provided by doctors of optometry as well as other professionals. Many patients with impaired vision can attain access to additional benefits and services.[472] (Evidence Grade: D)

Persons with glaucoma-related vision loss should be evaluated to determine their potential to benefit from low vision rehabilitation. This process provides the only currently available treatment option for patients with chronic vision loss. Vision rehabilitation can help individuals with vision loss reduce the risk of falls and attain maximum function, independence and quality of life.

I. SOCIOECONOMIC CONSIDERATIONS

1. Access and Cost of Care

The socioeconomic burden from glaucoma increases significantly as the disease progresses.[473] Access to professional glaucoma care and treatment is often affected by affordability[474] as well as availability. Frequency of examinations and likelihood of laser or surgical treatment all increase with glaucoma progression, leading to increased costs of care. Early POAG assessments and treatments that decrease or prevent progression should have a social economic benefit.[475]

Medical social workers can play a pivotal role in helping glaucoma patients overcome barriers to care, which are numerous and include lack of insurance, doctor visit costs, poor transportation and language issues.[476] (Evidence Grade: C)

2. Lifestyle

Enhanced lifestyle strategies, especially those affecting cardiovascular factors, such as obesity, diabetes and sleep apnea, may directly enhance the treatment of several eye diseases including POAG.[477] (Evidence Grade: D) However,

there is currently insufficient evidence that changing lifestyle habits (e.g., environmental factors, exercise, diet) has a proven effect on the progression of glaucoma.[478,479] It is possible that lifestyle plays an important role, yet the lack of robust randomized controlled trials currently precludes any definite conclusions. Awareness of the possible influences of certain habits, however, should help guide clinical advice on an individual patient basis.[478]

J. ALTERNATIVE/COMPLEMENTARY MEDICINE

There is little evidence-based medicine that assesses whether alternative and complementary therapies may prevent glaucoma or slow down POAG progression.[480] POAG patients should be educated on the primary role of IOP reduction in POAG management so that alternative and complementary therapies which lack robust effectivity evidence are not used to replace conventional and evidence-based treatments.[481]

Some patients may want to use medical marijuana (cannabis) to treat glaucoma even though scientific evidence does not support more than a possible modest and transient effect on IOP with numerous reported adverse systemic and ophthalmic effects.[482-484,485] (Evidence Grade: D) Even when patients have been counseled and educated, many may still believe in the treatment, especially when they are dissatisfied with their other treatment options.[486,487]

It is impossible to draw reliable conclusions from available data to support the use of acupuncture for the treatment of glaucoma.[488] There is some evidence that sleeping in a 30 degree head-up position lowers nocturnal IOP.[489] (Evidence Grade: C). Also, meditation, although not an FDA-approved intervention for glaucoma, may be a useful adjunctive therapy for POAG patients through stress reduction.[490]

Nutritional supplementation, especially with flavonoids or forskolin, holds considerable theoretical promise in glaucoma treatment, especially as an adjunct to IOP-lowering therapy.[491] (Evidence Grade: A) Oral nutritional supplements such as vitamins (e.g., B1, B2), ginkgo biloba and resveratrol also have theoretical promise for treatment of glaucoma or concomitant OSD,[492] but to date have shown no real superiority to conventional treatments.

Oral antioxidant supplementation with or without omega-3 fatty acids does not appear useful as an adjuvant treatment for mild/moderate POAG in the short term[493] (Evidence Grade: B). However, forskolin and rutin given as oral treatment appear to contribute to a better control and a small reduction of IOP in patients who were poorly responsive to maximum tolerated medical treatment.[494] Anthocyanins and ginkgo biloba extract may be helpful in improving NTG patients' visual function.[495] (Evidence Grade: C) While promising, these effects have yet to be validated or generally accepted.

K. TELEHEALTH

Eye care delivery systems strive to improve quality while reducing costs and removing barriers to care such as travel time.[496] (Evidence Grade: B) Telehealth/telemedicine programs (including tele-glaucoma initiatives) may contribute toward reaching this goal, particularly among underserved populations at-risk for chronic blinding diseases.[497] (Evidence Grade: D)

Telehealth ranges from patient self-administered screening [e.g., computer-tablet VF[498] (Evidence Grade: D) or self-tonometry in selected cases[499]] to clinical batteries of tests administered by technical personnel with remote professional decision-making, to digital sensors used to confirm eyedrop medication utilization, provide reminders and notifications and aid in medication administration.[500] While diagnostic results in tele-glaucoma are in fair to good agreement compared to in-person care, sensitivity is very variable. As there is only fair agreement between remote and in-person glaucoma assessments, remote assessment alone may be inappropriate for the management of glaucoma.[501] (Evidence Grade: D)

When compared to in-person care, tele-glaucoma is more time and cost-effective, shows high patient satisfaction and fair to good agreement with in-person care; however, there is great variation in the reported sensitivity of tele-

glaucoma screening, warranting further studies to establish its efficacy. For glaucoma management, both sensitivity and specificity must be further improved before being employed extensively.[502] (Evidence Grade: A)

AOA_Policy_Telehealth.pdf

The following results have been reported from several studies utilizing tele-glaucoma care:

- Telehealth may be an effective screening tool for glaucoma, specifically for remote and underserved communities.[503] (Evidence Grade: B) Between one third and one half of patients had favorable attitudes towards using telemedicine for glaucoma care.[504]
- A virtual glaucoma clinic was found to offer a safe, logistically viable option for professional care decisions in selective patients with glaucoma of low progressive risk for significant visual loss.[505]
- Good correlation was noted for diagnosis into "no glaucoma," "glaucoma," and "glaucoma suspect" between subjects evaluated through a set of tele-glaucoma stations (without either VF or anterior segment examination) and clinical exams.[506]
- Low-risk POAG suspects were followed for two years by tele-evaluation of vision, IOP and OCT assessment of the RNFL and were only referred for more thorough evaluation if evidence of progression was noted. Patient satisfaction and retention were both high and the number of patients who met the criteria for additional care and treatment were similar to the results of the OHTS study.[507]
- A comprehensive tele-glaucoma protocol (remotely provided by optometrists or comprehensive ophthalmologists with decision making by glaucoma specialists) showed high reliability with respect to clinical decision making and treatments, was cost effective, and demonstrated both high patient satisfaction and improved wait times for evaluation.[508]

EVIDENCE-BASED ACTION STATEMENT: Ocular telehealth programs can provide increased access to care but should not be used alone or for the assessment or management of moderate or advanced diseases in patients with primary open-angle glaucoma (POAG).[501-503]
Evidence Quality: Grade B. Study type(s): Systematic Review, Cross-sectional, Cohort-prospective **Level of Confidence:** High **Clinical Recommendation Level:** Strong Recommendation. This recommendation should be followed unless clear and compelling rationale for an alternative approach is present.
Evidence Statements: There is great variation in the reported sensitivity of tele-glaucoma screening, warranting further studies to establish its efficacy. For glaucoma management, both sensitivity and specificity must be further improved before being employed extensively.[502] (Evidence Grade: A) Telehealth may be an effective screening tool for glaucoma, specifically for remote and under-served communities.[503] (Evidence Grade: B) As there is only fair agreement between remote and in-person glaucoma assessments, remote assessment alone may be inappropriate for the management of glaucoma.[501] (Evidence Grade: D)

Potential Benefits: Increased access to care.	**Potential Risks/Harms:** Patients may mistakenly equate telehealth screening with an in-person eye examination..

Benefits and Harms Assessment: Benefits equal harms.
Potential Costs: Direct and indirect cost of testing.
Value Judgments: None.
Role of Patient Preferences: Large.
Intentional Vagueness: None.
Gaps in Evidence: Research on the sensitivity and specificity of telehealth screening and management services for patients with primary open angle glaucoma.

L. CONCLUSION

Primary open-angle glaucoma (POAG), the most common type of glaucoma, is a serious and significant public health concern and a leading cause of permanent vision loss in the United States. Most cases of vision loss from POAG occur pain-free and without warning signs. As such, the disease has historically been referred to as the "silent thief of vision." Early in the disease process, glaucoma commonly degrades peripheral vision. If the disease progresses and the patient goes untreated, or not treated aggressively enough, central vision can also be compromised with the possibility of total loss of vision or legal blindness. These changes in vision are permanent.

High quality peripheral and central vision are essential components to maintaining quality of life. Progressive vision loss due to POAG and the other forms of glaucoma are a significant economic burden to the individual and to society. Treatment is aimed at stabilizing the condition. However, no medication, laser treatment or surgical intervention is capable of restoring vision lost from glaucoma.

Certain risk factors such as family history, increasing age, belonging to certain racial/ethnic populations, decreased socioeconomic status, limited access to eye care, history of eye trauma and an extensive list of systemic health conditions increase the risk of developing glaucoma. All individuals need to be made aware of these risk factors and the benefits of early diagnosis and treatment.

Technologies to detect glaucoma in its earliest stages are continually improving. Annual in-person, comprehensive eye and vision examinations with an emphasis on patient education and access to diagnostic resources is the best way to identify the disease in its early phases. If the disease advances despite treatment, some patients may be referred to other eye care providers for additional intervention to slow progression. In cases of POAG with vision loss, patients may be referred to providers who specialize in vision rehabilitation or low vision services.

Doctors of optometry make up the frontlines of glaucoma diagnosis and treatment and as such should continually educate themselves and their patients on the most current forms of glaucoma management. With early diagnosis and treatment, doctors of optometry can lessen the burden of glaucoma related vision loss in the United States and improve patient's quality of life.

V. REFERENCES

1. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, editors. *Clinical Practice Guidelines We Can Trust*. Washington, D.C.: The National Academic Press, 2011.
2. Institute of Medicine Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Eden J, Levit L, Berg A, Morton S, editors. *Finding What Works in Health Care: Standards for Systematic Reviews*. Washington, D.C.: The National Academic Press, 2011.
3. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology* 2014;121(11):2081-90. doi: 10.1016/j.ophtha.2014.05.013.
4. Ang GS, Eke T. Lifetime visual prognosis for patients with primary open-angle glaucoma. *Eye (Lond)* 2007;21(5):604-8. doi: 10.1038/sj.eye.6702284
5. Malihi M, Moura Filho ER, Hodge DO, et al. Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota. *Ophthalmology* 2014;121(1):134-41. doi: 10.1016/j.ophtha.2013.09.003
6. Mokhles P, Schouten JSAG, Beckers HJM, et al. A systemic review of end-of-life visual impairment in open-angle glaucoma: an epidemiological autopsy. *J Glaucoma* 2016;25(7):623-28. doi: 10.1097/IJG.0000000000000389
7. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. *Arch Ophthalmol* 2002;120(6):714-20. doi: 10.1001/archopht.120.6.714
8. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. *Arch Ophthalmol* 2003;121(1):48-56. doi: 10.1001/archopht.121.1.48
9. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. *Am J Ophthalmol* 2000;130(4):429-40. doi: 10.1016/s0002-9394(00)00538-9
10. Gordon M, Kass MA. What we have learned from the Ocular Hypertension Treatment Study. *Am J Ophthalmol* 2018;189:248-49. doi: 10.1016/j.jajo.2018.02.016
11. Kass MA, Gordon MO, Gao F, et al. Delaying treatment of ocular hypertension: the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 2010;128(3):276-87. doi: 10.1001/archophthalmol.2010.20
12. Anderson DR, Normal Tension Glaucoma S. Collaborative Normal Tension Glaucoma Study. *Curr Opin Ophthalmol* 2003;14(2):86-90. doi: 10.1097/00055735-200304000-00006
13. Leske MC, Heijl A, Hyman L, et al. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. *Curr Opin Ophthalmol* 2004;15(2):102-6. doi: 10.1097/00055735-200404000-00008
14. David RCC, Moghimi S, Ekici E, et al. Rates of retinal nerve fiber layer thinning in distinct glaucomatous optic disc phenotypes in early glaucoma. *Am J Ophthalmol* 2021;229:8-17. doi: 10.1016/j.ajo.2021.04.010
15. Casson RJ, Chidlow G, Wood JP, et al. Definition of glaucoma: clinical and experimental concepts. *Clin Exp Ophthalmol* 2012;40(4):341-9. doi: 10.1111/j.1442-9071.2012.02773.x
16. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. *JAMA* 2014;311(18):1901-11. doi: 10.1001/jama.2014.3192
17. Leske MC. Open-angle glaucoma -- an epidemiologic overview. *Ophthalmic Epidemiol* 2007;14(4):166-72. doi: 10.1080/09286580701501931
18. Killer HE, Pircher A. Normal tension glaucoma: a review of current understanding and mechanisms of the pathogenesis *Eye (Lond)* 2018;32(5):924-30.
19. Song BJ, Caprioli J. New directions in the treatment of normal tension glaucoma. *Indian J Ophthalmol* 2014;62(5):529-37. doi: 10.4103/0301-4738.133481
20. Quaranta L, Riva I, Gerardi C, et al. Quality of life in glaucoma: a review of the literature. *Adv Ther* 2016;33(6):959-81. doi: 10.1007/s12325-016-0333-6
21. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the Early Manifest Glaucoma Trial. *Ophthalmology* 2007;114(11):1965-72. doi: 10.1016/j.ophtha.2007.03.016

22. Traynis I, De Moraes CG, Raza AS, et al. Prevalence and nature of early glaucomatous defects in the central 10 degrees of the visual field. *JAMA Ophthalmol* 2014;132(3):291-7. doi: 10.1001/jamaophthalmol.2013.7656
23. Glen FC, Crabb DP, Smith ND, et al. Do patients with glaucoma have difficulty recognizing faces? *Invest Ophthalmol Vis Sci* 2012;53(7):3629-37. doi: 10.1167/iovs.11-8538
24. Ogata NG, Boer ER, Daga FB, et al. Visual crowding in glaucoma. *Invest Ophthalmol Vis Sci* 2019;60(2):538-43.
25. Ramulu PY, Maul E, Hochberg C, et al. Real-world assessment of physical activity in glaucoma using an accelerometer. *Ophthalmology* 2012;119(6):1159-66. doi: 10.1016/j.ophtha.2012.01.013
26. Friedman DS, Freeman E, Munoz B, et al. Glaucoma and mobility performance: the Salisbury Eye Evaluation Project. *Ophthalmology* 2007;114(12):2232-7. doi: 10.1016/j.ophtha.2007.02.001
27. Black AA, Wood JM, Lovie-Kitchin JE, et al. Visual impairment and postural sway among older adults with glaucoma. *Optom Vis Sci* 2008;85(6):489-97. doi: 10.1097/OPX.0b013e31817882db
28. Sotimehin AE, Yonge AV, Mihailovic A, et al. Locations, circumstances, and outcomes of falls in patients with glaucoma. *Am J Ophthalmol* 2018;192:131-41. doi: 10.1016/j.ajo.2018.04.024
29. Ramulu PY, Mihailovic A, West SK, et al. Predictors of falls per step and falls per year at and away from home in glaucoma. *Am J Ophthalmol* 2019;200:169-78. doi: 10.1016/j.ajo.2018.12.021
30. Rolle T, Dallorto L, Caffasso R, et al. Reading ability in primary open-angle glaucoma: evaluation with Radner reading charts. *Optom Vis Sci* 2019;96(1):55-61. doi: 10.1097/OPX.0000000000001319
31. Mathews PM, Rubin GS, McCloskey M, et al. Severity of vision loss interacts with word-specific features to impact out-loud reading in glaucoma. *Invest Ophthalmol Vis Sci* 2015;56(3):1537-45. doi: 10.1167/iovs.15-15462
32. Kwon M, Liu R, Patel BN, et al. Slow reading in glaucoma: is it due to the shrinking visual span in central vision? *Invest Ophthalmol Vis Sci* 2017;58(13):5810-18. doi: 10.1167/iovs.17-22560
33. Swenor BK, Varadaraj V, Dave P, et al. Impact of the ability to divide attention on reading performance in glaucoma. *Invest Ophthalmol Vis Sci* 2017;58(5):2456-62. doi: 10.1167/iovs.17-21520
34. Blane A. Through the looking glass: a review of the literature investigating the impact of glaucoma on crash risk, driving performance, and driver self-regulation in older drivers. *J Glaucoma* 2016;25(1):113-21. doi: 10.1097/ijg.0000000000000193
35. Ekici F, Loh R, Waisbourd M, et al. Relationships between measures of the ability to perform vision-related activities, vision-related quality of life, and clinical findings in patients with glaucoma. *JAMA Ophthalmol* 2015;133(12):1377-85. doi: 10.1001/jamaophthalmol.2015.3426
36. Rossi GC, Pasinetti GM, Scudeller L, et al. Ocular surface disease and glaucoma: how to evaluate impact on quality of life. *J Ocul Pharmacol Ther* 2013;29(4):390-4. doi: 10.1089/jop.2011.0159
37. Camp A, Wellik SR, Tzu JH, et al. Dry eye specific quality of life in veterans using glaucoma drops. *Cont Lens Anterior Eye* 2015;38(3):220-5. doi: 10.1016/j.clae.2015.02.001
38. Fiscella RG, Lee J, Davis EJ, et al. Cost of illness of glaucoma: a critical and systematic review. *PharmacoEconomics* 2009;27(3):189-98. doi: 10.2165/00019053-200927030-00002
39. Blumberg DM, Prager AJ, Liebmann JM, et al. Cost-related medication nonadherence and cost-saving behaviors among patients with glaucoma before and after the implementation of Medicare Part D. *JAMA Ophthalmol* 2015;133(9):985-96. doi: 10.1001/jamaophthalmol.2015.1671
40. Prager AJ, Liebmann JM, Cioffi GA, et al. Self-reported function, health resource use, and total health care costs among Medicare beneficiaries with glaucoma. *JAMA Ophthalmol* 2016;134(4):357-65. doi: 10.1001/jamaophthalmol.2015.5479
41. Schehlein EM, Im LT, Robin AL, et al. Nonmedical out-of-pocket patient and companion expenditures associated with glaucoma care. *J Glaucoma* 2017;26(4):343-48. doi: 10.1097/ijg.0000000000000619
42. Alqudah A, Mansberger SL, Gardiner SK, et al. Vision-related quality of life in glaucoma suspect or early glaucoma patients. *J Glaucoma* 2016;25(8):629-33. doi: 10.1097/ijg.0000000000000445

43. Fernandez Lopez E, Karaca EE, Ekici F, et al. Symptoms reported by patients with varying stages of glaucoma: review of 401 cases. *Can J Ophthalmol* 2014;49(5):420-5. doi: 10.1016/j.jcjo.2014.07.014

44. Stagg BC, Granger A, Guetterman TC, et al. The burden of caring for and treating glaucoma: the patient perspective. *Ophthalmol Glaucoma* 2022;5(1):32-39. doi: 10.1016/j.ogla.2021.04.011

45. Jampel HD, Frick KD, Janz NK, et al. Depression and mood indicators in newly diagnosed glaucoma patients. *Am J Ophthalmol* 2007;144(2):238-44. doi: 10.1016/j.ajo.2007.04.048

46. Janz NK, Wren PA, Guire KE, et al. Fear of blindness in the Collaborative Initial Glaucoma Treatment Study: patterns and correlates over time. *Ophthalmology* 2007;114(12):2213-20. doi: 10.1016/j.ophtha.2007.02.014

47. Mogil RS, Tirsi A, Lee JM, et al. Glaucoma patient-reported concerns and associated factors. *Am J Ophthalmol* 2017;178:9-17. doi: 10.1016/j.ajo.2017.03.009

48. Otori Y, Takahashi G, Urashima M, et al. Evaluating the quality of life of glaucoma patients using the State-Trait Anxiety Inventory. *J Glaucoma* 2017;26(11):1025-29. doi: 10.1097/ijg.0000000000000761

49. Chan EW, Chiang PPC, Liao J, et al. Glaucoma and associated visual acuity and field loss significantly affect glaucoma-specific psychosocial functioning. *Ophthalmology* 2015;122(3):494-501. doi: 10.1016/j.ophtha.2014.09.030

50. American Public Health Association. Falls prevention in adults 65 years and over: a call for increased use of an evidence-based falls prevention algorithm. *Policy number 20235, November 14,* 2023.

51. E Jian-Yu, Mihailovic A, Schrack JA, et al. Characterizing longitudinal changes in physical activity and fear of falling after falls in glaucoma. *J Am Geriatr Soc* 2021;69(5):1249-56. doi: 10.1111/jgs.17014

52. Bhorade AM, Pearlmutter MS, Sabapathypillai SL, et al. Rate of falls, fear of falling, and avoidance of activities at-risk for falls in older adults with glaucoma. *Am J Ophthalmol* 2021;227:275-83. doi: 10.1016/j.ajo.2021.02.017

53. Adachi S, Yuki K, Awano-Tanabe S, et al. Factors associated with the occurrence of a fall in subjects with primary open-angle glaucoma. *BMC Ophthalmol* 2017;17(1):213. doi: 10.1186/s12886-017-0613-1

54. Baig S, Diniz-Filho A, Wu Z, et al. Association of fast visual field loss with risk of falling in patients with glaucoma. *JAMA Ophthalmol* 2016;134(8):880-6. doi: 10.1001/jamaophthalmol.2016.1659

55. Hattenhauer MG, Johnson DH, Ing HH, et al. The probability of blindness from open-angle glaucoma. *Ophthalmology* 1998;105(11):2099-104. doi: 10.1016/S0161-6420(98)91133-2

56. Peters D, Bengtsson B, Heijl A. Factors associated with lifetime risk of open-angle glaucoma blindness. *Acta Ophthalmol* 2014;92(5):421-25. doi: 10.1111/aos.12203

57. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. *Lancet* 2017;5(12):e1221-34. doi: 10.1016/s2214-109x(17)30393-5

58. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology* 2014;121(11):2081-90. doi: 10.1016/j.ophtha.2014.05.013

59. Zhang N, Wang J, Li Y, et al. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. *Sci Rep* 2021;11(1):13762. doi: 10.1038/s41598-021-92971-w

60. Kapetanakis VV, Chan MP, Foster PJ, et al. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. *Br J Ophthalmol* 2016;100(1):86-93. doi: 10.1136/bjophthalmol-2015-307223

61. Vajaranant TS, Wu S, Torres M, et al. The changing face of primary open-angle glaucoma in the United States: demographic and geographic changes from 2011 to 2050. *Am J Ophthalmol* 2012;154(2):303-14.e3. doi: 10.1016/j.ajo.2012.02.024

62. Gupta P, Zhao D, Guallar E, et al. Prevalence of glaucoma in the United States: The 2005-2008 National Health and Nutrition Examination Survey. *Invest Ophthalmol Vis Sci* 2016;57(6):2905-13. doi: 10.1167/iovs.15-18469

63. Kwon YH, Fingert JH, Kuehn MH, et al. Primary open-angle glaucoma. *N Engl J Med* 2009;360(11):1113-24. doi: 10.1056/NEJMra0804630

64. Cedrone C, Mancino R, Cerulli A, et al. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. *Prog Brain Res* 2008;173:3-14. doi: 10.1016/s0079-6123(08)01101-1

65. Tielsch JM, Katz J, Sommer A, et al. Family history and risk of primary open angle glaucoma: The Baltimore Eye Survey. *Arch Ophthalmol* 1994;112(1):69-73.

66. Nannini D, Torres M, Chen YD, et al. African ancestry is associated with higher intraocular pressure in Latinos. *Ophthalmology* 2016;123(1):102-8. doi: 10.1016/j.ophtha.2015.08.042

67. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among White and Black Americans. *Arch Ophthalmol* 1991;109(8):1090-95.

68. Bourne RR, Taylor HR, Flaxman SR, et al. Number of people blind or visually impaired by glaucoma worldwide and in world regions 1990 - 2010: a meta-analysis. *PloS One* 2016;11(10):e0162229. doi: 10.1371/journal.pone.0162229

69. Leske MC, Wu SY, Hennis A, et al. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. *Ophthalmology* 2008;115(1):85-93. doi: 10.1016/j.ophtha.2007.03.017

70. Nemesure B, Honkanen R, Hennis A, et al. Incident open-angle glaucoma and intraocular pressure. *Ophthalmology* 2007;114(10):1810-5. doi: 10.1016/j.ophtha.2007.04.003

71. Bengtsson B, Leske MC, Hyman L, et al. Fluctuation of intraocular pressure and glaucoma progression in the Early Manifest Glaucoma Trial. *Ophthalmology* 2007;114(2):205-9. doi: 10.1016/j.ophtha.2006.07.060

72. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. *Surv Ophthalmol* 2008;53 Suppl1:S3-10. doi: 10.1016/j.survophthal.2008.08.006

73. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol* 2002;120(6):701-13. doi: 10.1001/archopht.120.6.701

74. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. *Arch Ophthalmol* 2002;120(10):1268-79. doi: 10.1001/archopht.120.10.1268

75. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. *Lancet* 2015;385(9975):1295-304. doi: 10.1016/S0140-6736(14)62111-5

76. De Voogd S, Ikram K, Wolfs RCW, et al. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. *Ophthalmology* 2005;112(9):1487-93. doi: 10.1016/j.ophtha.2005.04

77. Green CM, Kearns LS, Wu J, et al. How significant is a family history of glaucoma? Experience from the Glaucoma Inheritance Study in Tasmania. *Clin Exp Ophthalmol* 2007;35(9):793-9. doi: 10.1111/j.1442-9071.2007.01612.x

78. Gramer G, Weber BH, Gramer E. Results of a patient-directed survey on frequency of family history of glaucoma in 2170 patients. *Invest Ophthalmol Vis Sci* 2014;55(1):259-64. doi: 10.1167/iovs.13-13020

79. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. *JAMA* 1991;266(3):369-74.

80. Varma R, Ying-Lai M, Francis BA, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. *Ophthalmology* 2004;111(8):1439-48. doi: 10.1016/j.ophtha.2004.01.025

81. Mitchell P, Hourihan F, Sandbach J, et al. The relationship between glaucoma and myopia: the Blue Mountains Eye Study. *Ophthalmology* 1999;106(10):2010-15.

82. Perera SA, Wong TY, Wan-Ting T, et al. Refractive error, axial dimensions, and primary open-angle glaucoma. *Arch Ophthalmol* 2010;128(7):900-05.

83. Marcus MW, De Vries MM, Montolio FGJ, et al. Myopia as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. *Ophthalmology* 2011;118(10):1989-94. doi: 10.1016/j.ophtha.2011.03.012

84. Jonas JB, Wang YX, Dong L, et al. High myopia and glaucomatous-like optic neuropathy. *Asia Pac J Ophthalmol (Phila)* 2020;9(3):234-38. doi: 10.1097/APO.0000000000000288

85. Lee YA, Shih YF, Lin LLK, et al. Association between high myopia and progression of visual field loss in primary open-angle glaucoma. *J Formos Med Assoc* 2008;107(12):952-57.

86. Perdicchi A, Lester M, Scuderi G, et al. Visual field damage and progression in glaucomatous myopic eyes. *Eur J Ophthalmol* 2007;17(4):534-37.

87. Jonas JB, Panda-Jonas S, Wang YX. Glaucoma neurodegeneration and myopia. *Prog Brain Res* 2020;257:1-17. doi: 10.1016/bs.pbr.2020.06.014

88. Lee EJ, Han JC, Kee C. Intereye comparison of ocular factors in normal tension glaucoma with asymmetric visual field loss in Korean population. *PloS One* 2017;12(10):e0186236. doi: 10.1371/journal.pone.0186236

89. Wang SY, Melles R, Lin SC. The impact of central corneal thickness on the risk for glaucoma in a large multiethnic population. *J Glaucoma* 2014;23(9):606-12. doi: 10.1097/ijg.0000000000000088

90. Francis BA, Varma R, Chopra V, et al. Intraocular pressure, central corneal thickness, and prevalence of open-angle glaucoma: the Los Angeles Latino Eye Study. *Am J Ophthalmol* 2008;146(5):741-6. doi: 10.1016/j.ajo.2008.05.048

91. Zhou M, Wang W, Huang W, et al. Diabetes mellitus as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. *PloS One* 2014;9(8):e102972. doi: 10.1371/journal.pone.0102972

92. Bae HW, Lee N, Lee HS, et al. Systemic hypertension as a risk factor for open-angle glaucoma: a meta-analysis of population-based studies. *PloS One* 2014;9(9):e108226. doi: 10.1371/journal.pone.0108226

93. Charlson ME, de Moraes CG, Link A, et al. Nocturnal systemic hypotension increases the risk of glaucoma progression. *Ophthalmology* 2014;121(10):2004-12. doi: 10.1016/j.ophtha.2014.04.016

94. Medeiros FA, Freitas D, Lisboa R, et al. Corneal hysteresis as a risk factor for glaucoma progression: a prospective longitudinal study. *Ophthalmology* 2013;120(8):1533-40. doi: 10.1016/j.ophtha.2013.01.032

95. Susanna BN, Ogata NG, Jammal AA, et al. Corneal biomechanics and visual field progression in eyes with seemingly well-controlled intraocular pressure. *Ophthalmology* 2019;126(12):1640-46. doi: 10.1016/j.ophtha.2019.07.023

96. Estrela T, Jammal AA, Mariottoni EB, et al. The relationship between asymmetries of corneal properties and rates of visual field progression in glaucoma patients. *J Glaucoma* 2020;29(10):872-77. doi: 10.1097/IJG.0000000000001625

97. Wu A, Khawaja AP, Pasquale LR, et al. A review of systemic medications that may modulate the risk of glaucoma. *Eye (Lond)* 2020;34(1):12-28. doi: 10.1038/s41433-019-0603-z

98. Sheppard JD, Comstock TL, Cavet ME. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. *Adv Ther* 2016;33(4):532-52. doi: 10.1007/s12325-016-0315-8

99. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. *Drug safety* 2008;31(2):127-41.

100. Bielory B, Bielory L. Over-the-counter migration of steroid use: impact on the eye. *Curr Opin Allergy Clin Immunol* 2014;14(5):471-76. doi: 10.1097/ACL.0000000000000099

101. Razeghinejad MR, Myers JS, Katz LJ. Iatrogenic glaucoma secondary to medications. *Am J Med* 2011;124(1):20-5. doi: 10.1016/j.amjmed.2010.08.011

102. Chen VC, Ng MH, Chiu WC, et al. Effects of selective serotonin reuptake inhibitors on glaucoma: a nationwide population-based study. *PloS One* 2017;12(3):e0173005. doi: 10.1371/journal.pone.0173005

103. Stein JD, Khawaja AP, Weizer JS. Glaucoma in adults-screening, diagnosis, and management: a review. *JAMA* 2021;325(2):164-74. doi: 10.1001/jama.2020.21899

104. Muskens RP, de Voogd S, Wolfs RC, et al. Systemic antihypertensive medication and incident open-angle glaucoma. *Ophthalmology* 2007;114(12):2221-6. doi: 10.1016/j.ophtha.2007.03.047

105. Pershing S, Bakri SJ, Moshfeghi DM. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. *Ophthalmic Surg Lasers Imaging Retina* 2013;44(5):460-4. doi: 10.3928/23258160-20130909-07

106. Eadie B, Etminan M, Carleton BC, et al. Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery. *JAMA Ophthalmol* 2017;135(4):363-68. doi: doi:10.1001/jamaophthalmol.2017.0059

107. Abedi G, Adelman RA, Salim S. Incidence and mangement of elevated intraocular pressure with antivascular endothelial growth factor agents. *Semin Ophthalmol* 2013;28(3):126-30.

108. Bressler SB, Almuktar T, Bhorade A, et al. Repeated intravitreous ranibizumad injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypertensive treatment. *JAMA Ophthalmol* 2015;133(5):589-97.

109. Mansoori T, Mohan GP, Agraharam SG, et al. Incidence and risk factors for intraocular pressure rise after the scleral buckle surgery for retinal detachment. *J Curr Ophthalmol* 2021;33(4):444-48. doi: 10.4103/joco.joco_108_21

110. Xu XH, Zou JY, Geng W, et al. Association between glaucoma and the risk of Alzheimer's disease: a systematic review of observational studies. *Acta Ophthalmol* 2019;97(7):665-71. doi: 10.1111/aos.14114

111. Ghiso JA, Doudevski I, Ritch R, et al. Alzheimer's disease and glaucoma: mechanistic similarities and differences. *J Glaucoma* 2013;22 Suppl 5:S36-8. doi: 10.1097/IJG.0b013e3182934af6

112. Helmer C, Malet F, Rougier MB, et al. Is there a link between open-angle glaucoma and dementia? The Three-City-Alienor cohort. *Ann Neurol* 2013;74(2):171-9. doi: 10.1002/ana.23926

113. Ou Y, Grossman DS, Lee PP, et al. Glaucoma, Alzheimer's disease and other dementia: a longitudinal analysis. *Ophthalmic Epidemiol* 2012;19(5):285-92. doi: doi:10.3109/09286586.2011.649228

114. Lee J, Choi J, Kim S, et al. Relationship between daytime variability of blood pressure or ocular perfusion pressure and glaucomatous visual field progression. *Am J Ophthalmol* 2015;160(3):522-27.

115. Leske MC. Ocular perfusion pressure and glaucoma: clinical trial and epidemiologic findings. *Curr Opin Ophthalmol* 2009;20(2):73-8. doi: 10.1097/ICU.0b013e32831eef82

116. Memarzadeh F, Ying-Lai M, Chung J, et al. Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study. *Invest Ophthalmol Vis Sci* 2010;51(6):2872-7. doi: 10.1167/iovs.08-2956

117. Rim TH, Lee SY, Kim SH, et al. Increased incidence of open-angle glaucoma among hypertensive patients: an 11-year nationwide retrospective cohort study. *J Hypertens* 2017;35(4):729-36. doi: 10.1097/hjh.0000000000001225

118. Chopra V, Varma R, Francis BA, et al. Type 2 diabetes mellitus and the risk of open-angle glaucoma: the Los Angeles Latino Eye Study. *Ophthalmology* 2008;115(2):227-32.e1. doi: 10.1016/j.ophtha.2007.04.049

119. Kim M, Jeoung JW, Park KH, et al. Metabolic syndrome as a risk factor in normal-tension glaucoma. *Acta Ophthalmol* 2014;92(8):e637-43. doi: 10.1111/aos.12434

120. Zaleska-Zmijewska A, Janiszewski M, Wawrzyniak ZM, et al. Is atrial fibrillation a risk factor for normal-tension glaucoma? *Medicine* 2017;96(43):e8347. doi: 10.1097/md.0000000000008347

121. Perez-Rico C, Gutierrez-Diaz E, Mencia-Gutierrez E, et al. Obstructive sleep apnea-hypopnea syndrome (OSAHS) and glaucomatous optic neuropathy. *Graefes Arch Clin Exp Ophthalmol* 2014;252(9):1345-57. doi: 10.1007/s00417-014-2669-4

122. Hashim SP, Al Mansouri FA, Farouk M, et al. Prevalence of glaucoma in patients with moderate to severe obstructive sleep apnea: ocular morbidity and outcomes in a 3 year follow-up study. *Eye (Lond)* 2014;28(11):1304-9. doi: 10.1038/eye.2014.195

123. Faridi O, Park SC, Liebmann JM, et al. Glaucoma and obstructive sleep apnoea syndrome. *Clin Exp Ophthalmol* 2012;40(4):408-19. doi: 10.1111/j.1442-9071.2012.02768.x

124. Ingold N, Campos AI, Han X, et al. Is genetic risk for sleep apnea causally linked with glaucoma susceptibility? *Invest Ophthalmol Vis Sci* 2022;63(1):25. doi: 10.1167/iovs.63.1.25

125. Keenan TD, Goldacre R, Goldacre MJ. Associations between obstructive sleep apnoea, primary open angle glaucoma and age-related macular degeneration: record linkage study. *Br J Ophthalmol* 2017;101(2):155-59. doi: 10.1136/bjophthalmol-2015-308278

126. Wozniak D, Bourne R, Peretz G, et al. Obstructive sleep apnea in patients with primary-open angle glaucoma: no role for a screening program. *J Glaucoma* 2019;28(8):668-75. doi: 10.1097/IJG.0000000000001296

127. Lin HC, Chien CW, Hu CC, et al. Comparison of comorbid conditions between open-angle glaucoma patients and a control cohort: a case-control study. *Ophthalmology* 2010;117(11):2088-95. doi: 10.1016/j.ophtha.2010.03.003

128. Mabuchi F, Yoshimura K, Kashiwagi K, et al. High prevalence of anxiety and depression in patients with primary open-angle glaucoma. *J Glaucoma* 2008;17(7):552-7. doi: 10.1097/IJG.0b013e31816299d4

129. Jung KI, Park CK. Mental health status and quality of life in undiagnosed glaucoma patients: a nationwide population-based study. *Medicine* 2016;95(19):e3523. doi: 10.1097/md.0000000000003523

130. Khanna CL, Leske DA, Holmes JM. Factors associated with health-related quality of life in medically and surgically treated patients with glaucoma. *JAMA Ophthalmology* 2018 doi: 10.1001/jamaophthalmol.2018.0012

131. Anderson DR, Hendrickson A. Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve. *Invest Ophthalmol* 1974;13(10):771-83.

132. Quigley H, Anderson DR. The dynamics and location of axonal transport blockade by acute intraocular pressure elevation in primate optic nerve. *Invest Ophthalmol* 1976;15(8):606-16.

133. Quigley HA, Anderson DR. Distribution of axonal transport blockade by acute intraocular pressure elevation in the primate optic nerve head. *Invest Ophthalmol Vis Sci* 1977;16(7):640-4.

134. Levy NS, Crapps EE, Bonney RC. Displacement of the optic nerve head. Response to acute intraocular pressure elevation in primate eyes. *Arch Ophthalmol* 1981;99(12):2166-74. doi: 10.1001/archopht.1981.03930021042012

135. Levy NS, Crapps EE. Displacement of optic nerve head in response to short-term intraocular pressure elevation in human eyes. *Arch Ophthalmol* 1984;102(5):782-6. doi: 10.1001/archopht.1984.01040030630037

136. Burgoyne CF, Quigley HA, Thompson HW, et al. Measurement of optic disc compliance by digitized image analysis in the normal monkey eye. *Ophthalmology* 1995;102(12):1790-9. doi: 10.1016/s0161-6420(95)30792-0

137. Burgoyne CF, Varma R, Quigley HA, et al. Global and regional detection of induced optic disc change by digitized image analysis. *Arch Ophthalmol* 1994;112(2):261-8. doi: 10.1001/archopht.1994.01090140137035

138. Fortune B, Yang H, Strouthidis NG, et al. The effect of acute intraocular pressure elevation on peripapillary retinal thickness, retinal nerve fiber layer thickness, and retardance. *Invest Ophthalmol Vis Sci* 2009;50(10):4719-26. doi: 10.1167/iovs.08-3289

139. Heickell AG, Bellezza AJ, Thompson HW, et al. Optic disc surface compliance testing using confocal scanning laser tomography in the normal monkey eye. *J Glaucoma* 2001;10(5):369-82. doi: 10.1097/00061198-200110000-00002

140. Ivers KM, Yang H, Gardiner SK, et al. In vivo detection of laminar and peripapillary scleral hypercompliance in early monkey experimental glaucoma. *Invest Ophthalmol Vis Sci* 2016;57(9):388-403. doi: 10.1167/iovs.15-18666

141. Morgan WH, Chauhan BC, Yu DY, et al. Optic disc movement with variations in intraocular and cerebrospinal fluid pressure. *Invest Ophthalmol Vis Sci* 2002;43(10):3236-42.

142. Quigley HA, Pease ME. Change in the optic disc and nerve fiber layer estimated with the glaucoma-scope in monkey eyes. *J Glaucoma* 1996;5(2):106-16.

143. Sharma S, Tun TA, Baskaran M, et al. Effect of acute intraocular pressure elevation on the minimum rim width in normal, ocular hypertensive and glaucoma eyes. *Br J Ophthalmol* 2018;102(1):131-35. doi: 10.1136/bjophthalmol-2017-310232

144. Strouthidis NG, Fortune B, Yang H, et al. Effect of acute intraocular pressure elevation on the monkey optic nerve head as detected by spectral domain optical coherence tomography. *Invest Ophthalmol Vis Sci* 2011;52(13):9431-7. doi: 10.1167/iovs.11-7922

145. Burgoyne CF. A biomechanical paradigm for axonal insult within the optic nerve head in aging and glaucoma. *Exp Eye Res* 2011;93(2):120-32. doi: 10.1016/j.exer.2010.09.005

146. Downs JC. Optic nerve head biomechanics in aging and disease. *Exp Eye Res* 2015;133:19-29. doi: 10.1016/j.exer.2015.02.011

147. Patel N, McAllister F, Pardon L, et al. The effects of graded intraocular pressure challenge on the optic nerve head. *Exp Eye Res* 2018;169:79-90. doi: 10.1016/j.exer.2018.01.025

148. Burgoyne CF, Downs JC. Premise and prediction-how optic nerve head biomechanics underlies the susceptibility and clinical behavior of the aged optic nerve head. *J Glaucoma* 2008;17(4):318-28. doi: 10.1097/IJG.0b013e31815a343b

149. Czerpak CA, Ling YTT, Jefferys JL, et al. The curvature, collagen network structure, and their relationship to the pressure-induced strain response of the human lamina cribrosa in normal and glaucoma eyes. *J Biomech Eng* 2023;145(10) doi: 10.1115/1.4062846

150. Allingham RR, Liu Y, Rhee DJ. The genetics of primary open-angle glaucoma: a review. *Exp Eye Res* 2009;88(4):837-44. doi: 10.1016/j.exer.2008.11.003

151. Wang HW, Sun P, Chen Y, et al. Research progress on human genes involved in the pathogenesis of glaucoma (Review). *Mol Med Rep* 2018;18(1):656-74. doi: 10.3892/mmr.2018.9071

152. Khawaja AP, Bailey JNC, Wareham NJ, et al. Genome-wide analyses identify 68 new loci associated with intraocluar pressure and improve risk predicition for primary open-angle glaucoma. *Nat Genet* 2018;50(6):778-82.

153. Gharahkhani P, Jorgenson E, Hysi P, et al. Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries. *Nat Commun* 2021;12(1):1258. doi: 10.1038/s41467-020-20851-4

154. Fan BJ, Wiggs JL. Glaucoma: genes, phenotypes, and new directions for therapy. *J Clin Invest* 2010;120(9):3064-72. doi: 10.1172/jci43085

155. Leske MC, Heijl A, Hyman L, et al. Early Manifest Glaucoma Trial: design and baseline data. *Ophthalmology* 1999;106(11):2144-53. doi: 10.1016/s0161-6420(99)90497-9

156. Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. *Am J Ophthalmol* 1998;126(4):498-505. doi: 10.1016/s0002-9394(98)00272-4

157. Erdem E. Long-term (>8 years) evaluation of progression in patients with low-pressure glaucoma. *Eur J Ophthalmol* 2015;25(6):490-95. doi: DOI: 10.5301/ejo.5000624

158. Kass MA, Heuer DK, Higginbotham EJ, et al. Assessment of cumulative incidence and severity of primary open-angle glaucoma among participants in the Ocular Hypertension Treatment Study after 20 years of follow-up. *JAMA Ophthalmol* 2021;139(5):1-9. doi: 10.1001/jamaophthalmol.2021.0341

159. Garg A, Vickerstaff V, Nathwani N, et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinial outcomes, predictors of success, and safety from the Laser in Glaucoma and Ocular Hypertension Trial. *Ophthalmology* 2019;126(9):1238-48. doi: 10.1016/j.ophtha.2019.04.012

160. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. *Health Technol Assess* 2019;23(31):1-102. doi: 10.3310/hta23310

161. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: six year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. *Ophthalmology* 2023:139-51.

162. Ederer F, Gaasterland DE, Sullivan EK, et al. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. *Control Clin Trials* 1994;15(4):299-325. doi: 10.1016/0197-2456(94)90046-9

163. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. *Ophthalmology* 1998;105(7):1146-64. doi: 10.1016/s0161-6420(98)97013-0

164. Ederer F, Gaasterland DA, Dally LG, et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. *Ophthalmology* 2004;111(4):651-64. doi: 10.1016/j.ophtha.2003.09.025

165. Musch DC, Gillespie BW, Niziol LM, et al. Factors associated with intraocular pressure before and during 9 years of treatment in the Collaborative Initial Glaucoma Treatment Study. *Ophthalmology* 2008;115(6):927-33. doi: 10.1016/j.ophtha.2007.08.010

166. Musch DC, Gillespie BW, Lichter PR, et al. Visual field progression in the Collaborative Initial Glaucoma Treatment Study: the impact of treatment and other baseline factors. *Ophthalmology* 2009;116(2):200-7. doi: 10.1016/j.ophtha.2008.08.051

167. Musch DC, Gillespie BW, Niziol LM, et al. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. *Ophthalmology* 2011;118(9):1766-73. doi: 10.1016/j.ophtha.2011.01.047

168. Gedde SJ, Heuer DK, Parrish RK, 2nd. Review of results from the Tube Versus Trabeculectomy Study. *Curr Opin Ophthalmol* 2010;21(2):123-8. doi: 10.1097/ICU.0b013e3283360b68

169. Gedde SJ, Herndon LW, Brandt JD, et al. Surgical complications in the Tube Versus Trabeculectomy Study during the first year of follow-up. *Am J Ophthalmol* 2007;143(1):23-31. doi: 10.1016/j.ajo.2006.07.022

170. Kotecha A, Feuer WJ, Barton K, et al. Quality of life in the Tube Versus Trabeculectomy Study. *Am J Ophthalmol* 2017;176:228-35. doi: 10.1016/j.ajo.2017.01.019

171. Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. *Am J Ophthalmol* 2012;153(5):789-803 e2. doi: 10.1016/j.ajo.2011.10.026

172. Lascaratos G, Garway-Heath DF, Burton R, et al. The United Kingdom Glaucoma Treatment Study: a multicenter, randomized, double-masked, placebo-controlled trial: baseline characteristics. *Ophthalmology* 2013;120(12):2540-5. doi: 10.1016/j.ophtha.2013.07.054

173. Founti P, Bunce C, Khawaja AP, et al. Risk factors for visual field deterioriation in the United Kingdom Glaucoma Treatment study. *Ophthalmology* 2020;127(12):1642-51. doi: 10.1016/j.ophtha.2020.06.009

174. Chou R, Selph S, Blazina I, et al. Screening for glaucoma in adults: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2022;327(20):1998-2012. doi: 10.1001/jama.2022.6290

175. Burr JM, Mowatt G, Hernandez R, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. *Health Technol Assess* 2007;11(41):iii-iv, ix-x, 1-190. doi: 10.3310/hta11410

176. van Zyl T, Su Z, Zhou E, et al. Providing prescheduled appointments as a strategy for improving follow-up compliance after community-based glaucoma screening: results from an urban underserved population. *J Community Health* 2015;40(1):27-33. doi: 10.1007/s10900-014-9890-2

177. Altangerel U, Nallamshetty HS, Uhler T, et al. Knowledge about glaucoma and barriers to follow-up care in a community glaucoma screening program. *Can J Ophthalmol* 2009;44(1):66-69. doi: 10.3129/i08-175

178. Salim S, Du H, Wan J. Comparison of intraocular pressure measurements and assessment of intraobserver and interobserver reproducibility with the portable ICare rebound tonometer and Goldmann applanation tonometer in glaucoma patients. *J Glaucoma* 2013;22(4):325-9. doi: 10.1097/IJG.0b013e318237caa2

179. Dey A, David RL, Asokan R, et al. Can corneal biomechanical properties explain difference in tonometric measurement in normal eyes? *Optom Vis Sci* 2018;95(2):120-28. doi: 10.1097/OPX.0000000000001175

180. Lee JY, Sung KR, Lee JY. Comparison of the progression of high- and low-tension glaucoma as determined by two different criteria. *Korean J Ophthalmol* 2016;30(1):40-7. doi: 10.3341/kjo.2016.30.1.40

181. Cheng J, Kong X, Xiao M, et al. Twenty-four-hour pattern of intra-ocular pressure in untreated patients with primary open-angle glaucoma. *Acta Ophthalmol* 2016;94(6):e460-7. doi: 10.1111/aos.12963

182. Kim SH, Lee EJ, Han JC, et al. The effect of diurnal fluctuation in intraocular pressure on the evaluation of risk factors of progression in normal tension glaucoma. *PloS One* 2016;11(10):e0164876. doi: 10.1371/journal.pone.0164876

183. Agnifili L, Mastropasqua R, Frezzotti P, et al. Circadian intraocular pressure patterns in healthy subjects, primary open angle and normal tension glaucoma patients with a contact lens sensor. *Acta Ophthalmol* 2015;93(1):e14-21. doi: 10.1111/aos.12408

184. Gautam N, Kaur S, Kaushik S, et al. Postural and diurnal fluctuations in intraocular pressure across the spectrum of glaucoma. *Br J Ophthalmol* 2016;100(4):537-41. doi: 10.1136/bjophthalmol-2015-306861

185. Johnson TV, Ramulu PV, Quigley HA, et al. Low sensitivity of the Van Herick angle assessment for detecting gonioscopic angle closure independant of observer expertise. *Am J Ophthalmol* 2018;195(11):63-71.

186. Desmond T, Tran V, Maharaj M, et al. Diagnostic accuracy of AS-OCT vs gonioscopy for detecting angle closure: a systematic review and meta-analysis. *Graefes Arch Clin Exp Ophthalmol* 2022;260(1):1-23. doi: 10.1007/s00417-021-05271-4

187. Dueker DK, Singh K, Lin SC, et al. Corneal thickness measurement in the management of primary open-angle glaucoma: a report by the American Academy of Ophthalmology. *Ophthalmology* 2007;114(9):1779-87. doi: 10.1016/j.ophtha.2007.04.068

188. Herndon LW, Weizer JS, Stinnett SS. Central corneal thickness as a risk factor for advanced glaucoma damage. *Arch Ophthalmol* 2004;122(1):17-21. doi: 10.1001/archopht.122.1.17

189. Brandt JD, Gordon MO, Gao F, et al. Adjusting intraocular pressure for central corneal thickness does not improve prediction models for primary open-angle glaucoma. *Ophthalmology* 2012;119(3):437-42. doi: 10.1016/j.ophtha.2011.03.018

190. Copt RP, Thomas R, Mermoud A. Corneal thickness in ocular hypertension, primary open-angle glaucoma, and normal tension glaucoma. *Arch Ophthalmol* 1999;117(1):14-6. doi: 10.1001/archopht.117.1.14

191. Shetgar AC, Mulimani MB. The central corneal thickness in normal tension glaucoma, primary open angle glaucoma and ocular hypertension. *J Clin Diagn Res* 2013;7(6):1063-7. doi: 10.7860/JCDR/2013/4292.3022

192. Banister K, Boachie C, Bourne R, et al. Can automated imaging for optic disc and retinal nerve fiber layer analysis aid glaucoma detection? *Ophthalmology* 2016;123(5):930-8. doi: 10.1016/j.ophtha.2016.01.041

193. Qiu M, Boland MV, Ramulu PY. Cup-to-disc ratio asymmetry in U.S. adults: prevalence and association with glaucoma in the 2005-2008 National Health and Nutrition Examination Survey. *Ophthalmology* 2017;124(8):1229-36. doi: 10.1016/j.ophtha.2017.03.049

194. Wang L, Damji KF, Munger R, et al. Increased disk size in glaucomatous eyes vs normal eyes in the Reykjavik Eye Study. *Am J Ophthalmol* 2003;135(2):226-28.

195. Nixon GJ, Watanabe RK, Sullivan-Mee M, et al. Influence of optic disc size on identifying glaucomatous optic neuropathy. *Optom Vis Sci* 2017;94(6):654-63.

196. Jonas JB, Schiro D. Localised wedge shaped defects of the retinal nerve fibre layer in glaucoma. *Br J Ophthalmol* 1994;78(4):285-90. doi: 10.1136/bjo.78.4.285

197. Kim JA, Lee EJ, Kim TW. Evaluation of parapapillary choroidal microvasculature dropout and progressive retinal nerve fiber layer thinning in patients with glaucoma. *JAMA Ophthalmol* 2019;137(7):810-16. doi: 10.1001/jamaophthalmol.2019.1212

198. Morgan JE, Bourtsoukli I, Rajkumar KN, et al. The accuracy of the inferior>superior>nasal>temporal neuroretinal rim area rule for diagnosing glaucomatous optic disc damage. *Ophthalmology* 2012;119(4):723-30. doi: 10.1016/j.ophtha.2011.10.004

199. Kim MJ, Kim SH, Hwang YH, et al. Novel screening method for glaucomatous eyes with myopic tilted discs: the crescent moon sign. *JAMA Ophthalmol* 2014;132(12):1407-13. doi: 10.1001/jamaophthalmol.2014.2860

200. Lee JE, Sung KR, Lee JY, et al. Implications of optic disc tilt in the progression of primary open-angle glaucoma. *Invest Ophthalmol Vis Sci* 2015;56(11):6925-31. doi: 10.1167/iovs.15-17892

201. Mahmoudinezhad G, Lin M, Rabiolo A, et al. Rate of visual field decay in glaucomatous eyes with acquired pits of the optic nerve. *Br J Ophthalmol* 2021;105(3):381-86. doi: 10.1136/bjophthalmol-2020-315980

202. Kawasaki R, Wang JJ, Rochtchina E, et al. Retinal vessel caliber is associated with the 10-year incidence of glaucoma: the Blue Mountains Eye Study. *Ophthalmology* 2013;120(1):84-90. doi: 10.1016/j.ophtha.2012.07.007

203. Herschler J, Osher RH. Baring of the circumlinear vessel. An early sign of optic nerve damage. *Arch Ophthalmol* 1980;98(5):865-9. doi: 10.1001/archopht.1980.01020030859012

204. Shon K, Hye Jo Y, Won Shin J, et al. Nasalization of central retinal vessel trunk predicts rapid progression of central visual field in open-angle glaucoma. *Sci Rep* 2020;10(1):3789. doi: 10.1038/s41598-020-60355-1

205. Budenz DL, Huecker JB, Gedde SJ, et al. Thirteen-year follow-up of optic disc hemorrhages in the Ocular Hypertension Treatment Study. *Am J Ophthalmol* 2017;174:126-33. doi: 10.1016/j.ajo.2016.10.023

206. Razeghinejad MR, Nowroozzadeh MH. Optic disk hemorrhage in health and disease. *Surv Ophthalmol* 2017;62(6):784-802. doi: 10.1016/j.survophthal.2017.04.001

207. Jasty U, Harris A, Siesky B, et al. Optic disc haemorrhage and primary open-angle glaucoma: a clinical review. *Br J Ophthalmol* 2020;104(11):1488-91. doi: 10.1136/bjophthalmol-2019-314583

208. Jonas JB, Martus P, Budde WM, et al. Morphologic predictive factors for development of optic disc hemorrhages in glacuoma. *Invest Ophthalmol Vis Sci* 2002;43(9):2956-61.

209. Furlanetto RL, De Moraes CG, Teng CC, et al. Risk factors for optic disc hemorrhage in the low-pressure glaucoma treatment study. *Am J Ophthalmol* 2014;157(5):945-52. doi: 10.1016/j.ajo.2014.02.009

210. Lee EJ, Kim TW, Weinreb RN, et al. beta-Zone parapapillary atrophy and the rate of retinal nerve fiber layer thinning in glaucoma. *Invest Ophthalmol Vis Sci* 2011;52(7):4422-7. doi: 10.1167/iovs.10-6818

211. Sullivan-Mee M, Patel NB, Pensyl D, et al. Relationship between juxtapapillary choroidal volume and beta-zone parapapillary atrophy in eyes with and without primary open-angle glaucoma. *Am J Ophthalmol* 2015;160(4):637-47.e1. doi: 10.1016/j.ajo.2015.06.024

212. Budenz DL, Anderson DR, Feuer WJ, et al. Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. *Ophthalmology* 2006;113(12):2137-43. doi: 10.1016/j.ophtha.2006.06.022

213. Kitaoka Y, M. T, Yokoyama Y, et al. Estimation of the disc damage likelihood scale in primary open-angle glaucom: the glaucoma stereo analysis study. *Graefes Arch Clinl Exp Ophthalmol* 2016;254(4):523-28.

214. Sandhu S, Rudnisky C, Arora S, et al. Compressed 3D and 2D digital images versus standard 3D slide film for the evaluation of glaucomatous optic nerve features. *Br J Ophthalmol* 2018;102(3):364-68. doi: 10.1136/bjophthalmol-2017-310447

215. Yokoyama Y, Tanito M, Nitta K, et al. Stereoscopic analysis of optic nerve head parameters in primary open angle glaucoma: the Glaucoma Stereo Analysis Study. *PloS One* 2014;9(6):e99138. doi: 10.1371/journal.pone.0099138

216. Alhadeff PA, De Moraes CG, Chen M, et al. The association between clinical features seen on fundus photographs and glaucomatous damage detected on visual fields and optical coherence tomography scans. *J Glaucoma* 2017;26(5):498-504. doi: 10.1097/ijg.0000000000000640

217. Breusegem C, Fieuws S, Stalmans I, et al. Agreement and accuracy of non-expert ophthalmologists in assessing glaucomatous changes in serial stereo optic disc photographs. *Ophthalmology* 2011;118(4):742-6. doi: 10.1016/j.ophtha.2010.08.019

218. Banegas SA, Anton A, Morilla-Grasa A, et al. Agreement among spectral-domain optical coherence tomography, standard automated perimetry, and stereophotography in the detection of glaucoma progression. *Invest Ophthalmol Vis Sci* 2015;56(2):1253-60. doi: 10.1167/iovs.14-14994

219. Tatham AJ, Medeiros FA. Detecting structural progression in glaucoma with optical coherence tomography. *Ophthalmology* 2017;124(12S):S57-S65. doi: 10.1016/j.ophtha.2017.07.015

220. Chauhan BC, O'Leary N, AlMobarak FA, et al. Enhanced detection of open-angle glaucoma with an anatomically accurate optical coherence tomography-derived neuroretinal rim parameter. *Ophthalmology* 2013;120(3):535-43. doi: 10.1016/j.ophtha.2012.09.055

221. Enders P, Adler W, Kiessling D, et al. Evaluation of two-dimensional Bruch's membrane opening minimum rim area for glaucoma diagnostics in a large patient cohort. *Acta Ophthalmol* 2019;97(1):60-67. doi: 10.1111/aos.13698

222. Rebolleda G, Casado A, Oblanca N, et al. The new Bruch's membrane opening - minimum rim width classification improves optical coherence tomography specificity in tilted discs. *Clin Ophthalmol* 2016;10:2417-25. doi: 10.2147/OPTH.S120237

223. Sato S, Ukegawa K, Nitta E, et al. Influence of disc size on the diagnostic accuracy of Cirrus spectral-domain optical coherence tomography in glaucoma. *Hindawi J Ophthalmol* 2018 doi: 10.1155/2018/5692404

224. Wong D, Chua J, Baskaran M, et al. Factors affecting the diagnostic performance of circumpapillary retinal nerve fibre layer measurement in glaucoma. *Br J Ophthalmol* 2021;105(3):397-402. doi: 10.1136/bjophthalmol-2020-315985

225. Hong SW, Lee SB, Jee DH, et al. Evaluation of interocular retinal nerve fiber layer thickness symmetry as a diagnostic modality for glaucoma. *J Glaucoma* 2016;25(9):e763-71. doi: 10.1097/ijg.0000000000000496

226. Liu T, Tatham AJ, Gracitelli CPB, et al. Rates of retinal nerve fiber layer loss in contralateral eyes of glaucoma patients with unilateral progression by conventional methods. *Ophthalmology* 2015;122(11):2243-51. doi: 10.1016/j.ophtha.2015.07.027

227. Sevim MS, Buttanri B, Acar BT, et al. Ability of fourier-domain optical coherence tomography to detect retinal ganglion cell complex atrophy in glaucoma patients. *J Glaucoma* 2013;22(7):542-9. doi: 10.1097/IJG.0b013e31824d1f97

228. Tenkumo K, Hirooka K, Baba T, et al. Evaluation of relationship between retinal nerve fiber layer thickness progression and visual field progression in patients with glaucoma. *Jpn J Ophthalmol* 2013;57(5):451-56.

229. Kim KE, Jeoung JW, Park KH, et al. Diagnostic classification of macular ganglion cell and retinal nerve fiber layer analysis: differentiation of false-positives from glaucoma. *Ophthalmology* 2015;122(3):502-10. doi: 10.1016/j.ophtha.2014.09.031

230. Kansal V, Armstrong JJ, Pintwala R, et al. Optical coherence tomography for glaucoma diagnosis: an evidence based meta-analysis. *PloS One* 2018;13(1):e0190621. doi: 10.1371/journal.pone.0190621

231. Gardiner SK, Fortune B, Demirel S. Localized changes in retinal nerve fiber layer thickness as a predictor of localized functional change in glaucoma. *Am J Ophthalmol* 2016;170:75-82. doi: 10.1016/j.ajo.2016.07.020

232. Kuang TM, Zhang C, Zangwill LM, et al. Estimating lead time gained by optical coherence tomography in detecting glaucoma before development of visual field defects. *Ophthalmology* 2015;122(10):2002-9. doi: 10.1016/j.ophtha.2015.06.015

233. Malik R, Swanson WH, Garway-Heath DF. 'Structure-function relationship' in glaucoma: past thinking and current concepts. *Clin Exp Ophthalmol* 2012;40(4):369-80. doi: 10.1111/j.1442-9071.2012.02770.x

234. Abe RY, Diniz-Filho A, Zangwill LM, et al. The relative odds of progressing by structural and functional tests in glaucoma. *Invest Ophthalmol Vis Sci* 2016;57(9):421-8. doi: 10.1167/iovs.15-18940

235. Hood DC, Kardon RH. A framework for comparing structural and functional measures of glaucomatous damage. *Prog Ret Eye Res* 2007;26:688-710.

236. Hood DC, De Moraes CG. Four questions for every clinician diagnosing and monitoring glaucoma. *J Glaucoma* 2018;27(8):657-64. doi: 10.1097/IJG.0000000000001010

237. Giovannini A, Amato G, Mariotti C. The macular thickness and volume in glaucoma: an analysis in normal and glaucomatous eyes using OCT. *Acta Ophthalmol Scand Suppl* 2002;236:34-6. doi: 10.1034/j.1600-0420.80.s236.44.x

238. Greenfield DS, Bagga H, Knighton RW. Macular thickness changes in glaucomatous optic neuropathy detected using optical coherence tomography. *Arch Ophthalmol* 2003;121(1):41-6. doi: 10.1001/archopht.121.1.41

239. Renard J-P, Fenolland JR, Girard JM. Glaucoma progression analysis by spectral-domain optical coherence tomography (SD-OCT). *J Fr Ophtalmol* 2019;42(1):499-516. doi: 10.1016/j.jfo.2019.03.001

240. Kim EK, Park HL, Park CK. Segmented inner plexiform layer thickness as a potential biomarker to evaluate open-angle glaucoma: dendritic degeneration of retinal ganglion cell. *PloS One* 2017;12(8):e0182404. doi: 10.1371/journal.pone.0182404

241. Mwanza JC, Oakley JD, Budenz DL, et al. Macular ganglion cell-inner plexiform layer: automated detection and thickness reproducibility with spectral domain-optical coherence tomography in glaucoma. *Invest Ophthalmol Vis Sci* 2011;52(11):8323-9. doi: 10.1167/iovs.11-7962

242. Engin CD, Aydin R, Al-Aswad LA. Retinal inner plexiform layer (IPL) alterations in patients with glaucoma. *Invest Ophthalmol Vis Sci* 2018;59:2115.

243. Dascalescu D, Corbu C, Coviltir V, et al. The ganglion cell complex as a useful tool in glaucoma assessment. *Rom J Ophthalmol* 2018;62(4):300-03. doi: 10.22336/rjo.2018.46

244. Loewen NA, Zhang X, Tan O, et al. Combining measurements from three anatomical areas glaucoma diagnosis using Fourier-domain optical coherence tomography. *Br J Ophthalmol* 2015;99(9):1224-29. doi: 10.1136/bjophthalmol-2014-305907

245. Kim HJ, Jeoung JW, Yoo BW, et al. Patterns of glaucoma progression in retinal nerve fiber and macular ganglion cell-inner plexiform layer in spectral-domain optical coherence tomography. *Jpn J Ophthalmol* 2017;61(4):324-33. doi: 10.1007/s10384-017-0511-3

246. Akil H, Huang AS, Francis BA, et al. Retinal vessel density from optical coherence tomography angiography to differetiate early glaucoma, pre-perimetric glaucoma, and normal eyes. *PloS One* 2017;12(2):1-12.

247. Chung JK, Hwang YH, Wi JM, et al. Glaucoma diagnostic ability of the optical coherence tomography angiography vessel density parameters. *Curr Eye Res* 2017;42(11):1458-67. doi: 10.1080/02713683.2017.1337157

248. Geyman LS, Garg RA, Suwan Y, et al. Peripapillary perfused capillary density in primary open-angle glaucoma across disease stage: an optical coherence tomography angiography study. *Br J Ophthalmol* 2017;101(9):1261-68. doi: 10.1136/bjophthalmol-2016-309642

249. Scripsema NK, Garcia PM, Bavier RD, et al. Optical coherence tomography angiography analysis of perfused peripapillary capillaries in primary open-angle glaucoma and normal-tension glaucoma. *Invest Ophthalmol Vis Sci* 2016;57(9):Oct611-oct20. doi: 10.1167/iovs.15-18945

250. Yarmohammadi A, Zangwill LM, Diniz-Filho A, et al. Relationship between optical coherence tomography angiography vessel density and severity of visual field loss in glaucoma. *Ophthalmology* 2016;123(12):2498-508. doi: 10.1016/j.ophtha.2016.08.041

251. Wesselink C, Jansonius NM. Glaucoma progression detection with frequency doubling technology (FDT) compared to standard automated perimetry (SAP) in the Groningen Longitudinal Glaucoma Study. *Ophthalmic Physiol Opt* 2017;37(5):594-601. doi: 10.1111/opo.12401

252. Fujitani K, Su D, Ghassibi MP, et al. Assessment of patient perception of glaucomatous visual field loss and its association with disease severity using Amsler grid. *PloS One* 2017;12(9):e0184230. doi: 10.1371/journal.pone.0184230

253. Keltner JL, Johnson CA, Cello KE, et al. Classification of visual field abnormalities in the ocular hypertension treatment study. *Arch Ophthalmol* 2003;121(5):643-50. doi: 10.1001/archopht.121.5.643

254. Blumberg DM, De Moraes CG, Prager AJ, et al. Association between undetected 10-2 visual field damage and vision-related quality of life in patients with glaucoma. *JAMA Ophthalmol* 2017;135(7):742-47. doi: 10.1001/jamaophthalmol.2017.1396

255. Keltner JL, Johnson CA, Quigg JM, et al. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group. *Arch Ophthalmol* 2000;118(9):1187-94. doi: 10.1001/archopht.118.9.1187

256. Tafreshi A, Sample PA, Liebmann JM, et al. Visual function-specific perimetry to identify glaucomatous visual loss using three different definitions of visual field abnormality. *Invest Ophthalmol Vis Sci* 2009;50(3):1234-40. doi: 10.1167/iovs.08-2535

257. Chauhan BC, Garway-Heath DF, Goni FJ, et al. Practical recommendations for measuring rates of visual field change in glaucoma. *Br J Ophthalmol* 2008;92(4):569-73. doi: 10.1136/bjo.2007.135012

258. Shields MB, Spaeth GL. The glaucomatous process and the evolving definition of glaucoma. *J Glaucoma* 2012;21(3):141-3. doi: 10.1097/IJG.0b013e31820719f6

259. Parekh AS, Tafreshi A, Dorairaj SK, et al. Clinical applicability of the International Classification of Disease and Related Health Problems (ICD-9) glaucoma staging codes to predict disease severity in patients with open-angle glaucoma. *J Glaucoma* 2014;23(1):e18-22. doi: 10.1097/ijg.0000000000000033

260. Mills RP, Budenz DL, Lee PP, et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. *Am J Ophthalmol* 2006;141(1):24-30. doi: 10.1016/j.ajo.2005.07.044

261. Medeiros FA, Lisboa R, Weinreb RN, et al. A combined index of structure and function for staging glaucomatous damage. *Arch Ophthalmol* 2012;130(5):E1-10.

262. Brusini P, Filacorda S. Enhanced Glaucoma Staging System (GSS 2) for classifying functional damage in glaucoma. *J Glaucoma* 2006;15(1):40-6.

263. Wachtl J, Toteberg-Harms M, Frimmel S, et al. A new Glaucoma Severity Score combining structural and functional defects. *Klin Monbl Augenheilkd* 2017;234(4):468-73. doi: 10.1055/s-0042-123725

264. Ng M, Sample PA, Pascual JP, et al. Comparison of visual field severity classification systems for glaucoma. *J Glaucoma* 2012;21(8):551-61. doi: 10.1097/IJG.0b013e31821dac66

265. De Moraes CG, Sun A, Jarukasetphon R, et al. Association of macular visual field measurements with glaucoma staging systems. *JAMA Ophthalmol* 2019;137(2):139-45.

266. Naka M, Kanamori A, Tatsumi Y, et al. Comparison of mean deviation with AGIS and CIGTS scores in association with structural parameters in glaucomatous eyes. *J Glaucoma* 2009;18(5):379-84. doi: 10.1097/IJG.0b013e3181879e75

267. American Academy of Ophthalmology, American Academy of Ophthalmic Executives, American Glaucoma Society. Glaucoma Quick Reference Guide: Glaucoma Stage Definitions. 2015

268. Boland MV, Ervin AM, Friedman DS, et al. Comparitive effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. preventive services task force. *Ann Intern Med* 2013;158(4):271-79.

269. Hitchings R, Tan J. Target pressure. *J Glaucoma* 2001;10(5 Suppl 1):S68-70. doi: 10.1097/00061198-200110001-00024

270. Sihota R, Angmo D, Ramaswamy D, et al. Simplifying "target" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. *Indian J Ophthalmol* 2018;66(4):495-505. doi: 10.4103/ijo.IJO_1130_17

271. Artes PH, Chauhan BC, Keltner JL, et al. Longitudinal and cross-sectional analyses of visual field progression in participants of the ocular hypertension treatment study. *Arch Ophthalmol* 2010;128(12):1528-732.

272. Ohnell H, Heijl A, Brenner L, et al. Structural and functional progression in the Early Manifest Glaucoma Trial. *Ophthalmology* 2016;123(6):1173-80. doi: 10.1016/j.ophtha.2016.01.039

273. Stewart WC, Kolker AE, Sharpe ED, et al. Factors associated with long-term progression or stability in primary open-angle glaucoma. *Am J Ophthalmol* 2000;130(3):274-9. doi: 10.1016/s0002-9394(00)00487-6

274. Ghate D, Edelhauser HF. Barriers to glaucoma drug delivery. *J Glaucoma* 2008;17(2):147-56. doi: 10.1097/IJG.0b013e31814b990d

275. Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. *Acta Ophthalmol* 2018;96(3):e277-e84. doi: 10.1111/aos.13568

276. Law SK. Switching within glaucoma medication class. *Curr Opin Ophthalmol* 2009;20(2):110-5. doi: 10.1097/ICU.0b013e32831d1fc7

277. Webers CA, Beckers HJ, Nuijts RM, et al. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. *Drugs Aging* 2008;25(9):729-59.

278. Flach AJ. The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies. *Trans Am Ophthalmol Soc* 2008;106:138-48.

279. Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops; a pharmacokinetic perspective. *Clin Ophthalmol* 2016;10:2433-41.

280. van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure–lowering effects of all commonly used glaucoma drugs a meta-analysis of randomized clinical trials. *Opthalmology* 2005;112(7):1177-85.

281. Lusthaus JA, Goldberg I. Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma. *Expert Opin Investig Drugs* 2016;25(10):1201-8. doi: 10.1080/13543784.2016.1223042

282. Riva I, Katsanos A, Floriani I, et al. Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. *J Glaucoma* 2014;23(8):535-40. doi: 10.1097/ijg.0000000000000073

283. Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. *Ophthalmology* 2016;123(1):129-40. doi: 10.1016/j.ophtha.2015.09.005

284. Morales DR, Dreischulte T, Lipworth BJ, et al. Respiratory effect of beta-blocker eye drops in asthma: population-based study and meta-analysis of clinical trials. *Br J Clin Pharmacol* 2016;82(3):814-22. doi: 10.1111/bcp.13006

285. Maenpaa J, Pelkonen O. Cardiac safety of ophthalmic timolol. *Expert Opin Drug Saf* 2016;15(11):1549-61. doi: 10.1080/14740338.2016.1225718

286. Arthur S, Cantor LB. Update on the role of alpha-agonists in glaucoma management. *Expert Eye Res* 2011;93(3):271-83.

287. Oh DJ, Chen JL, Vajaranant TS, et al. Brimonidine tartrate for the treatment of glaucoma. *Expert Opin Pharmacotherapy* 2019;20(1):115-22. doi: 10.1080/14656566.2018.1544241

288. Lu LJ, Tsai JC, Liu J. Novel pharmacologic candidates for treatment of primary open-angle glaucoma. *Yale J Biol Med* 2017;90(1):111-18.

289. Schehlein EM, Robin AL. Rho-associated kinase inhibitors: evolving strategies in glaucoma treatment. *Drugs* 2019;79(10):1031-36. doi: 10.1007/s40265-019-01130-z

290. Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. *Eye (Lond)* 2020;34(1):72-88. doi: 10.1038/s41433-019-0671-0

291. Schuman JS. Short- and long-term safety of glaucoma drugs. *Expert Opin Drug Saf* 2002;1(2):181-94. doi: 10.1517/14740338.1.2.181

292. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. *Drugs Aging* 2005;22(1):1-21. doi: 10.2165/00002512-200522010-00001

293. Weinreb RN, Bacharach J, Fechtner RD, et al. 24-hour intraocular pressure control with fixed-dose combination brinzolamide 1%/brimonidine 0.2%; a multicenter, radomized trial. *Ophthalmology* 2019;126(8):1095-104.

294. Gandolfi SA, Lim J, Sanseau AC, et al. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. *Adv Ther* 2014;31(12):1213-27. doi: 10.1007/s12325-014-0168-y

295. Kim TW, Kim M, Lee EJ, et al. Intraocular pressure-lowering efficacy of dorzolamide/timolol fixed combination in normal-tension glaucoma. *J Glaucoma* 2014;23(5):329-32. doi: 10.1097/IJG.0b013e3182741f4d

296. Sinha S, Lee D, Kolomeyer NN, et al. Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension. *Expert Opin Pharmacotherapy* 2020;21(1):39-45. doi: 10.1080/14656566-2019.1685499

297. Renieri G, Fuhrer K, Scheithe K, et al. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients. *J Ocul Pharmacol Ther* 2010;26(6):597-603. doi: 10.1089/jop.2010.0060

298. Siesky B, Harris A, Ehrlich R, et al. Short-term effects of brimonidine/timolol and dorzolamide/timolol on ocular perfusion pressure and blood flow in glaucoma. *Adv Ther* 2012;29(1):53-63. doi: 10.1007/s12325-011-0092-3

299. Steensberg AT, Mullertz OO, Virgili G, et al. Evaluation of generic versus original prostaglandin analogues in the treatment of glaucoma. *Ophthalmol Glaucoma* 2020;3(1):51-59. doi: 10.1016/j.ogla.2019.10.002

300. Digiuni M, Manni G, Vetrugno M, et al. An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension. *J Glaucoma* 2013;22(9):707-12.

301. Aref AA. Generic drugs for the treatment of ocular conditions: changing the treatment landscape. *Expert Rev Clin Pharmacol* 2014;7(5):551-3. doi: 10.1586/17512433.2014.928197

302. Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. *Am J Ophthalmol* 2003;135(3):688-703. doi: 10.1016/S0002-9394(03)00098-9

303. Orme M, Collins S, Dakin H, et al. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. *Curr Med Res Opin* 2010;26(3):511-28. doi: 10.1185/03007990903498786

304. Oddone F, Rossetti L, Tanga L, et al. Effects of topical bimatoprost 0.01% and timolol 0.5% on circadian IOP, blood pressure and perfusion pressure in patients with glaucoma or ocular hypertension: a randomized, double masked, placebo-controlled clinical trial. *PloS One* 2015;10(10):e0140601. doi: 10.1371/journal.pone.0140601

305. Chabi A, Baranak C, Lupinacci R, et al. Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial. *Int J Clin Pract* 2016;70(7):577-86. doi: 10.1111/ijcp.12815

306. Cheng JW, Cheng SW, Yu DY, et al. Meta-analysis of alpha2-adrenergic agonists versus carbonic anhydrase inhibitors as adjunctive therapy. *Curr Med Res Opin* 2012;28(4):543-50. doi: 10.1185/03007995.2012.665363

307. Delval L, Baudouin C, Gabisson P, et al. Safety and efficacy of unpreserved timolol 0.1% gel in patients controlled by preserved latanoprost with signs of ocular intolerance. *J Fr Ophtalmol* 2013;36(4):316-23. doi: 10.1016/j.jfo.2012.04.015

308. Medeiros FA, Martin KR, Peace J, et al. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR Study. *Am J Ophthalmol* 2016;168:250-59. doi: 10.1016/j.ajo.2016.05.012

309. Weinreb RN, Scassellati Sforzolini B, Vittitow J, et al. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO Study. *Ophthalmology* 2016;123(5):965-73. doi: 10.1016/j.ophtha.2016.01.019

310. Aref AA. Sustained drug delivery for glaucoma: current data and future trends. *Curr Opin Ophthalmol* 2017;28(2):169-74. doi: 10.1097/icu.0000000000000334

311. Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. *Cornea* 2010;29(6):618-21. doi: 10.1097/ICO.0b013e3181c325b2

312. Saade CE, Lari HB, Berezina TL, et al. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study. *Can J Ophthalmol* 2015;50(2):132-6. doi: 10.1016/j.jcjo.2014.11.006

313. Pérez-Bartolomé F, Martínez-de-la-Casa JM, Arriola-Villalobos P, et al. Ocular surface disease in patients under topical treatment for glaucoma. *Eur J Ophthalmol* 2017;27(6):694-704. doi: 10.5301/ejo.5000977

314. Awe OO, Onakpoya OH, Adeoye AO. Effect of long-term topical antiglaucoma medication use on the ocular surface. *Nigerian Med J* 2020;61(4):184-88. doi: 10.4103/nmj.NMJ_116_19

315. Villani E, Sacchi M, Magnani F, et al. The ocular surface in medically controlled glaucoma: an in vivo confocal study. *Invest Ophthalmol Vis Sci* 2016;57(3):1003-10. doi: 10/1167/ivos.15-17455

316. Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. *Br J Ophthalmol* 2018;102(11):1497-503. doi: 10.1136/bjophthalmol-2017-311544

317. Arici MK, Arici DS, Ozec AV, et al. Apoptotic effects of topical antiglaucoma medications on conjunctival epithelium in glaucoma patients. *Eur J Ophthalmol* 2014;24(1):63-70. doi: 10.5301/ejo.5000324

318. Arita R, Itoh K, Maeda S, et al. Comparison of the long-term effects of various topical antiglaucoma medications on meibomian glands. *Cornea* 2012;31(11):1229-34. doi: 10.1097/ICO.0b013e31823f8e7d

319. Chen HY, Lin CL, Tsai YY, et al. Association between glaucoma medication usage and dry eye in Taiwan. *Optom Vis Sci* 2015;92(9):e227-32. doi: 10.1097/opx.0000000000000667

320. Kashkouli MB, Rezaee R, Nilforoushan N, et al. Topical antiglaucoma medications and lacrimal drainage system obstruction. *Ophthal Plast Reconstr Surg* 2008;24(3):172-5. doi: 10.1097/IOP.0b013e3181706829

321. Ohtani S, Shimizu K, Nejima R, et al. Conjunctival bacteria flora of glaucoma patients during long-term administration of prostaglandin analog drops. *Invest Ophthalmol Vis Sci* 2017;58(10):3991-96. doi: 10.1167/ iovs.16-20853

322. Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. *Eur J Ophthalmol* 2007;17(3):341-9.

323. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. *Curr Opin Ophthalmol* 2007;18(2):134-9. doi: 10.1097/ICU.0b013e328089f1c8

324. Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. *Prog Retin Eye Res* 2010;29(4):312-34. doi: 10.1016/j.preteyeres.2010.03.001

325. Zhang X, Vadoothker S, Munir WM, et al. Ocular surface disease and glaucoma medications: a clinical approach. *Eye Contact Lens* 2019;45(1):11-18. doi: 10.1097/ICL.0000000000000544

326. Batra R, Tailor R, Mohamed S. Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control. *J Glaucoma* 2014;23(1):56-60. doi: 10.1097/IJG.0b013e318264cd68

327. Monaco G, Cacioppo V, Consonni D, et al. Effects of osmoprotection on symptoms, ocular surface damage, and tear film modifications caused by glaucoma therapy. *Eur J Ophthalmol* 2011;21(3):243-50. doi: 10.5301/ejo.2010.5730

328. Dubrulle P, Labbe A, Brasnu E, et al. Influence of treating ocular surface disease on intraocular pressure in glaucoma patients intolerant to their topical treatments: a report of 10 cases. *J Glaucoma* 2018;27(12):1105-11. doi: 10.1097/IJG.0000000000001041

329. Stalmans I, Lemij H, Clarke J, et al. Signs and symptoms of ocular surface disease: the reasons for patient dissatisfaction with glaucoma treatments. *Clin Ophthalmology* 2020;14:3675-80. doi: 10.2147/OPTH.S269586

330. Mathew S, Harris A, Ridenour CM, et al. Management of glaucoma in pregnancy. *J Glaucoma* 2019;28(10):937-44. doi: 10.1097/IJG.0000000000001324

331. Strelow B, Fleischman D. Glaucoma in pregnancy: an update. *Curr Opin Ophthalmol* 2020;31(2):114-22. doi: 10.1097/ICU.0000000000000641

332. Salim S. Glaucoma in pregnancy. *Curr Opin Ophthalmol* 2014;25(2):93-7. doi: 10.1097/icu.0000000000000029

333. Chi SC, Kang YN, Hwang DK, et al. Selective laser trabeculoplasty versus medication for open-angle glaucoma: a systematic review and meta-analysis of randomized clinical trials. *Br J Ophthalmol* 2020;104(11):1500-07. doi: 10.1136/bjophthalmol-2019-315613

334. Nagar M, Ogunyomade A, O'Brart DPS, et al. A randomized, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. *Br J Ophthalmol* 2005;89(11):1413-71. doi: 10.1136/bjo.2004.052795

335. Samples JR, Singh K, Lin SC, et al. Laser trabeculoplasty for open-angle glaucoma: a report by the American Academy of Ophthalmology. *Ophthalmology* 2011;118(11):2296-302. doi: 10.1016/j.ophtha.2011.04.037

336. Toteberg-Harms M, Meier-Gibbons F. Is laser trabeculoplasy the new star in glaucoma treatment. *Curr Opin Ophthalmol* 2021;32(2):141-47. doi: 10.1097/ICU.0000000000000732

337. Zhang L, Weizer JS, Musch DC. Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty. *Cochrane Database Syst Rev* 2017;2(2):CD010746. doi: 10.1002/14651858.CD010746.pub2

338. The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group. *Ophthalmology* 1990;97(11):1403-13.

339. Francis BA, Loewen N, Hong B, et al. Repeatability of selective laser trabeculoplasty for open-angle glaucoma. *BMC Ophthalmol* 2016;16(128) doi: 10.1186/s12886-016-0299-9

340. Hutnik C, Crichton A, Ford B, et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty in glaucoma patients treated previously with 360o selective laser trabeculoplasty. *Ophthalmology* 2019;126(2):223-32. doi: 10.1016/j.ophtha.2018.09.037

341. Garg A, Vickerstaff V, Nathwani N, et al. Efficacy of repeat selective laser trabeculoplasty in medication-naive open-angle glaucoma and ocular hypertension during the LIGHT trial. *Ophthalmology* 2020;127(4):467-76. doi: 10.1016/j.ophtha.2019.10.023

342. Keyser MD, Belder MD, Groot VD. Randomized prospective study of the use of anti-inflammatory drops after selective laser trabeculoplasty. *J Glaucoma* 2017;26(2):e22-e29. doi: 10.1097/IJG.0000000000000522

343. Schlote T, Kynigopoulos M. Selective laser trabeculoplasty (SLT): 1-year results in early and advanced open angle glaucoma. *Int Ophthalmol* 2016;36(1):55-61. doi: 10.1007/s10792-015-0079-1

344. Wright DM, Konstantakopoulou E, Montesano G, et al. Visual field outcomes from the multicenter, randomized controlled Laser in Glaucoma and Ocular Hypertension Trial. *Ophthalmology* 2020;127(10):1313-21. doi: 10.1016/j.ophtha.2020.03.029

345. De Keyser M, De Belder M, De Belder J, et al. Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients. *Acta Ophthalmol* 2018;96(5):e577-e81. doi: 10.1111/aos.13509

346. McIlraith I, Strasfeld M, Colev G, et al. Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. *J Glaucoma* 2006;15(2):124-30.

347. Katz LJ, Steinmann WC, Kabir A, et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma:a prospective randomized trial. *J Glaucoma* 2012;21(7):460-68. doi: 10.1097/IJG.0b013e318218287f

348. Ang GS, Fenwick EK, Constantinou M, et al. Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the glaucoma initial treatment study randomized clinical trial. *Br J Ophthalmol* 2020;104(6):813-21. doi: 10.1136/bjoophthalmol-2018-313396

349. Bhardwaj N, Niles PI, Greenfield DS, et al. The impact of surgical intraocular pressure reduction on visual function using variious criteria to define visual field progression. *J Glaucoma* 2013;22(8):632-37. doi: 10.1097/IJG.0b013e3182567cfc

350. Marchini G, Ceruti P, Vizzari G. Management of concomitant cataract and glaucoma. *Dev Ophthalmol* 2012;50:146-56. doi: 10.1159/000334796

351. Coh P, Moghimi S, Chen RI, et al. Lens position parameters as predictors of intraocular pressure reduction after cataract surgery in glaucomatous versus nonglaucomatous eyes. *Invest Ophthalmol Vis Sci* 2016;57(6):2593-99. doi: 10.1167/ivos.16.19384

352. Chen PP, Lin SC, Junk AK, et al. The effect of phacoemulsification on intraocular pressure in glaucoma patients: a report by the American Academy of Ophthalmology. *Ophthalmology* 2015;122(7):1294-307. doi: 10.1016/j.ophtha.2015.03.021

353. Bartolome FP, Rodriguez IA, Goyal S, et al. Phacoemulsification plus endoscopic cyclophotocoagulation versus phacoemulsification alone in primary open-angle glaucoma. *Eur J Ophthalmol* 2017;28(2):168-74. doi: 10.5301/ejo.5001034

354. Kerr NM, Wang J, Barton K. Minimally invasive glaucoma surgery as a primary stand-alone surgery for glaucoma. *Clin Exp Ophthalmol* 2017;45(4):393-400.

355. Fingeret M, Dickerson JE, Jr. The role of minimally invasive glaucoma surgery devices in the management of glaucoma. *Optom Vis Sci* 2018;95(2):155-62. doi: 10.1097/OPX.0000000000001173

356. Pahlitzsch M, Gonnermann J, Maier AB, et al. Modified goniotomy as an alternative to trabectome in primary open angle glaucoma and pseudoexfoliation glaucoma: 1 year results. *Can J Ophthalmol* 2017;52(1):92-98. doi: 10.1016/j.jcjo.2016.07.011

357. Wecker T, Neuburger M, Bryniok L, et al. Ab interno trabeculectomy with the trabectome as a valuable therapeutic option for failed filtering blebs. *J Glaucoma* 2016;25(9):758-62. doi: 10.1097/ijg.0000000000000492

358. Agrawal P, Bradshaw SE. Systemic literature review of clinical and economic outcomes of micro-invasive glaucoma surgery (MIGS) in primary open-angle glaucoma. *Ophthalmol Ther* 2018;7(1):49-73. doi: 10.1007/s40123-018-0131-0

359. Matlach J, Dhillon C, Hain J, et al. Trabeculectomy versus canaloplasty (TVC study) in the treatment of patients with open-angle glaucoma: a prospective randomized clinical trial. *Acta Ophthalmol* 2015;93(8):753-61. doi: 10.1111/aos.12722

360. Riva I, Brusini P, Oddone F, et al. Canaloplasty in the treatment of open-angle glaucoma: a review of patient selection and outcomes. *Adv Ther* 2019;36(1):31-43. doi: 10.1007/s12325-018-0842-6

361. Zahid S, Musch DC, Niziol LM, et al. Risk of endophthalmitis and other long-term complications of trabeculectomy in the Collaborative Initial Glaucoma Treatment Study (CIGTS). *Am J Ophthalmol* 2013;155(4):674-80, 80.e1. doi: 10.1016/j.ajo.2012.10.017

362. Landers J, Martin K, Sarkies N, et al. A twenty-year follow-up study of trabeculectomy: risk factors and outcomes. *Ophthalmology* 2012;119(4):694-702. doi: 10.1016/j.ophtha.2011.09.043

363. Barton K, Gedde SJ, Budenz DL, et al. The Ahmed Baerveldt comparison study: methodology, baseline patient characteristics, and intraocular complications. *Ophthalmology* 2011;118(3):435-42. doi: 10.1016/j.ophtha.2010.07.015

364. Feinstein MA, Lee JH, Amoozgar B, et al. Comparison between pars plana and anterior endoscopic cyclophotocoagulation for the treatment of glaucoma. *Clin Exp Ophthalmol* 2018;47(6):766-73. doi: 10.1111/ceo.13501

365. Schell GJ, Lavieri MS, Helm JE, et al. Using filtered forcasting techniques to determine personalized monitoring schedules for patients with open-angle glaucoma. *Ophthalmology* 2014;121(8):1539-46.

366. Foot B, MacEwen C. Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome. *Eye (Lond)* 2017;31(5):771-75. doi: 10.1038/eye.2017.1

367. Aptel F, Aryal-Charles N, Girard J-M, et al. Progression of visual field in patients with primary open-angle glaucoma - ProgF study 1. *Acta Ophthalmol* 2015;93:e615-e20. doi: 10.1111/aos.12788

368. Zhang X, Parrish RK, Greenfield DS, et al. Predictive factors for the rate of visual field progression in the Advanced Imaging for Glaucoma Study. *Am J Ophthalmol* 2019;202:62-71. doi: 10.1016/ajo.2019.02.015

369. Wu Z, Medeiros F. Recent developments in visual field testing for glaucoma. *Curr Opin Ophthalmol* 2018;29:141-46.

370. Wu Z, Saunders LJ, Daga FB, et al. Frequency of testing to detect visual field progression derived using a longitudinal cohort of glaucoma patients. *Ophthalmology* 2017;124(6):786-92. doi: 10.1016/j.ophtha.2017.01.027

371. Ittoop SM, SooHoo JR, Seibold LK, et al. Systematic review of current devices for 24-h intraocular pressure monitoring. *Adv Ther* 2016;33(10):1679-90. doi: 10.1007/s12325-016-0388-4

372. Huang J, Katalinic P, Kalloniatis M, et al. Diurnal intraocular pressure fluctuations with self-tonometry in glaucoma patients and suspects: a clinical trial. *Optom Vis Sci* 2018;95(2):88-95.

373. Mansouri K, Weinreb RN. Meeting an unmet need in glaucoma: continuous 24-h monitoring of intraocular pressure. *Expert Rev Med Devices* 2012;9(3):225-31. doi: 10.1586/erd.12.14

374. Cvenkel B, Velkovska MA, Jordanova VD. Self-measurement with Icare HOME tonometer, patients' feasibility and acceptability. *Eur J Ophthalmol* 2020;30(2):258-63. doi: 10.1177/1120672118823124

375. Prea SM, Kong YXG, Mehta A, et al. Six-month longitudinal comparison of a portable tablet perimeter with Humphrey Field Analyzer. *Am J Ophthalmol* 2018;190(6):9-16.

376. Schultz AM, Graham EC, You Y, et al. Performance of iPad-based threshold perimetry in glaucoma and controls. *Clin Exp Ophthalmol* 2018;46(4):346-55.

377. Alawa KA, Nolan RP, Han E, et al. Low-cost, smartphone-based frequency doubling technology visual field testing using a head-mounted display. *Br J Ophthalmol* 2021;105(3):440-44. doi: 10.1136/bjophthalmol-2019-314031

378. Narang P, Agarwal A, Srinivasan M, et al. Advanced Vision Analyzer-Virtual Reality Perimeter: device validation, functional correlation and comparison with Humphrey Field Analyzer. *Ophthalmol Sci* 2021;1(2):100035. doi: 10.1016/j.xops.2021.100035

379. Pronin S, Brown L, Megaw R, et al. Measurement of intraocular pressure by patients with glaucoma. *JAMA Ophthalmol* 2017;135(10):1030-36. doi: doi:10.1001/jamaophthalmol.2017.3151

380. Mudie LI, LaBarre S, Varadaraj V, et al. The Icare HOME (TA022) Study: performance of an intraocular pressure measuring device for self-tonometry by glaucoma patients. *Ophthalmology* 2016;123(8):1675-84. doi: 10.1016/j.ophtha.2016.04.044

381. Tan S, Yu M, Baig N, et al. Agreement of patient-measured intraocular pressure using rebound tonometry with Goldmann applination tonometry (GAT) in glaucoma patients. *Sci Rep* 2017;7:42067. doi: 10.1038/srep42067

382. Takagi D, Sawada A, Yamamoto T. Evaluation of a new rebound self-tonometer, Icare Home: comparison with Goldmann applination tonometer. *J Glaucoma* 2017;26(7):613-18. doi: 01.1097/IJG.0000000000000674

383. Burr JM, Botello-Pinzon P, Takwoingi Y, et al. Surveillance for ocular hypertension: an evidence synthesis and economic evaluation. *Health Technol Assess* 2012;16(29):1-271. doi: 10.3310/hta16290

384. Boland MV, Quigley HA, Lehmann HP. The impact of risk calculation on treatment recommendations made by glaucoma specialists in cases of ocular hypertension. *J Glaucoma* 2008;17(8):631-8. doi: 10.1097/IJG.0b013e3181659e6a

385. Zangwill LM, Jain S, Dirkes K, et al. The rate of structural change: the confocal scanning laser ophthalmoscopy ancillary study to the Ocular Hypertension Treatment Study. *Am J Ophthalmol* 2013;155(6):971-82. doi: 10.1016/j.ajo.2013.01.020

386. Demirel S, De Moraes CG, Gardiner SK, et al. The rate of visual field change in the Ocular Hypertension Treatment Study. *Invest Ophthalmol Vis Sci* 2012;53(1):224-7. doi: 10.1167/iovs.10-7117

387. Hirooka K, Manabe S, Tenkumo K, et al. Use of the structure-function relationship in detecting glaucoma progression in early glaucoma. *BMC Ophthalmol* 2014;14:118. doi: 10.1186/1471-2415-14-118

388. Tatham AJ, Medeiros FA. Detecting structural progression in glaucoma with optical coherence tomography. *Ophthalmology* 2017;124(12):S57-S65. doi: 10.1016/j.ophtha.2017.07.015

389. Banegas SA, Anton A, Morilla A, et al. Evaluation of the retinal nerve fiber layer thickness, the mean deviation, and the visual field index in progressive glaucoma. *J Glaucoma* 2016;25(3):229-35. doi: 10.1097/IJG.0000000000000280

390. Yu M, Lin C, Weinreb RN, et al. Risk of visual field progression in glaucoma patients with progressive retinal nerve fiber layer thinning. *Ophthalmology* 2016;123(6):1201-10. doi: 10.1016/j.ophtha.2016.02.017

391. Hood DC, Xin D, Wang D, et al. A region-of-interest approach for detecting progression of glaucomatous damage with optical coherence tomography. *JAMA Ophthalmol* 2015;133(12):1438-44. doi: 10.1001/jamaophthalmol.2015.3871

392. Thenappan A, De Moraes CG, Wang DL, et al. Optical coherence tomography and glaucoma progression: a comparison of a region of interest approach to average retinal nerve fiber layer thickness. *J Glaucoma* 2017;26(5):473-77. doi: 10.1097/ijg.0000000000000654

393. Leung CK, Cheung CY, Weinreb RN, et al. Evaluation of retinal nerve fiber layer progression in glaucoma: a study on optical coherence tomography guided progression analysis. *Invest Ophthalmol Vis Sci* 2010;51(1):217-22. doi: 10.1167/iovs.09-3468

394. Shin JW, Sung KR, Lee J, et al. Factors associated with visual field progression in Cirrus optical coherence tomography-guided progression analysis: a topographic approach. *J Glaucoma* 2017;26(6):555-60. doi: 10.1097/ijg.0000000000000680

395. Diniz-Filho A, Delano-Wood L, Daga FB, et al. Association between neurocognitive decline and visual field variability in glaucoma. *JAMA Ophthalmology* 2017;135(7):734-39. doi: 10.1001/jamaophthalmol.2017.1279

396. Hu R, Wang C, Yangshun G, et al. Comparison of standard automated perimetry, short-wavelength automated perimetry, and frequency-doubling technology perimetry to monitor glaucoma progression. *Medicine* 2016;95(7):e2618. doi: 10.1097/MD.0000000000002618

397. De Moraes CG, Lieberman JM, Park SC, et al. Optic disc progression and rates of visual field change in treated glaucoma. *Acta Ophthalmol* 2013;91(2):e86-e91. doi: 10.1111/j.1755-3768.2012.02577.

398. Medeiros FA, Alencar LM, Sample PA, et al. The relation between intraocular pressure reduction and rates of progressive visual field loss in eyes with optic disc hemorrhage. *Ophthalmology* 2010;117(11):2061-66. doi: 10.1016/j.ophtha.2010.02.015

399. Aref AA, Budenz DL. Detecting visual field progression. *Ophthalmology* 2017;124(12s):S51-s56. doi: 10.1016/j.ophtha.2017.05.010

400. Aoki S, Murata H, Fujino Y, et al. Investigating the usefulness of a cluster-based trend analysis to detect visual field progression in patients with open-angle glaucoma. *Br J Ophthalmol* 2017;101(12):1658-65. doi: 10.1136/bjophthalmol-2016-310069

401. Gardiner SK, Swanson WH, Goren D, et al. Assessment of the reliability of standard automated perimetry in regions of glaucomatous damage. *Ophthalmology* 2014;121(7):1359-69. doi: 10.1016/j.ophtha.2014.01.020

402. De Moraes CG, Juthani VJ, Leibmann JM, et al. Risk factors for visual field progression in glaucoma. *Arch Ophthalmol* 2011;129(5):562-68.

403. Liebmann K, De Moraes GC, Liebmann JM. Measuring rates of visual field progression in linear versus nonlinear scales: implications for understanding the relationship between baseline damage and target rates of glaucoma progression. *J Glaucoma* 2017;26(8):721-25. doi: 10.1097/IJG.0000000000000710

404. Han YS, Ha A, Kim YK, et al. Norman-tension glaucoma management: a survey of glaucoma sub-specialists in Korea. *Korean J Ophthalmol* 2020;34(6):425-31. doi: 10.3341/kjo.2020.0061

405. Cho H-K, Suh W, Kee C. Visual and structural prognosis of the untreated fellow eyes of unilateral normal tension glaucoma patients. *Graefes Arch Clin Exp Ophthalmol* 2015;253(9):1547-55. doi: 10.1007/s00417-015-3081-4

406. Leaney JC, Nguyen V, Miranda E, et al. Bruch's membrane opening minimum rim width proides objective differentiation between glaucoma and nonglaucomatous optic neuropathies. *Am J Ophthalmol* 2020;218:164-72. doi: 10.1016/ajo.2020.05.034

407. Kim M, Kim DM, Park KH, et al. Intraocular pressure reduction with topical medications and progression of normal-tension glaucoma: a 12-year mean follow-up study. *Acta Ophthalmol Scand* 2013;91(4):e270-5. doi: 10.1111/aos.12082

408. Anderson DR, Drance SM, Schulzer M. Natural history of normal-tension glaucoma. *Ophthalmology* 2001;108(2):247-53.

409. Budenz DL. A clinician's guide to the assessment and managment of nonadherence in glaucoma. *Ophthalmology* 2009;116:S43-S47. doi: 10.1016/j.ophtha.2009.06.022

410. Hoevenaars JGMM, Schouten JSA, G., van den Borne B, et al. Socioeconomic differences in glaucoma patients' knowledge, need for information and expectations of treatment. *Acta Ophthalmol Scand* 2006;84(1):84-91. doi: 10.1111/j.1600-0420.2005.00587.x

411. Sleath B, Davis S, Sayner R, et al. African American patient preferences for glaucoma education. *Optom Vis Sci:* 2017;94(4):482-86.

412. Muir KW, Ventura A, Stinnett SS, et al. The influence of health literacy level on an educational intervention to improve glaucoma medication adherence. *Patient Educ Couns* 2012;87(2):160-64. doi: 10.1016/j.pec.2011.09.009

413. Juzych MS, Randhawa S, Shukairy A, et al. Functional health literacy in patients with glaucoma in urban settings. *Arch Ophthalmol* 2008;126(5):718-24.

414. Muir KW, Santiago-Turla C, Stinnett SS, et al. Health literacy and vision-related quality of life. *Br J Ophthalmol* 2008;92(6):779-82. doi: 10.1136/bjo.2007.134452

415. Kuo YS, Liu CJL, Cheng HC, et al. Impact of socioeconomic status on vision-related quality of life in primary open-angle glaucoma. *Eye (Lond)* 2017;31(10):1480-87. doi: 10.1038/eye.2017.99

416. Murakami Y, Lee BW, Duncan M, et al. Racial and ethnic disparities in adherence to glaucoma follow-up visits in a county hospital population. *Arch Ophthalmol* 2011;129(7):872-78.

417. Djafari F, Lesk MR, Giguere CE, et al. Impact of a brief educational intervention on glaucoma persistence: a randomized controlled clinical trial. *Ophthal Epidemiology* 2015;22(6):380-86. doi: 10.3109/09286586.2015.1083036

418. Williams AM, Muir KW, Rosdahl JA. Readability of patient education materials in ophthalmology: a single-institution study and systematic review. *BMC Ophthalmol* 2016;16 doi: 10.1186/s12886-016-0315-0

419. Mikhail D, Visscher KL, Chen N, et al. Patient-appropriate health literacy educational materials in ophthalmology. *Can J Ophthalmol* 2015;50(1):19-25. doi: 10.1016/j.jcjo.2014.08.002

420. Hahn SR, Friedman DS, Quigley HA, et al. Effect of patient-centered communication training on discussion and detection of nonadherence in glaucoma. *Ophthalmology* 2010;117(7):1339-47.

421. Friedman DS, Hahn SR, Quigley HA, et al. Doctor-patient communication in glaucoma care: analysis of videotaped encounters in community-based office practice. *Ophthalmology* 2009;116(12):2277-85. doi: 10.1016/j.ophtha.2009.04.052

422. Gray TA, Fenerty C, Harper R, et al. Preliminary survey of educational support for patients prescribed ocular hypotensive therapy. *Eye (Lond)* 2010;24(12):1777-86. doi: 10.1038/eye.2010.121

423. Peterson KM, Huisingh CE, Girkin C, et al. Patient satisfaction with care in an uban tertiary referral academic glaucoma clinic in the US. *Patient Prefer Adherence* 2018;12:775-81. doi: 10.2147/PPA>S162439

424. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. *Surv Ophthalmol* 2008;53:S57-S67.

425. Sleath B, Sayner R, Blalock SJ, et al. Patient question-asking about glaucoma and glaucoma medications during videotaped medical visits. *Health Communication* 2015;30(7):660-68. doi: 10.1080/10410236.2014.888387

426. McClelland JF, Bodle L, Little JA. Investigation of medication adherence and reasons for poor adherence in patients on long-term glaucoma treatment regimes. *Patient Prefer Adherence* 2019;13:431-39. doi: 10.2147/PPA.S176412

427. Skalicky SE, D'Mellow G, House P, et al. Glaucoma Australia educational impact study: a randomized short-term clnical trial evaluating the association between glaucoma education and patient knowledge, anxiety and treatment satisfaction. *Clin Exp Ophthalmol* 2018;46(3):222-31. doi: 10.1111/ceo.13016

428. Fiscella R, Caplan E, Kamble P, et al. The effect of an educational intervention on adherence to intraocular pressure-lowering medications in a large cohort of older adults with glaucoma. *J Manag Care Spec Pharm* 2018;24(12):1284-94. doi: 10.18553/jmcp.2018.17465

429. Newman-Casey PA, Killeen OJ, Renner M, et al. Access to and experiences with, e-health technology among glaucoma patients and their relationship with medical adherence. *Telemed J E Health* 2018;24:1026-35. doi: 10.1089/tjm.2017.0324

430. Sleath B, Sayner R, Vitko M, et al. Glaucoma patient-provider communication about vision quality-of-life. *Patient Educ Couns* 2017;100(4):703-09. doi: 10.1016/j.pec.2016.11018

431. Sleath B, Carpenter DM, Blalock SJ, et al. Applying the resources and supports in self-management of framework to examine ophthalmologist-patient communication and glaucoma medication adherence. *Health Educ Research* 2015;30(5):693-705. doi: 10.1093/her/cyv034

432. Waterman H, Evans JR, Gray TA, et al. Intervensions for improving adherence to ocular hypertensive therapy. *Cochrane Database Syst Rev* 2013(4):CD006132. doi: 10.1002/14651858.CD006132.pub3

433. Boland MV, Chang DS, Frazier T, et al. Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence; the Automated Dosing Reminder Study. *JAMA Ophthalmology* 2014;132(7):838-44. doi: 10.1001/jamaophthalmol.2014.856

434. Newman-Casey PA, Weizer JS, Heisler M, et al. Systematic review of educational interventions to improve glaucoma medication adherence. *Semin Ophthalmol* 2013;28(3):191-201. doi: 10.3109/08820538.2013.771198

435. Cate H, Bhattacharya D, Clark A, et al. Improving adherence to glaucoma medication: a randomized controlled trial of a patient-centered intervention (The Norwich Adherence Glaucoma Study). *BMC Ophthalmol* 2014;14:32.

436. Traverso CE, Walt JG, Stern LS, et al. Pharmacotherapy compliance in patients with ocular hypertension or primary open-angle glaucoma. *J Ocul Pharmacol Ther* 2009;25(1):77-82. doi: 10.1089/jop.2008.0079

437. Rossi GCM, Pasinetti GM, Schudeller L, et al. Do adherence rates and glaucomatous visual field progression correlate? *Eur J Ophthalmol* 2011;21(4):410-14. doi: 10.5301/EJO.2010.6112

438. Newman-Casey PA, Niziol LM, Gillespie BW, et al. The association between medication adherence and visual field progression in the Collaborative Initial Glaucoma Treatment Study (CIGTS). *Ophthalmology* 2020;127(4):477-83. doi: 10.1016/j.ophtha.2019.10.022

439. Newman-Casey PA, Blachley T, Lee PP, et al. Patterns of glaucoma medication adherence over four years of follow-up. *Ophthalmology* 2015;122(10):2010-21. doi: 10.1016/j.ophtha.2015.06.039

440. Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. *Ophthalmology* 2015;122(7):1308-16. doi: 10.1016/j.ophtha.2015.03.026

441. Stein JD, Shekhawat N, Talwar N, et al. Impact of the introduction of generic latanoprost on glaucoma medication adherence. *Ophthalmology* 2015;122(4):738-47. doi: 10.1016/j.ophtha.2014.11.022

442. Gomes BF, Paredes AF, Madeira N, et al. Assessment of eye drop instillation technique in glaucoma patients. *Arq Bras Oftalmol* 2017;80(4):238-41. doi: 10.5935/0004-2749.20170058

443. Goldshtein I, Shalev V, Zigman N, et al. The Maccabi Glaucoma Study: treatment patterns and persistance with glaucoma therapy in a large Israeli health maintenance organization. *J Glaucoma* 2016;25(4):e386-e91.

444. Reardon G, Schwartz GF, Kotak S. Persistance on prostoglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy. *BMC Ophthalmol* 2010;10:5.

445. Schwartz GF, Burk C, Bennett T, et al. Adherence and persistence with glaucoma therapy: brimonidine/timolol versus dorzolamide/timolol and various two-bottle combinations. *J Clin Exp Ophthalmol* 2012;3(8):1000248. doi: 10.4172/2155-9570.1000248

446. Leung V, C., Jin Y-P, Hatch W, et al. The relationship between sociodemographic factors and persistence with topical glaucoma medications. *J Glaucoma* 2015;24(1):69-76. doi: 10.1097/IJG.0000000000000081

447. Salman M, Andrews C, Heisler M, et al. Psychosocial predictors of glaucoma medication adherence among the Support, Educate, Empower (SEE) personalized glaucoma coaching pilot study participants. *Am J Ophthalmol* 2020;216:207-18. doi: 10.1016/j.ajo.2020.02.009

448. Lim MC, Watnik MR, Imson KR, et al. Adherence to glaucoma medication: the effect of interventions an association with personality type. *J Glaucoma* 2013;22(6):439-46. doi: 10.1097/IJG.0b013e31824cd0ae

449. Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma. *Ophthalmology* 2008;15(8):1320-27. doi: 10.1016/j.ophtha.2007.11.023

450. Slota C, Sauner R, Vitko M, et al. Glaucoma patient expression of medication problems and nonadherence. *Optom Vis Sci* 2015;92(5):537-43. doi: 10.1097/OPX.0000000000000574

451. Okeke CO, Quigley HA, Jampel HD, et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. *Ophthalmology* 2009;116(12):2286-93. doi: 10.1016/j.ophtha.2009.05.026

452. Lai Y, Wu Y, Chai C, et al. The effect of patient education and telemedicine reminders on adherence to eye drops for glaucoma. *Ophthal Glaucoma* 2020;3(5):369-76. doi: 10.1016/j.ogla.2020.05.005

453. Carpenter DM, Blalock SJ, Sayner R, et al. Communication predicts medication self-efficacy in glaucoma patients. *Optom Vis Sci* 2016;93(7):731-37. doi: 10.1097/OPX.0000000000000856

454. Castel OC, Keinan-Boker L, Geyer O, et al. Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting. *Fam Pract* 2014;31(4):453-61. doi: 10.1093/fampra/cmu031

455. Gupta R, Patil B, Shah BM, et al. Evaluating eye drop instillation technique in glaucoma patients. *J Glaucoma* 2012;21(3):189-92. doi: 10.1097/IJG.0b013e31820bd2e1

456. Moore DB, Hammer JD, Akhtari R, et al. Squeeze me if you can: variability in force requirements to extract a drop from common glaucoma bottles. *J Glaucoma* 2016;25(9):780-84. doi: 10.1097/IJG.0000000000000506

457. Dietlein TS, Jordan JF, Luke C, et al. Self-application of single-use eyedrop containers in an elderly population: comparisons with standard eyedrop bottle and with younger patients. *Acta Ophthalmol Scand* 2008;86(8):856-59. doi: 10.1111/j.1755-3768.2007.01155.x

458. Gao X, Yang Q, Huang W, et al. Evaluating eye drop instillation technique and its determinants in glaucoma patients. *J Ophthalmol* 2018;2018 doi: 10.1155//2018/1376020

459. Hennessy AL, Katz J, Covert D, et al. Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss. *Ophthalmology* 2010;117(12):2345-52. doi: 10/1016/j.ophtha.2010.03.040

460. Davis SA, Carpenter DM, Blalock SJ, et al. A randomized controlled trial of an online educational video intervention to improve glaucoma eye drop technique. *Patient Educ Couns* 2019;102(5):937-43. doi: 10.116/j.pec.2018.12.019

461. Davis SA, Carpenter DM, Blalock SJ, et al. Glaucoma patient preferences for video education on eye drop technique. *Optom Vis Sci* 2019;96(5):325-30. doi: 10.1097/OPX.0000000000001375

462. Newman-Casey PA, Musser JA, Niziol LM, et al. Integrating patient education into the glaucoma clinical encounter: a lean analysis. *J Glaucoma* 2019;28(5):415-22. doi: 10.1097/IJG.0000000000001192

463. Johnson DM, Stratford S, Shyu AP, et al. The impact of educational workshops on individuals at risk for glaucoma in the Philadelphia Glaucoma Detection and Treatment Project. *Patient Edu Couns* 2016;99(4):659-64. doi: 10.1016/j.pec.2015.11.026

464. Shtein RM, Newman-Casey PA, Herndon L, et al. Assessing the role of family/support system perspective in patients with glaucoma. *J Glaucoma* 2016;25(7):e676-e80. doi: 10.1097/IJG.0000000000000332

465. Amro R, Cox CL, Waddington K, et al. Glaucoma expert patient programme and ocular hypotensive treatment. *Br J Nursing* 2010;19(20):1287-92.

466. Chen X, Chen Y, Sun X. Notable role of glaucoma club on patients' knowledge of glaucoma. *Clin Exp Ophthalmol* 2009;37(6):590-94. doi: 10.1111/j.1442-9071.2009.02101.x

467. Varadaraj V, Friedman DS, Boland MV. Association of an electronic health record-linked glaucoma medical reminder with patient satisfaction. *JAMA Ophthalmol* 2019;137(3):240-45. doi: 10.1001/jamaophthalmol.2018.6066

468. Glanz K, Beck AD, Bundy L, et al. Impact of a health communication intervention to improve glaucoma treatment adherence: results of the I-Sight trial. *Arch Ophthalmol* 2012;130(10):1252-58. doi: 10.1001/archophthalmol.2012.1607

469. Daly R, Agarwal PK. Is patient knowledge of glaucoma improved by using a glaucoma logbook? *J Glaucoma* 2018;27(5):470-75. doi: 10.1097/IJG.0000000000000943

470. Nordmann J-P, Denis P, Vigneux M, et al. Development of the conceptual framework for the Eye-Drop Satisfaction Questionnaire (EDSQ) in glaucoma using a qualitative study. *BMC Health Serv Res* 2007;7:124. doi: 10.1186/1472-6963/7/124

471. Bilger M, Wong TT, Lee JY, et al. Using adherence-contingent rebates on chronic disease treatment costs to promote medication adherence: results from a randomized controlled trial. *Appl Health Econ Health Policy* 2019;17(6):841-55. doi: 10.1007/s40258-019-00497-0

472. Rosenberg EA, Sperazza LC. The visually impaired patient. *Am Fam Physician* 2008;77(10):1431-36.

473. De Moraes CG, Lieberman JM, Medeiros FA, et al. Management of advanced glaucoma: characterization and monitoring. *Surv Ophthalmol* 2016;61(5):597-615. doi: 10.1016/j.survophthal.2016.03.006

474. Blumberg D. Affordability of glaucoma treatment around the globe. *JAMA Ophthalmology* 2018;136(11):1279-80. doi: 10.1001/jamaophthalmol.2018.3670

475. Berenson KL, Kymes S, Walt JG, et al. The relationship of mean deviation scores and resource utilization among patients with glaucoma. *J Glaucoma* 2009;18(5):390-94.

476. Fudemberg SJ, Amarasekera DC, Silverstein MH, et al. Overcoming barriers to eye care: patient response to a medical social worker in a glaucoma service. *J Community Health* 2016;41(4):845-49. doi: 10.1007/s10900.016.0162-1

477. Sharts-Hopko NC. Lifestyle strategies for the prevention of vision loss. *Holist Nurs Pract* 2010;24(5):284-91.

478. Hecht I, Achiron A, Man V, et al. Modifiable factors in the management of glaucoma: a systematic review of current evidence. *Graefes Arch Clin Exp Ophthalmol* 2017;255(4):789-96. doi: 10.1007/s00417-016-3518-4

479. Hanyuda A, Rosner BA, Wiggs JL, et al. Low-carbohydrate-diet scores and the risk of primary open-angle glaucoma: data from three US cohorts. *Eye (Lond)* 2020;34(8):1465-75. doi: 10.1038/s41433-020-0820-5

480. Parikh RS, Parikh SR. Alternative therapy in glaucoma management: is there any role? *Indian J Ophthalmol* 2011;59:S158-60. doi: 10.4103/0301-4738.73679

481. Wan MJ, Daniel S, Kassam F, et al. Survey of complementary and alternative medicine use in glaucoma patients. *J Glaucoma* 2012;21(2):79-82. doi: 10.1097/IJG.0b013e3182027c0c

482. Alexander SPH. Therapeutic potential of cannabis-related drugs. *Prog Neuro-psychopharmacol Biol Psychiatry* 2016;64:157-66. doi: 10.1016/j.pnpbp.2015.07.001

483. Sun X, Xu CS, Chadha N, et al. Marijuana for glaucoma: a recipe for disaster or treatment? *Yale J Biol Med* 2015;88(3):265-9.

484. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. *JAMA* 2015;313(24):2456-73. doi: 10.1001/jama.2015.6358

485. Wang MTM, Danish-Meyer HV. Cannabinoids and the eye. *Surv Ophthalmol* 2021;66(2):327-45. doi: 10.1016/survophthal.2020.07.002

486. Higginbotham EJ, Higginbotham LA. Shaping patients' perspective of medical marijuana for glaucoma treatment. *JAMA Ophthalmol* 2016;134(3):265-6. doi: 10.1001/jamaophthalmol.2015.5290

487. Belyea DA, Alhabshan R, Del Rio-Gonzalez AM, et al. Marijuana use among patients with glaucoma in a city with legalized medical marijuana use. *JAMA Ophthalmol* 2016;134(3):259-64. doi: 10.1001/jamaophthalmol.2015.5209

488. Law SK, Li T. Acupuncture for glaucoma. *Cochrane Database Syst Rev* 2013(5):Cd006030. doi: 10.1002/14651858.CD006030.pub3

489. Buys YM, Alasbali T, Jin YP, et al. Effect of sleeping in a head-up position on intraocular pressure in patients with glaucoma. *Ophthalmology* 2010;117(7):1348-51. doi: 10.1016/j.ophtha.2009.11.015

490. Dada T, Mittal D, Mohanty K, et al. Mindfulness meditation reduces intraocular pressure, lowers stress biomarkers and modulates gene expression in glaucoma: a randomized clinical trial. *J Glaucoma* 2018;27(12):1061-67. doi: 10.1097/IJG.0000000000001088

491. Loskutova E, O'Brien C, Loskutova I, et al. Nutritional supplementation in the treatment of glaucoma: a systematic review *Surv Ophthalmol* 2019;64(2):195-216. doi: 10.1061/j.survophthal.2018.09.005

492. Nebbioso M, Rusciano D, Pucci B, et al. Treatment of glaucomatous patients by means of food supplement to reduce the ocular discomfort: a double blind randomized trial. *Eur Rev Med Pharmacol Sci* 2013;17(8):1117-22.

493. Garcia-Medina JJ, Garcia-Medina M, Garrido-Fernandez P, et al. A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: an open-label, randomized, controlled trial. *Acta Ophthalmol Scand* 2015;93(6):546-54. doi: 10.1111/aos.12629

494. Vetrugno M, Uva MG, Russo V, et al. Oral administration of forskolin and rutin contributes to intraocular pressure control in primary open angle glaucoma patients under maximum tolerated medical therapy. *J Ocul Pharmacol Ther* 2012;28(5):536-41. doi: 10.1089/jop.2012.0021

495. Shim SH, Kim JM, Choi CY, et al. Ginkgo biloba extract and bilberry anthocyanins improve visual function in patients with normal tension glaucoma. *J Med Food* 2012;15(9):818-23. doi: 10.1089/jmf.2012.2241

496. Verma S, Arora S, Kassam F, et al. Northern Alberta remote teleglaucoma program: clinical outcomes and patient disposition. *Can J Ophthalmol* 2014;49(2):135-40. doi: 10.1016/j.jcjo.2013.11.005

497. Owsley C, Rhodes LA, McGwin G, Jr., et al. Eye care quality and accessibility improvement in the community (EQUALITY) for adults at risk for glaucoma: study rationale and design. *Int J Equity in Health* 2015;14 doi: 10.1186/s12939-015-0213-8

498. Johnson CA, Thapa S, George Kong YX, et al. Performance of an iPad application to detect moderate and advanced visual field loss in Nepal. *Am J Ophthalmol* 2017;182:147-54. doi: 10.1016/j.ajo.2017.08.007

499. Rojas CD, Reed DM, Moroi SE. Usefulness of iCare Home in telemedicine workflow to detect real-world intraocular pressure response to glaucoma medication change. *Ophthalmol Glaucoma* 2020;3(5):403-05. doi: 10.1016/j.ogla.2020.04.017

500. Erras A, Shahrvini B, Weinreb RN, et al. Review of glaucoma medication adherence monitoring in the digital health era. *Br J Ophthalmol* 2021;107:153-59 doi: 10.1136/bjophthalmol-2020-317918

501. Odden JL, Khanna CL, Choo CM, et al. Telemedicine in long-term care of glaucoma patients. *J Telemed Telecare* 2020;26(1-2):92-99. doi: 10.1177/1357633X1879175

502. Lam PY, Chow SC, Lai JSM, et al. A review on the use of telemedicine in glaucoma and possible roles in COVID-19 outbreak. *Surv Ophthalmol* 2021;66(6):999-1008. doi: 10.1016/j.survophthal.2021.03.008

503. Thomas SM, Jeyaraman M, Hodge WG, et al. The effectiveness of teleglaucoma versus in-patient examination for glaucoma screening: a systematic review and meta-analysis. *PloS One* 2014;9(12):e113779. doi: 10.1371/journal.pone.0113779

504. Rhodes LA, Huisingh CE, McGwin G, et al. Glaucoma patient knowledge, perceptions, and predispositions for telemedicine. *J Glaucoma* 2020;28(6):481-86. doi: 10.1097/IJG.0000000000001238

505. Clarke J, Puertas R, Kotecha A, et al. Virtual clinics in glaucoma care: face-to-face versus remote decision making. *Br J Ophthalmol* 2017;101(7):892-95. doi: 10.1136/bjophthalmol-2016-308993

506. Chandrasekaran S, Kass W, Thangamathesvaran L, et al. Tele-glaucoma versus clinical evaluation: the New Jersey Health Foundation prospective clinical study. *J Telemed Telecare* 2020;26(9):536-44. doi: 10.1177/1357633XI9845273

507. Modjtahedi BS, Chu K, Luong TQ, et al. Two-year outcomes of a pilot glaucoma suspect telemedicine monitoring project. *Clin Ophthalmol* 2018;12:2095-102.

508. Polat JK, Hughes EL, Brown EN, et al. Teleglaucoma initiative at a Veterans Affairs hospital. *Ophthalmol Glaucoma* 2021;4(6):632-37. doi: 10.1016/j.ogla.2021.03.016

VI. APPENDICES

Appendix 1:
Optometric Management of the Patient with Open-Angle Glaucoma: A Flow Chart



CCT—Central corneal thickness
EGPS—European Glaucoma Prevention Study
IOP— Intraocular pressure
NTG—Normal tension glaucoma
OH—Ocular hypertension
ONH—Optic nerve head
OHTS—Ocular Hypertension Treatment Study
POAG—Primary open-angle glaucoma
RNFL—Retinal nerve fiber layer
VF—Visual fields

Appendix 2: Abbreviations/Acronyms

ACG	Angle closure glaucoma
AGIS	Advanced Glaucoma Intervention Study
ALT	Argon laser trabeculoplasty
AOA	American Optometric Association
APON	Acquired pits of the optic nerve
AS-OCT	Anterior segment-optical coherence tomography
β-BLOCKERS	Beta blockers
BMO-MRA	Bruch's membrane opening-minimum rim area
BMO-MRW	Bruch's membrane opening-minimum rim width
BP	Blood pressure
CAI	Carbonic anhydrase inhibitors
CCT	Central corneal thickness
C/D	Cup-to-disc
CIGTS	Collaborative Initial Glaucoma Treatment Study
CNTGS	Collaborative Normal Tension Glaucoma Study
CPC	Cyclophotocoagulation
CPG	Clinical practice guideline
CPSD	Corrected pattern standard deviation
D	Diopter
dB	Decibel
DH	Disc hemorrhage
DM	Diabetes mellitus
EBO	Evidence-based optometry
EMGT	Early Manifest Glaucoma Trial
FDA	Food and Drug Administration
GCA	Ganglion cell analysis
GCC	Ganglion cell complex
GCIPL	Ganglion cell-inner plexiform layer
GDD	Glaucoma drainage devices
GDG	Guideline Development Group
GDRG	Guideline Development Reading Group
GHT	Glaucoma hemifield test
GSS	Glaucoma staging systems
HRQOL	Health related quality of life
IOM	Institute of Medicine
IOP	Intraocular pressure
IPL	Inner plexiform layer
LALES	Los Angeles Latino Eye Study

LiGHT	Laser in Glaucoma and Ocular Hypertension Trial
MAO	Monoamine oxidase
MD	Mean deviation
MIGS	Minimally-invasive glaucoma surgery
MMC	Mitomycin-C
mmHg	Millimeters of mercury
NASEM	National Academies of Sciences, Engineering and Medicine
NTG	Normal tension glaucoma
OAG	Open-angle glaucoma
OCT	Optical coherence tomography
OCT-A	Optical coherence tomography angiography
OH	Ocular hypertension
OHTS	Ocular Hypertension Treatment Study
ONH	Optic nerve head
OPP	Ocular perfusion pressure
OSA	Obstructive sleep apnea
OSD	Ocular surface disease
PGA	Prostaglandin analogs
POAG	Primary open-angle glaucoma
PSD	Pattern standard deviation
QoL	Quality of life
RGC	Retinal ganglion cell
RNFL	Retinal nerve fiber layer
SAP	Standard automated perimetry
SD-OCT	Spectral domain-optical coherence tomography
SLT	Selective laser trabeculoplasty
TM	Trabecular meshwork
TVT	Tube Versus Trabeculectomy
UKGTS	United Kingdom Glaucoma Treatment Study
VEGF	Vascular endothelial growth factor
VF	Visual field

Appendix 3:
Gaps in Research Evidence

During the development of this guideline, the Evidence-based Optometry GDG identified the following gaps in evidence as potential areas for future research:

- Research to develop more sensitive and reliable indicators for glaucoma progression.
- Research to develop clinically useful measures of ocular perfusion pressure and its influence on glaucoma progression.
- Research to further evaluate the utility of anterior segment-optical coherence tomography (AS-OCT), including longitudinal studies to determine the significance of eyes classified to have closed angles by AS-OCT but open by gonioscopy.
- Research to investigate the use of self-tonometry for the measurement of diurnal intraocular pressure fluctuation.
- Research to evaluate the complex relationship between glaucoma medication and ocular surface disease.
- Research to identify medication persistence rates in patients with glaucoma at different stages of disease progression.
- Research to identify the optimal strategy to detect RNFL progression with the RNFL thickness map.
- Research to investigate the utility and validity of clinical testing outside the office setting (home monitoring).
- Research on new visual field parameters aimed at reducing variability and improving patient acceptance.
- Research on current medical treatments compared with surgery, particularly for people with severe glaucoma and in ethnic groups.
- Research to determine how best to apply rate of change information to the individual ocular hypertensive patient.
- Research to investigate the role of deep layer microvasculature damage in the pathophysiology of glaucoma.
- Research on the sensitivity and specificity of telehealth screening and management services for patients with POAG.
- Research on the impact of diet/lifestyle on risks for POAG.

VII. METHODOLOGY FOR GUIDELINE DEVELOPMENT

This guideline was developed by the AOA Evidence-based Optometry Guideline Development Group (GDG). Clinical questions to be addressed in the guideline were identified and refined during an initial meeting of the GDG and served as the basis for a search of the clinical and research literature.

An English language literature search for the years 2009 to 2023 was conducted by a trained researcher. If the search did not produce results, the search parameters were extended an additional 5 years, and subsequently 10 years back. In addition, a review of selected earlier research publications from 1970 to 2000 was conducted to provide background support for the "Natural History of Primary Open-Angle Glaucoma" section of the guideline. The literature search was conducted using the following electronic databases:

- Centers for Disease Control and Prevention, National Center for Health Statistics
- Cochrane Library
- Google Scholar
- Ovid MEDLINE
- PubMed
- VisionCite
- Scopus



All references meeting the criteria were reviewed to determine their relevance to the clinical questions addressed in the guideline. They were assigned to two (three readers if there was a disagreement in grading) who independently reviewed and graded the quality of evidence and the clinical recommendations for each article, based on a previously defined system for grading quality.

During thirty-six articulation meetings of the Evidence-based Optometry Guideline Development Reading Group (GDRG), all evidence was reviewed and clinical recommendations were developed. Grading for the recommendations was based on the quality of the research and the benefits and risks of the procedure or therapy recommended. Where direct scientific evidence to support a recommendation was weak or lacking, a consensus of the GDRG members was required to approve a recommendation.

At the draft reading meeting of the Evidence-based Optometry Guideline Development Group (GDG), the guideline document was reviewed and edited and the completed draft was approved by the GDG by conference call. The approved draft of the guideline was then made available for peer and public review for 30 days for numerous stakeholders (individuals and organizations) to make comments. All suggested revisions were reviewed and, if accepted by the GDG, incorporated into the final guideline.

The guideline will be periodically reviewed and updated as new scientific and clinical evidence becomes available.

VIII. EVIDENCE-BASED OPTOMETRY GUIDELINE DEVELOPMENT GROUP

AOA Evidence-based Optometry Committee

- Carl Urbanski, O.D., Chair – *Private Practice, Family Vision Care of Kingston, Kingston, Pennsylvania*
- Diane Adamczyk, O.D. – *Professor, Director of Residency Education, State University of New York College of Optometry, New York, New York*
- John F. Amos, O.D., M.S. – *Emeritus Dean and Professor, UAB School of Optometry, University of Alabama at Birmingham, Birmingham, Alabama*
- Benjamin Casella, O.D. – *Private Practice, Casella Eye Center, Augusta, Georgia*
- Michael Chaglasian, O.D. – *Associate Professor, Illinois College of Optometry, Chicago, Illinois*
- Mitchell Dul, O.D., M.S. – *Professor, Department of Biologic and Vision Science, State University of New York College of Optometry, New York, New York*
- Bonnie Gauer, O.D., M.S. – *Private Practice, Roseburg, Oregon*
- Bennett McAllister, O.D. – *Associate Professor, Western University of Health Sciences College of Optometry, Pomona, California*
- Breanne McGhee, O.D. – *Ochsner Medical Center, New Orleans, Louisiana*
- Beatrice Reed, O.D. – *Retired, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas*
- Trennda Rittenbach, O.D. – *Technology-based Eye Care Services (TECS) VA Medical Center, Gig Harbor, Washington*
- Sean McKeown, O.D. – *Private Practice, Tri-County Vision, Willimantic, Connecticut*
- Gregory S. Wolfe, O.D., MPH – *Southern College of Optometry, The Eye Center, Memphis, Tennessee*

Multidisciplinary and Patient Stakeholders

- Christie Burdek – *Patient Advocate, O'Fallon, Missouri*
- Kellie Cannon – *Patient, Florissant, Missouri*

- Scott LaBorwit, MD – *Assistant Professor, Wilmer Eye Institute, John Hopkins University School of Medicine, Towson, Maryland*
- Danica Marrelli, O.D. – *Clinical Professor, Director, Ocular Diagnostic and Medical Eye Service University of Houston Optometry, Houston, Texas*
- Pinakin Davey, O.D., PhD. – *Professor, College of Optometry Western University of Health Services, Pomona, California*

Non-voting Members

- Barry Weissman, O.D., PhD. – *Editor/Writer, Emeritus Professor, Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, and Retired Professor of Optometry, Southern California College of Optometry at Marshall B. Ketchum University, Fullerton, California*
- Stephen C. Miller, O.D. – *Assistant Editor/Writer, Innovative Writing Works, St. Louis, Missouri*
- Beth Kneib, O.D. – *Former Director, Clinical Resources Group, American Optometric Association, Seattle, Washington*
- Andrew Morgenstern, O.D. – *Director, Clinical Resources Group, American Optometric Association, Alexandria, Virginia*
- Alisa G. Krewet – *Evidence-based Optometry, Program Specialist, Quality Improvement, American Optometric Association, St. Louis, Missouri*
- Liway Arceo – *Former Coordinator, Quality Improvement, American Optometric Association, St. Louis, Missouri*

Scientific Readers, Non-voting Members

- Daniel Cho, MD, PhD – *Craniofacial Plastic Surgery Fellow, University of Pennsylvania, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania*
- Jasna Despot, MS – *St. Louis, Missouri*
- Julia Frantz, MA – *St. Louis, Missouri*
- Angela Minic, MS – *Thornton, Colorado*